var title_f13_3_13360="Fluorosc looping guidewire";
var content_f13_3_13360=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F56108&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F56108&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    EUS-guided pancreatic pseudocyst drainage",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 398px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Fluoroscopic image demonstrating looping of a guidewire in a pseudocyst under EUS-guidance.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Kenneth E Fasanella, MD, and Michael K Sanders, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_3_13360=[""].join("\n");
var outline_f13_3_13360=null;
var title_f13_3_13361="Side view knee PI";
var content_f13_3_13361=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F51910&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F51910&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Side view of the knee",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 447px; height: 516px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_3_13361=[""].join("\n");
var outline_f13_3_13361=null;
var title_f13_3_13362="CT scan showing infected pancreatic necrosis";
var content_f13_3_13362=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F54160&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F54160&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    CT scan showing infected pancreatic necrosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 277px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Infected pancreatic necrosis can be diagnosed by the identification of air bubbles within an area of necrosis seen on contrast enhanced CT scan (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_3_13362=[""].join("\n");
var outline_f13_3_13362=null;
var title_f13_3_13363="RPL CT and MRI findings B";
var content_f13_3_13363=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F56979&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F56979&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    MRI images in Reversible posterior leukoencephalopathy syndrome (RPLS) (B",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 453px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Diffusion-weighted image (DWI) (A) shows slight hyperintensity within the hyperintense regions seen on FLAIR image. The corresponding ADC map (B) shows hyperintensity in these regions, suggestive of facilitated water diffusion and vasogenic edema. Follow-up study obtained two weeks later shows resolution of the hyperintense lesions on T2-weighted (C) and FLAIR (D) images.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Eric D Schwartz, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_3_13363=[""].join("\n");
var outline_f13_3_13363=null;
var title_f13_3_13364="Proton gantry system";
var content_f13_3_13364=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F72402&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F72402&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    The proton gantry system at the MGH northeast proton therapy center (MGH-NPTC)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 338px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    An isocentric gantry with a mobile proton beam source is used in conjunction with a robotic patient positioning treatment couch. The robotic unit has six degrees of freedom, three linear and three rotational. The patient is positioned to place the target lesion at the center of beam isocenter.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Massachusetts General Hospital.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_3_13364=[""].join("\n");
var outline_f13_3_13364=null;
var title_f13_3_13365="Magnesium sulfate: Patient drug information";
var content_f13_3_13365=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Magnesium sulfate: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27031?source=see_link\">",
"     see \"Magnesium sulfate: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/29/34262?source=see_link\">",
"     see \"Magnesium sulfate: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10029234\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop and treat low magnesium levels.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691662",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691887",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat high blood pressure during pregnancy.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692054",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat seizures.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691793",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat hard stools (constipation).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692135",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat wounds.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691647",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop early labor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10029233\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702437",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to magnesium or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701384",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a slow heartbeat without a working pacemaker.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10029238\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697312",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have myasthenia gravis, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697314",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have nerve disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10029239\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698207",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Low blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698189",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritation where the shot is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10029241\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure or a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699087",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699028",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad flushing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699032",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad itching.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad swelling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698512",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If seizures are worse or not the same after starting this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10029236\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705552",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Soaks:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695435",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mix powder with water.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695610",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Soak a clean, white cloth with the solution.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694494",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put the cloth on the affected part.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695649",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Soak affected part for 15 to 30 minutes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695976",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a muscle or vein.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given into a vein for a period of time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696366",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Your doctor will give this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10029237\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10029242\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10029243\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11219 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.80.101-E63CECF6F9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_3_13365=[""].join("\n");
var outline_f13_3_13365=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029234\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029233\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029238\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029239\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029241\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029236\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029237\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029242\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029243\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27031?source=related_link\">",
"      Magnesium sulfate: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/29/34262?source=related_link\">",
"      Magnesium sulfate: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_3_13366="Equine conjugated estrogens and medroxyprogesterone acetate: Patient drug information";
var content_f13_3_13366=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Equine conjugated estrogens and medroxyprogesterone acetate: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/37/37463?source=see_link\">",
"     see \"Equine conjugated estrogens and medroxyprogesterone acetate: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F167446\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Premphase&reg;;",
"     </li>",
"     <li>",
"      Prempro&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F167447\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Premphase&reg;;",
"     </li>",
"     <li>",
"      Premplus&reg;;",
"     </li>",
"     <li>",
"      Prempro&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10027356\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3576122",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Estrogens may raise your chances of having breast cancer.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700311",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Estrogens, when used in women after stopping periods (menopause), may raise the chance of uterine cancer. Progestins may lower this chance. A warning sign for cancer of the uterus is vaginal bleeding. Report any vaginal bleeding to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3576124",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take estrogens to stop heart disease or dementia. Using estrogens may raise your chances of having a heart attack, a stroke, or a blood clot.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10027358\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691539",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to put off soft, brittle bones (osteoporosis) in women after change of life.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691649",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or lower the signs of stopping periods (menopause).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692124",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat vaginal irritation and dryness caused by change of life.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10027357\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702062",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to estrogens (conjugated/equine), medroxyprogesterone, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703394",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Blood clots, breast cancer, liver disease, stroke, tumor where estrogen makes it grow, or vaginal bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703789",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have surgery and need bed rest.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701021",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are a heavy smoker (more than 15 cigarettes per day) and older than 35 years of age.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703881",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you turned yellow during pregnancy or with estrogen-based or hormone contraceptive use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701347",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you do not have a uterus and are using this drug to treat signs of stopping periods (menopause) or to put off soft, brittle bones (osteoporosis).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10027362\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There may be a higher chance of breast cancer.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697169",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any blood flow problems, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697221",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have gallbladder disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697265",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood pressure, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698524",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), you will need to watch your blood sugar closely.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697308",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have migraine headaches, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697148",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a weak heart, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698421",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell dentists, surgeons, and other doctors that you use this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698528",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking a blood thinner, have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698407",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have a bone density test. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698554",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do monthly breast self-exams and have a gynecologic exam every year.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have an eye exam every year.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696901",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take St John's wort, dong quai, black cohosh, saw palmetto, red clover, or ginseng with this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697111",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking this drug and have high blood pressure, talk with your doctor before using OTC products that may raise blood pressure. These include cough or cold drugs, diet pills, stimulants, ibuprofen or like products, and some natural products or aids.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697562",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit your drinking of wine, beer, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid cigarette smoking. People older than 35 years of age and/or smoking more than 15 cigarettes per day have more chance for heart disease.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10027363\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697923",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Enlarged breasts.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697963",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in sex ability.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10027365\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698626",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698619",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in strength on 1 side is greater than the other, trouble speaking or thinking, change in balance, or blurred eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699095",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling, warmth, or pain in the leg or arm.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698615",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in how contact lenses feel in the eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698598",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A lump in the breast or breast soreness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10027360\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695852",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug at the same time of day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695907",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug with food.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696101",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug works best when used with calcium/vitamin D and weight-bearing workouts like walking or PT (physical therapy).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10027361\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10027366\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10027367\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11003 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-5DB5CB92DE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_3_13366=[""].join("\n");
var outline_f13_3_13366=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167446\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167447\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027356\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027358\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027357\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027362\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027363\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027365\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027360\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027361\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027366\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027367\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?36/37/37463?source=related_link\">",
"      Equine conjugated estrogens and medroxyprogesterone acetate: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_3_13367="Tolmetin: Pediatric drug information";
var content_f13_3_13367=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Tolmetin: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33512?source=see_link\">",
"    see \"Tolmetin: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?16/38/16997?source=see_link\">",
"    see \"Tolmetin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709985\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1055764\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Analgesic, Non-narcotic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Nonsteroidal Anti-inflammatory Drug (NSAID), Oral",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1055758\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33512?source=see_link\">",
"      see \"Tolmetin: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &ge;2 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Anti-inflammatory: Initial: 20 mg/kg/day in 3-4 divided doses, then 15-30 mg/kg/day in 3-4 divided doses; maximum dose: 30 mg/kg/day in 4 divided doses; do not exceed 1800 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Analgesic: 5-7 mg/kg/dose every 6-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults: 400 mg 3 times/day; usual dose: 600 mg to 1.8 g/day; maximum dose: 2 g/day",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F229042\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral: 400 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 200 mg, 600 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F229028\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874842\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm089162.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm089162.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1055768\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: May administer with food, milk, or antacids to decrease GI adverse effects",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1055767\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of inflammatory and rheumatoid disorders, including juvenile idiopathic arthritis",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F14187959\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F229100\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Chest pain, hypertension, edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Depression, dizziness, drowsiness, headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Skin irritation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Weight gain/loss",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, constipation, diarrhea, flatulence, gastritis, heartburn, nausea, peptic ulcer, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Urinary tract infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Hemoglobin/hematocrit decreases (transient)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Visual disturbances",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: BUN increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Agranulocytosis, anaphylactoid reactions, CHF, dysuria, epistaxis, erythema multiforme, exfoliative dermatitis, fever, fluid retention, GI bleeding, GI perforation, glossitis, granulocytopenia, hematuria, hemolytic anemia, hepatic failure, hepatic necrosis, hepatitis, hepatitis (fulminant), interstitial nephritis, jaundice, liver function tests (abnormal), lymphadenopathy, macular changes, nephrotic syndrome, optic neuropathy, proteinuria, purpura, renal failure, retinal changes, serum sickness, stomatitis, Stevens-Johnson syndrome, thrombocytopenia, toxic epidermal necrolysis, urticaria",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1055771\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to tolmetin or any component; history of asthma, urticaria, or allergic-type reaction to aspirin, or other NSAIDs; patients with the \"aspirin triad\" [asthma, rhinitis (with or without nasal polyps), and aspirin intolerance] (fatal asthmatic and anaphylactoid reactions may occur in these patients); perioperative pain in the setting of coronary artery bypass graft (CABG)",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1055757\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with upper GI disease, impaired renal function, CHF, hypertension, and patients receiving anticoagulants; although rare, anaphylactoid reactions occur more commonly with tolmetin than other NSAIDs",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1055756\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     NSAIDs are associated with an increased risk of adverse cardiovascular thrombotic events, including potentially fatal MI and stroke",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; risk may be increased with duration of use or pre-existing cardiovascular risk factors or disease; carefully evaluate cardiovascular risk profile prior to prescribing; use the lowest effective dose for the shortest duration of time, taking into consideration individual patient treatment goals; alternate therapies should be considered for patients at high risk. Use is contraindicated for treatment of perioperative pain in the setting of CABG surgery",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; an increased incidence of MI and stroke was found in patients receiving COX-2 selective NSAIDs for the treatment of pain within the first 10-14 days after CABG surgery. NSAIDs may cause fluid retention, edema, and new onset or worsening of pre-existing hypertension; use with caution in patients with hypertension, CHF, or fluid retention. Concurrent administration of ibuprofen and potentially other nonselective NSAIDs may interfere with aspirin&rsquo;s cardioprotective effect.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     NSAIDs may increase the risk of gastrointestinal inflammation, ulceration, bleeding, and perforation",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . These events, which can be potentially fatal, may occur at any time during therapy and without warning. Avoid the use of NSAIDs in patients with active GI bleeding or ulcer disease. Use NSAIDs with extreme caution in patients with a history of GI bleeding or ulcers (these patients have a 10-fold increased risk for developing a GI bleed). Use NSAIDs with caution in patients with other risk factors which may increase GI bleeding (eg, concurrent therapy with aspirin, anticoagulants, and/or corticosteroids, longer duration of NSAID use, smoking, use of alcohol, and poor general health). Use the lowest effective dose for the shortest duration of time, taking into consideration individual patient treatment goals; alternate therapies should be considered for patients at high risk",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     NSAIDs may compromise existing renal function. Renal toxicity may occur in patients with impaired renal function, dehydration, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors; use with caution in these patients; monitor renal function closely. NSAIDs are not recommended for use in patients with advanced renal disease. Long-term use of NSAIDs may cause renal papillary necrosis and other renal injury. Rare cases of severe hepatic reactions (eg, fulminant hepatitis, liver failure) have occurred with NSAID use; closely monitor patients with any abnormal LFT;  discontinue if signs or symptoms of liver disease develop or if systemic manifestations occur",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Fatal asthmatic and anaphylactoid reactions may occur in patients with the \"aspirin triad\" who receive NSAIDs. NSAIDs may cause serious dermatologic adverse reactions including exfoliative dermatitis, Stevens-Johnson syndrome, and toxic epidermal necrolysis. Avoid use of NSAIDs in late pregnancy as they may cause premature closure of the ductus arteriosus.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300154\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F229037\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the anticoagulant effect of other Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Agents with Antiplatelet Properties. An increased risk of bleeding may occur. Nonsteroidal Anti-Inflammatory Agents may diminish the cardioprotective effect of Agents with Antiplatelet Properties. This interaction is likely specific to aspirin, and not to other antiplatelet agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aliskiren: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Aliskiren. Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of Aliskiren.  Management: Monitor renal function periodically in patients receiving aliskiren and any nonsteroidal anti-inflammatory agent.  Patients at elevated risk of renal dysfunction include those who are elderly, are volume depleted, or have pre-existing renal dysfunction.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglycosides: Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Angiotensin II Receptor Blockers: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Angiotensin II Receptor Blockers. The combination of these two agents may also significantly decrease glomerular filtration and renal function.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: Nonsteroidal Anti-Inflammatory Agents may enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidepressants (Tricyclic, Tertiary Amine): May enhance the antiplatelet effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Bisphosphonate Derivatives. Both an increased risk of gastrointestinal ulceration and an increased risk of nephrotoxicity are of concern.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Collagenase (Systemic): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May enhance the adverse/toxic effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of CycloSPORINE (Systemic). Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may increase the serum concentration of Nonsteroidal Anti-Inflammatory Agents. Specifically, elevated diclofenac concentrations have been reported.  Management: Consider alternatives to nonsteroidal anti-inflammatory agents (NSAIDs).  Monitor for evidence of nephrotoxicity, as well as increased serum cyclosporine concentrations and systemic effects (e.g., hypertension) during concomitant therapy with NSAIDs.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Dabigatran Etexilate. Agents with Antiplatelet Properties may increase the serum concentration of Dabigatran Etexilate. This mechanism applies specifically to clopidogrel.  Management: Increase monitoring for signs/symptoms of bleeding. The Canadian product monograph for dabigatran specifically recommends avoiding concomitant use with GIIb/IIIa inhibitors or ticlopidine, or with aspirin used for stroke prevention in atrial fibrillation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May enhance the anticoagulant effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Digoxin: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Digoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Drotrecogin Alfa (Activated): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Drotrecogin Alfa (Activated). Bleeding may occur.  Management: When possible, avoid use of drotrecogin within 7 days of use of any IIb/IIIa antagonists, higher dose aspirin (more than 650 mg/day), or use of other antiplatelet agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Eplerenone. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Eplerenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Floctafenine: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Glucosamine: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Haloperidol: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Haloperidol. Specifically including drowsiness and confusion.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Bleeding may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Bleeding may occur. Management: Concomitant treatment with these agents should generally be avoided. If used concomitantly, increased diligence in monitoring for adverse effects (eg, bleeding, bruising, altered mental status due to CNS bleeds) must be employed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrALAZINE: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of HydrALAZINE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ibritumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Nasal): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Systemic): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Lithium.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the diuretic effect of Loop Diuretics.  Management: Monitor for decreased therapeutic effects of loop diuretics with concurrent use of an NSAID. Consider avoiding concomitant use of these agents in CHF or cirrhosis with ascites. Concomitant use of bumetanide with indomethacin is  not recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Methotrexate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of other Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (COX-2 Inhibitor): Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of NSAID (COX-2 Inhibitor).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omacetaxine: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Omacetaxine. Specifically, the risk for bleeding-related events may be increased.  Management: Avoid concurrent use of nonsteroidal antiinflammatory drugs (NSAIDs) with omacetaxine in patients with a platelet count of less than 50,000/uL.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omega-3 Fatty Acids: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PEMEtrexed: NSAID (Nonselective) may increase the serum concentration of PEMEtrexed.  Management: Patients with mild-to-moderate renal insufficiency (estimated creatinine clearance 45-79 mL/min) should avoid NSAIDs for 2-5 days prior to, the day of, and 2 days after pemetrexed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentosan Polysulfate Sodium: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of bleeding may be increased by concurrent use of these agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium-Sparing Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Potassium-Sparing Diuretics. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PRALAtrexate: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of PRALAtrexate. More specifically, NSAIDS may decrease the renal excretion of pralatrexate.  Management: Closely monitor for increased pralatrexate serum levels and/or toxicity if used concomitantly with an NSAID. Monitor for decreased pralatrexate serum levels with NSAID discontinuation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Nonsteroidal Anti-Inflammatory Agents may enhance the neuroexcitatory and/or seizure-potentiating effect of Quinolone Antibiotics. Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Quinolone Antibiotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Rivaroxaban.  Management: Avoid concurrent use of clopidogrel with rivaroxaban unless the anticipated benefits outweigh the risks of bleeding.  Avoid concurrent use of rivaroxaban with other antiplatelet agents whenever possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: NSAID (Nonselective) may enhance the adverse/toxic effect of Salicylates. An increased risk of bleeding may be associated with use of this combination. NSAID (Nonselective) may diminish the cardioprotective effect of Salicylates. Salicylates may decrease the serum concentration of NSAID (Nonselective).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Choline Magnesium Trisalicylate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the antiplatelet effect of NSAID (Nonselective). NSAID (Nonselective) may diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors. Management: Consider using alternative analgesics, when appropriate, and/or addition of an gastroprotective agent.  Monitor patients closely for signs/symptoms of bleeding, and for evidence of diminished SSRI effectiveness with concurrent use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the antiplatelet effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: May enhance the nephrotoxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the risk of acute phosphate nephropathy may be enhanced. Management: Consider avoiding this combination by temporarily suspending treatment with NSAIDs, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, maintain adequate hydration and monitor renal function closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tositumomab and Iodine I 131 Tositumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse events may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Treprostinil: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Bleeding may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vancomycin: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Vancomycin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin E: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): NSAID (Nonselective) may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1055774\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food or milk may decrease the extent of oral absorption",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F229038\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5735563\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed in the initial animal reproduction studies; therefore, the manufacturer classifies tolmetin as pregnancy category C. NSAID exposure during the first trimester is not strongly associated with congenital malformations; however, cardiovascular anomalies and cleft palate have been observed following NSAID exposure in some studies. The use of an NSAID close to conception may be associated with an increased risk of miscarriage. Nonteratogenic effects have been observed following NSAID administration during the third trimester including myocardial degenerative changes, prenatal constriction of the ductus arteriosus, fetal tricuspid regurgitation, failure of the ductus arteriosus to close postnatally; renal dysfunction or failure, oligohydramnios; gastrointestinal bleeding or perforation, increased risk of necrotizing enterocolitis; intracranial bleeding (including intraventricular hemorrhage), platelet dysfunction with resultant bleeding; pulmonary hypertension. Because they may cause premature closure of the ductus arteriosus, use of NSAIDs late in pregnancy should be avoided (use after 31 or 32 weeks gestation is not recommended by some clinicians). The chronic use of NSAIDs in women of reproductive age may be associated with infertility that is reversible upon discontinuation of the medication.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1055763\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential, liver enzymes, occult blood loss, BUN, serum creatinine; periodic ophthalmologic exams",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1055755\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits prostaglandin synthesis by decreasing the activity of the enzyme, cyclooxygenase, which results in decreased formation of prostaglandin precursors",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1055770\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Well absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 99%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: In the liver via oxidation and conjugation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life, elimination: 5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Within 30-60 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Excreted in the urine as metabolites or conjugates",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1055762\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?16/38/16997?source=see_link\">",
"      see \"Tolmetin: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Tolmetin is a nonsteroidal anti-inflammatory drug (NSAID); NSAIDs may cause serious adverse reactions, especially with overuse; use exactly as directed; do not increase dose or frequency. NSAIDs may increase the risk for heart attack, stroke, or ulcers and bleeding in stomach or intestines; GI bleeding, ulceration, or perforation can occur with or without pain. Notify physician before use if you have hypertension, heart failure, heart or kidney disease, history of stomach ulcers or bleeding in stomach or intestines, or other medical problems. Read the patient Medication Guide that you receive with each prescription and refill of tolmetin.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     While using this medication, do not use alcohol, excessive amounts of vitamin C, other prescription or OTC medications containing aspirin or salicylate, or other NSAIDs without consulting prescriber. Tolmetin may cause dizziness or drowsiness and impair ability to perform activities requiring mental alertness or physical coordination.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Notify physician if stomach pain or upset occurs, if swelling or redness occurs in painful area, or if any new symptoms appear. Stop taking medication and report ringing in ears; persistent cramping or stomach pain; unresolved nausea or vomiting; respiratory difficulty or shortness of breath; unusual bruising or bleeding (mouth, urine, stool); skin rash; unusual swelling of extremities; chest pain; palpitations; or weight gain.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Berde C, Ablin A, Glazer J, et al, &ldquo;American Academy of Pediatrics Report of the Subcommittee on Disease-Related Pain in Childhood Cancer,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1990, 86(5 Pt 2):818-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/3/13367/abstract-text/2216644/pubmed\" id=\"2216644\" target=\"_blank\">",
"        2216644",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Giannini EH and Cawkwell GD, &ldquo;Drug Treatment in Children With Juvenile Rheumatoid Arthritis. Past, Present, and Future,&rdquo;",
"      <i>",
"       Pediatr Clin North Am",
"      </i>",
"      , 1995, 42(5):1099-125.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/3/13367/abstract-text/7567188 /pubmed\" id=\"7567188 \" target=\"_blank\">",
"        7567188",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hollingworth P, &ldquo;The Use of Non-Steroidal Anti-inflammatory Drugs in Paediatric Rheumatic Diseases,&rdquo;",
"      <i>",
"       Br J Rheumatol",
"      </i>",
"      , 1993, 32(1):73-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/3/13367/abstract-text/8422565 /pubmed\" id=\"8422565 \" target=\"_blank\">",
"        8422565",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rose CD and Doughty RA, &ldquo;Pharmacological Management of Juvenile Rheumatoid Arthritis,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 1992, 43(6):849-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/3/13367/abstract-text/1379157/pubmed\" id=\"1379157\" target=\"_blank\">",
"        1379157",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12847 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.234.146.186-8AB89F2CF9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_3_13367=[""].join("\n");
var outline_f13_3_13367=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709985\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055764\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055758\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229042\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229028\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874842\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055768\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055767\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14187959\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229100\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055771\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055757\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055756\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300154\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229037\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055774\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229038\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5735563\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055763\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055755\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055770\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055762\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12847\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12847|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33512?source=related_link\">",
"      Tolmetin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?16/38/16997?source=related_link\">",
"      Tolmetin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_3_13368="Acute arterial occlusion of the lower extremities (acute limb ischemia)";
var content_f13_3_13368=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Acute arterial occlusion of the lower extremities (acute limb ischemia)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/3/13368/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/3/13368/contributors\">",
"     Marc E Mitchell, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/3/13368/contributors\">",
"     Emile R Mohler III, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/3/13368/contributors\">",
"     Jeffrey P Carpenter, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/3/13368/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/3/13368/contributors\">",
"     Denis L Clement, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/3/13368/contributors\">",
"     James Hoekstra, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/3/13368/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/3/13368/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/3/13368/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION AND DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;According to the 2007 Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II), acute limb ischemia is defined as a sudden decrease in limb perfusion that causes a potential threat to limb viability (manifested by ischemic rest pain, ischemic ulcers,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    gangrene) in patients who present within two weeks of the acute event [",
"    <a class=\"abstract\" href=\"UTD.htm?13/3/13368/abstract/1\">",
"     1",
"    </a>",
"    ]. Patients with similar manifestations who present later than two weeks are considered to have chronic limb ischemia.",
"   </p>",
"   <p>",
"    The management of acute arterial occlusion remains a challenge for vascular specialists. Surgical thromboembolectomy and bypass grafting were the mainstays of therapy for many years [",
"    <a class=\"abstract\" href=\"UTD.htm?13/3/13368/abstract/2\">",
"     2",
"    </a>",
"    ]. Subsequently, thrombolytic therapy and percutaneous transluminal angioplasty (PTA) have become treatment options for selected patients.",
"   </p>",
"   <p>",
"    Despite these advances, the morbidity, mortality, and limb loss rates from acute lower extremity ischemia remain high. Thus, regardless of the treatment modality used, early diagnosis and rapid initiation of therapy are essential in order to salvage the ischemic extremity.",
"   </p>",
"   <p>",
"    The major causes and management approaches to acute limb ischemia will be reviewed here. Issues related to chronic limb ischemia (ie, similar manifestations in patients who present more than two weeks after symptom onset) are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/9/14486?source=see_link\">",
"     \"Clinical manifestations and evaluation of chronic critical limb ischemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/58/19370?source=see_link\">",
"     \"Treatment of chronic lower extremity critical limb ischemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute arterial occlusion can be the result of an embolus dislodged from a distant source, acute thrombosis of a previously patent artery or graft, or direct trauma to an artery. Common etiologies for each of these mechanisms are presented in the table (",
"    <a class=\"graphic graphic_table graphicRef58846 \" href=\"UTD.htm?11/0/11276\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Arterial emboli",
"    </span>",
"    &nbsp;&mdash;&nbsp;Eighty percent of arterial emboli originate in the heart and travel to the extremities; the lower extremities are affected much more frequently than the upper extremities [",
"    <a class=\"abstract\" href=\"UTD.htm?13/3/13368/abstract/3\">",
"     3",
"    </a>",
"    ]. The majority of these emboli occur in patients with significant underlying cardiac disease; the severity of the patient's underlying cardiac condition may increase the risk of surgery, and limit the options available for restoring blood flow to the ischemic extremity.",
"   </p>",
"   <p>",
"    Potential sources of emboli from the heart include left ventricular thrombus formation following myocardial infarction, and atrial thrombus in patients with atrial fibrillation. Up to 75 percent of patients with emboli to the lower extremities have a history of recent myocardial infarction or atrial fibrillation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/23/5497?source=see_link\">",
"     \"Left ventricular thrombus after acute myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/4/12361?source=see_link\">",
"     \"Echocardiography in detection of intracardiac sources of embolism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Arterial to arterial embolization of thrombus or plaque originating from aneurysms or atherosclerotic lesions is another well described occurrence and accounts for 20 percent of peripheral emboli. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/35/10809?source=see_link\">",
"     \"Embolism from aortic plaque: Thromboembolism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/15/31994?source=see_link\">",
"     \"Embolism from atherosclerotic plaque: Atheroembolism (cholesterol crystal embolism)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Emboli typically lodge where there is an acute narrowing of the artery, such as an atherosclerotic plaque or a point where the vessel branches; the common femoral, common iliac, and popliteal artery bifurcations are the most frequent locations. In a large series of arterial embolism, for example, the following frequencies were noted [",
"    <a class=\"abstract\" href=\"UTD.htm?13/3/13368/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Femoral &ndash; 28 percent",
"     </li>",
"     <li>",
"      Arm &ndash; 20 percent",
"     </li>",
"     <li>",
"      Aortoiliac &ndash; 18 percent",
"     </li>",
"     <li>",
"      Popliteal &ndash; 17 percent",
"     </li>",
"     <li>",
"      Visceral and other &ndash; 9 percent each",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In comparison to thromboemboli, atheroemboli are less likely to produce symptoms of acute limb ischemia. Atheroembolism is discussed in detail elsewhere. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Blue toe syndrome'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/15/31994?source=see_link\">",
"     \"Embolism from atherosclerotic plaque: Atheroembolism (cholesterol crystal embolism)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Arterial thrombosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thrombosis of a previously patent but stenotic artery is a well known complication of atherosclerosis. Occlusion of atherosclerotic vessels may occur by two mechanisms:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Progressive atherosclerotic narrowing of the artery, with resultant low flow, stasis, and eventual thrombosis",
"     </li>",
"     <li>",
"      Intraplaque hemorrhage and local hypercoagulability (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/7/25721?source=see_link\">",
"       \"The role of the vulnerable plaque in acute coronary syndromes\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The ischemia resulting from arterial thrombosis in the face of underlying atherosclerosis is usually less severe than that following an acute embolus. This difference is primarily due to the collateral circulation that develops over time in patients with atherosclerosis and chronically narrowed vessels. Collaterals are frequently so extensive that patients notice no change or only a mild increase in their symptoms of chronic ischemia when a major atherosclerotic vessel becomes occluded.",
"   </p>",
"   <p>",
"    Arteritides, ergotism, and hypercoagulable states can also result in arterial thrombosis, occlusion, and acute extremity ischemia. While these conditions most frequently affect the venous circulation, certain hypercoagulable states favor arterial thrombosis (eg, antiphospholipid antibodies and hyperhomocysteinemia). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/31/23034?source=see_link\">",
"     \"Clinical manifestations of the antiphospholipid syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Arterial trauma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute arterial occlusion complicating vascular or cardiac diagnostic and interventional procedures has become a more frequent cause of acute extremity ischemia. The incidence of arterial complications following interventional cardiac catheterization (including hematomas, arteriovenous fistulae, pseudoaneurysms, arterial occlusion, and cholesterol emboli) has been reported to range from 1.5 to 9 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?13/3/13368/abstract/5\">",
"     5",
"    </a>",
"    ]. Although acute arterial occlusion occurs in less than 1 percent of interventional catheterization procedures, this complication demands immediate surgical consultation [",
"    <a class=\"abstract\" href=\"UTD.htm?13/3/13368/abstract/6\">",
"     6",
"    </a>",
"    ]. Intimal flaps and dissections are frequently the cause of the occlusion, and operative repair of the vessel may be required. Thromboemboli can also develop at the sheath site or catheter tip, with embolization occurring during sheath removal. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/42/42665?source=see_link\">",
"     \"Complications of diagnostic cardiac catheterization\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Arterial injury due to extremity trauma (blunt or penetrating) can also lead to acute limb ischemia. The diagnosis and management of arterial injury in association with severe extremity injury is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/57/12186?source=see_link\">",
"     \"Severe extremity injury in the adult patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CLINICAL EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A thorough history and physical examination is the first step in the evaluation of the patient with acute extremity ischemia (",
"    <a class=\"graphic graphic_table graphicRef75112 \" href=\"UTD.htm?40/47/41723\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?13/3/13368/abstract/7\">",
"     7",
"    </a>",
"    ]. The five \"P's\" of acute ischemia or large vessels include pain, pulselessness, pallor, paresthesias, and paralysis. In addition, small vessel occlusion can cause the blue toe syndrome. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Blue toe syndrome'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pain &ndash; Pain associated with acute ischemia is usually located distally in the extremity, gradually increases in severity, and progresses proximally as the length of ischemia increases. Later, the pain may decrease in severity due to progressive ischemic sensory loss. It is essential to determine if the patient had symptoms of chronic ischemia before the acute event occurred. Patients with an embolus usually have no preexisting ischemic symptoms, and can frequently pinpoint the exact time that symptoms began. Thus, the sudden and dramatic development of ischemic symptoms in a previously asymptomatic patient is most consistent with an embolus, while gradually increasing symptoms in a patient with chronic ischemia is indicative of thrombosis.",
"     </li>",
"     <li>",
"      Pulses &ndash; The quality and character of the peripheral pulses must be evaluated. If pulses are not palpable, a hand held Doppler should be used. It is rare to have acute limb-threatening ischemia without a major pulse deficit. The status of the pulses in the contralateral extremity is also important. The presence of a pulse deficit in an asymptomatic contralateral extremity is an indication of underlying chronic arterial occlusive disease and suggests that acute thrombosis of an already diseased vessel is the most likely cause of the acute occlusion. By contrast, the presence of normal pulses in the contralateral extremity suggests the absence of chronic occlusive disease, and increases the likelihood that an embolus is the etiology of acute occlusion.",
"     </li>",
"     <li>",
"      Skin perfusion &ndash; The skin of both the normal and affected extremity should be examined for temperature, color, and capillary refill. The skin of the ischemic extremity is typically cool and pale with delayed capillary filling. The level of arterial obstruction is usually one joint above the line of demarcation between the normal and ischemic tissue. Both extremities should also be examined for signs of chronic ischemia such as atrophy of the skin, hair loss, and thickened nails.",
"     </li>",
"     <li>",
"      Neurologic examination &ndash; A careful neurologic examination must be performed. Subjective sensory deficits such as numbness or paresthesias are signs of early nerve dysfunction secondary to ischemia. Major loss of sensory or motor function is indicative of advanced ischemia. The anterior compartment of the lower leg is most sensitive to ischemia, and sensory deficits over the dorsum of the foot are often the earliest neurologic sign of vascular insufficiency.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Blue toe syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The blue toe syndrome is characterized by the sudden appearance of a cool, painful, cyanotic toe or forefoot in the often perplexing presence of strong pedal pulses and a warm foot (",
"    <a class=\"graphic graphic_picture graphicRef58761 \" href=\"UTD.htm?2/15/2289\">",
"     picture 1",
"    </a>",
"    ). There may also be scattered areas of petechiae or cyanosis of the soles of the feet. Bilateral lower extremity involvement usually indicates an embolic source that is located above the aortic bifurcation.",
"   </p>",
"   <p>",
"    The blue toe syndrome is usually due to embolic occlusion of digital arteries with atherothrombotic material from proximal arterial sources. These episodes portend similar and more severe episodes in the future. Thus, identification and eradication of the embolic source is usually indicated [",
"    <a class=\"abstract\" href=\"UTD.htm?13/3/13368/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Expeditious evaluation by angiography is required to evaluate the source; complete exclusion and bypass of the diseased segment are indicated. However, caution is advised for performing angiography in patients who have other signs suggestive of multiple atheroemboli, such as livedo reticularis, since angiography may lead to further embolization. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/15/31994?source=see_link\">",
"     \"Embolism from atherosclerotic plaque: Atheroembolism (cholesterol crystal embolism)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     CLASSIFICATION OF ACUTE LIMB ISCHEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following clinical categories of acute limb ischemia are commonly used with the essential distinguishing clinical features presented in the table (",
"    <a class=\"graphic graphic_table graphicRef75112 \" href=\"UTD.htm?40/47/41723\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?13/3/13368/abstract/7,9,10\">",
"     7,9,10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Viable &ndash; Limbs that are viable are under no immediate threat of tissue loss. There is no sensory loss or muscle weakness and both arterial and venous Doppler signals are audible",
"     </li>",
"     <li>",
"      Marginally-threatened &ndash; Limbs that are marginally-threatened are salvageable if treated promptly. There is minimal (in the toes) or no sensory loss, no muscle weakness, arterial Doppler signals are often inaudible, and venous Doppler signals are audible.",
"     </li>",
"     <li>",
"      Immediately-threatened &ndash; Immediately-threatened limbs are salvageable with emergent revascularization. Sensory loss involves more than the toes and may be associated with rest pain. There is mild to moderate muscle weakness, arterial Doppler signals are usually inaudible, and venous Doppler signals are audible.",
"     </li>",
"     <li>",
"      Irreversible (nonviable) &ndash; Limbs with irreversible ischemia have major tissue loss",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      permanent nerve damage. Sensory loss is profound, muscle weakness is profound with paralysis and possible rigor, and arterial and venous Doppler signals are inaudible. These nonviable extremities require major amputation regardless of the therapy that is instituted. Revascularization may be required to permit healing of the amputation or amputation at a lower level.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     IMAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arteriography is the diagnostic procedure that provides the most useful information in the setting of acute arterial occlusion. In addition to demonstrating detailed arterial anatomy, arteriography can usually distinguish between thrombosis and embolism.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An embolus will often demonstrate a sharp cutoff with a rounded reverse meniscus sign. The embolus may also be visible as an intraluminal filling defect if the vessel is not completely occluded. Other findings which are most consistent with an embolus include the presence of otherwise normal vessels, the absence of collateral circulation, and the presence of multiple filling defects.",
"     </li>",
"     <li>",
"      Arterial thrombosis is usually visualized as a sharp or tapered, but not rounded, cutoff on arteriography. Diffuse atherosclerosis with well developed collateral circulation is generally present.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although all patients with acute extremity ischemia would benefit from the information obtained from arteriography, it is not possible to perform this test in every case. Patients with a threatened extremity, for example, cannot tolerate the several hour delay in revascularization while arteriography is being performed. Thus, patients with a viable extremity should generally undergo diagnostic arteriography, while those with a threatened extremity should have immediate surgical revascularization with intraoperative arteriography as necessary. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Viable extremity'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H506060463\">",
"     'Threatened extremity'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the diagnosis of acute arterial occlusion has been made by history and physical examination, anticoagulation is initiated. Subsequent treatment varies depending upon the classification of acute ischemia. The options include thrombolytic therapy (with or without percutaneous intervention) or surgery.",
"   </p>",
"   <p>",
"    It is difficult to compare published results of the treatment of acute extremity ischemia because of different methods used to describe the severity of ischemia and differences in the duration of ischemia. However, it is clear that acute extremity ischemia is associated with high rates of hospital morbidity and mortality, and high rates of limb loss. Limb loss rates as high as 30 percent and hospital mortality as high as 20 percent have been quoted in surgical series [",
"    <a class=\"abstract\" href=\"UTD.htm?13/3/13368/abstract/2\">",
"     2",
"    </a>",
"    ]. Cardiopulmonary complications account for the majority of the deaths, underscoring the severity of the baseline medical condition of these patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Anticoagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the diagnosis of acute arterial occlusion has been made by history and physical examination, the 2012 American College of Chest Physicians (ACCP) guideline on antithrombotic therapy for peripheral artery occlusive disease and the 2007 TASC II consensus document on the management of PAD recommend that the patient should immediately receive an intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    bolus followed by a continuous heparin infusion [",
"    <a class=\"abstract\" href=\"UTD.htm?13/3/13368/abstract/1,11\">",
"     1,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Anticoagulation prevents further propagation of thrombus, and inhibits thrombosis distally in the arterial and venous systems due to low flow and stasis. Time is crucial; the decision to administer",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    is based upon the clinical evaluation and should not be delayed while waiting for diagnostic procedures to be performed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Viable extremity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intraarterial thrombolysis is an alternative to surgical therapy in patients with ischemic but viable extremities [",
"    <a class=\"abstract\" href=\"UTD.htm?13/3/13368/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. The usefulness of thrombolytic therapy is limited by the severity and duration of the ischemia, and the length of time required to achieve dissolution of the thrombus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Thrombolytic therapy versus surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients found to have an ischemic but viable extremity on clinical examination should undergo urgent arteriography to plan surgical or percutaneous revascularization. Several trials have demonstrates that thrombolytic therapy is a safe and effective alternative to surgery in appropriately selected patients. Although many patients treated with thrombolytic therapy will subsequently require surgical or percutaneous revascularization, the magnitude and complexity of the procedure required to revascularize the extremity is frequently less than in those not receiving prior thrombolytic therapy.",
"   </p>",
"   <p>",
"    Clinical features are useful to help determine if thrombolytic therapy (with or without percutaneous intervention), or surgical revascularization is the most appropriate treatment. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The presumed etiology (embolus versus thrombus)",
"     </li>",
"     <li>",
"      The location and length of the lesion",
"     </li>",
"     <li>",
"      The duration of symptoms",
"     </li>",
"     <li>",
"      The availability of autologous vein for bypass grafting",
"     </li>",
"     <li>",
"      The suitability of the patient for surgery",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As an example, a proximal embolus at the bifurcation of the common femoral artery is an ideal lesion for embolectomy. On the other hand, embolus to a distal vessel (eg, to the tibial artery) may be best treated with a thrombolytic agent. The major use of PTA is in the treatment of an underlying lesion after the clot has been lysed with thrombolytic therapy.",
"   </p>",
"   <p>",
"    After initial observational studies suggested efficacy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/3/13368/abstract/13,14\">",
"     13,14",
"    </a>",
"    ], randomized trials compared surgical revascularization to intraarterial thrombolytic therapy in the treatment of acute ischemic but viable lower extremities [",
"    <a class=\"abstract\" href=\"UTD.htm?13/3/13368/abstract/15-19\">",
"     15-19",
"    </a>",
"    ]. The results from the TOPAS and STILE trials illustrate the range of findings.",
"   </p>",
"   <p>",
"    A randomized, prospective, double blind study of thrombolysis or peripheral arterial surgery (TOPAS) was performed in 544 patients who had acute lower extremity ischemia for 14 days or less [",
"    <a class=\"abstract\" href=\"UTD.htm?13/3/13368/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Phase 1 of this trial compared three different doses of catheter directed recombinant urokinase (rUK) and found that a dose of 4000 international units per minute",
"    <span class=\"nowrap\">",
"     (IU/min)",
"    </span>",
"    for four hours, followed by 2000",
"    <span class=\"nowrap\">",
"     IU/min",
"    </span>",
"    for a maximum of 48 hours provided the maximum lytic efficacy at a minimal bleeding risk [",
"    <a class=\"abstract\" href=\"UTD.htm?13/3/13368/abstract/15\">",
"     15",
"    </a>",
"    ]; recanalization was achieved in 80 percent and complete lysis of thrombus in 68 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?13/3/13368/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Part 2 included 544 patients with acute arterial occlusion of less than 14 days in duration who were randomly assigned to the above rUK regimen or surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?13/3/13368/abstract/16\">",
"     16",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There was no significant difference between the groups in amputation-free survival rates at six months (72 versus 75 percent with surgery), which was the primary end point, or one year (65 versus 70 percent).",
"     </li>",
"     <li>",
"      Among patients treated with thrombolytic therapy, the amputation-free survival rates were better with bypass graft compared to native vessel occlusion.",
"     </li>",
"     <li>",
"      There was no significant difference between the groups in mortality at six months (16 versus 12 percent with surgery) or one year (20 versus 17 percent).",
"     </li>",
"     <li>",
"      Major (including intracranial) hemorrhage was more common with rUK (12.5 versus 5.5 percent, respectively).",
"     </li>",
"     <li>",
"      Among the patients who received rUK, 40 percent required subsequent surgery at six months. However, there was a reduced requirement for open surgical procedures after thrombolytic therapy at six months (315 versus 551 in those assigned to surgery).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The STILE trial consisted of 393 patients with nonembolic arterial and graft occlusion who presented with new or progressive symptoms of limb ischemia symptoms of up to six months duration [",
"    <a class=\"abstract\" href=\"UTD.htm?13/3/13368/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. The patients were randomly assigned to treatment with surgery or intraarterial catheter-directed thrombolysis with recombinant tissue plasminogen activator or urokinase. Failure of catheter placement occurred in 28 percent of patients assigned to thrombolytic therapy.",
"   </p>",
"   <p>",
"    Patients with ischemia of 14 days or less who were treated with thrombolysis had a significantly lower rate of amputation (6 versus 18 percent) and shorter hospital stays compared to the surgical group. By contrast, patients with ischemia for longer than 14 days did better with surgical revascularization with significant reductions at one year in the rates of major amputation (0 versus 10 percent with thrombolytic therapy [35 versus 65 percent]) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/3/13368/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For the patients receiving thrombolysis who subsequently required surgery, the magnitude of the surgical procedure was reduced (compared to those not receiving prior thrombolytic therapy) in 56 percent. Factors associated with a relatively poor outcome after thrombolytic therapy included femoral-popliteal occlusion, diabetes, and critical limb ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?13/3/13368/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A Cochrane review evaluated the best approach to thrombolytic therapy when this form of treatment is chosen [",
"    <a class=\"abstract\" href=\"UTD.htm?13/3/13368/abstract/20\">",
"     20",
"    </a>",
"    ]. Intraarterial rather than intravenous administration of the drug results in a better clinical outcome and reduced incidence of bleeding complications. The angiographic catheter should be placed within the thrombus for optimal results. High dose and forced infusion techniques result in more rapid thrombolysis, but may increase bleeding risk and do not appear to improve clinical outcomes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Recommendations of others",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of thrombolytic therapy is primarily limited to patients with acute limb ischemia and viable extremities. Based in part upon the observations in TOPAS and STILE, the following recommendations have been made by major society guidelines:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The 2005 American College of",
"      <span class=\"nowrap\">",
"       Cardiology/American",
"      </span>",
"      Heart Association",
"      <span class=\"nowrap\">",
"       (ACC/AHA)",
"      </span>",
"      guidelines on PAD, which were produced in collaboration with major vascular medicine, vascular surgery, and interventional radiology societies, concluded that there was general agreement that catheter-based thrombolytic therapy is effective and beneficial and is indicated in patients with acute limb ischemia of less than 14 days duration [",
"      <a class=\"abstract\" href=\"UTD.htm?13/3/13368/abstract/10\">",
"       10",
"      </a>",
"      ]. The evidence was considered less well established for patients with acute limb ischemia of more than 14 days duration.",
"      <br/>",
"      <br/>",
"      The guidelines also concluded that the weight of evidence was in factor of mechanical thromboembolectomy as adjunctive therapy of acute limb ischemia resulting from peripheral arterial occlusion.",
"     </li>",
"     <li>",
"      The 2012 American College of Chest Physicians guideline on antithrombotic therapy for peripheral artery disease suggested catheter-based thrombolytic therapy in patients with acute limb ischemia [",
"      <a class=\"abstract\" href=\"UTD.htm?13/3/13368/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H506060463\">",
"    <span class=\"h2\">",
"     Threatened extremity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with a threatened extremity should undergo emergent surgical revascularization. The majority of these patients have had an embolic event, and irreversible changes can occur within as little as four to six hours of profound ischemia. While pharmacologic thrombolysis may successfully dissolve the embolus (see below), the time required is usually too long to allow this to be an acceptable alternative to surgery.",
"   </p>",
"   <p>",
"    At surgery, an embolus will be found in the majority of patients. Embolectomy is often all that is required to relieve the occlusion and provide adequate blood flow to the extremity. Most surgeons perform an intraoperative completion arteriogram after the embolectomy to evaluate the adequacy of distal blood flow. Intraoperative thrombolytic therapy may also be used if there are small emboli in the distal runoff vessels. Depending upon the length and severity of the ischemia, a fasciotomy may be required to prevent the development of a compartment syndrome.",
"   </p>",
"   <p>",
"    The 2012 American College of Chest Physicians (ACCP) guidelines on antithrombotic therapy recommended the use of oral anticoagulation to prevent recurrent embolism after embolectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/3/13368/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Patients with nonviable extremities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with nonviable extremities should undergo prompt amputation. Arteriography is usually not necessary, since the level of amputation is determined by clinical findings and by the viability of tissues at the time of surgery. Every effort should be made to preserve as many joints as possible, in order to decrease the work of ambulating with a prosthesis and to improve the chances for successful rehabilitation. Delays in amputation of a nonviable extremity can result in infection, myoglobinuria, acute renal failure, and hyperkalemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/58/19370?source=see_link\">",
"     \"Treatment of chronic lower extremity critical limb ischemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H506059593\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute limb ischemia is a sudden decrease in limb perfusion that may threaten limb viability and is usually due to acute arterial occlusion which may be due to emboli from a proximal source, acute thrombosis of a previously patent, often atherosclerotic artery, or related to arterial trauma. Embolism accounts for the majority of cases of acute extremity ischemia. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction and definitions'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The classic physical signs of acute limb ischemia are the five \"P's&rdquo; (pain, pulselessness, pallor, paresthesias and paralysis). Subjective sensory deficits are signs of early nerve dysfunction, and major sensory or motor loss is indicative of advanced ischemia. Signs and symptoms of ischemia occur distal to the point of vascular occlusion. The blue toe syndrome, which is characterized by a cool, painful, cyanotic toe or forefoot, often with preserved pulses, is typically the result of embolic occlusion of the foot arteries but it may herald more severe, future embolic episodes. Bilateral lower extremity involvement usually indicates an embolic source that is located above the aortic bifurcation. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Clinical evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A complete examination of the extremity is performed and documented and should include classification (",
"      <a class=\"graphic graphic_table graphicRef75112 \" href=\"UTD.htm?40/47/41723\">",
"       table 2",
"      </a>",
"      ) of the degree of ischemia to assist in stratifying further diagnostic evaluation and treatment. Viable limbs are under no immediate threat of tissue loss. Marginally-threatened limbs are salvageable if treated promptly. Immediately-threatened limbs are salvageable with emergent revascularization, whereas limbs with irreversible ischemia will require major amputation regardless of any therapy that is instituted. Patients with viable or marginally-threatened limbs are usually candidates for urgent arteriography to evaluate arterial anatomy and to potentially institute thrombolytic therapy in an interventional radiology suite. In contrast, patients with an immediately-threatened extremity should preferentially undergo treatment in a surgical suite. Clinical features that help determine the appropriateness of thrombolytic therapy versus surgical revascularization include (see",
"      <a class=\"local\" href=\"#H12\">",
"       'Classification of acute limb ischemia'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Treatment'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The presumed etiology of ischemia (embolus versus thrombus)",
"     </li>",
"     <li>",
"      The location and length of the lesion",
"     </li>",
"     <li>",
"      The duration of symptoms",
"     </li>",
"     <li>",
"      The availability of autologous vein for bypass grafting",
"     </li>",
"     <li>",
"      The suitability of the patient for surgery",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Once a diagnosis of acute arterial occlusion has been made by history and physical examination, we initiate anticoagulation with a bolus of intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      followed by a continuous heparin infusion according to the recommendations of the 2012 American College of Chest Physicians (ACCP) guideline on antithrombotic therapy for peripheral artery occlusive disease and the 2007 TASC II consensus document on the management of PAD. Anticoagulation prevents propagation of thrombus in the arterial and venous systems due to low flow. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Anticoagulation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Catheter-based thrombolytic therapy is primarily reserved for patients with acute limb ischemia and a viable extremity (",
"      <a class=\"graphic graphic_table graphicRef75112 \" href=\"UTD.htm?40/47/41723\">",
"       table 2",
"      </a>",
"      ). We agree with recommendations made in major society guidelines that catheter-based thrombolytic therapy is effective and beneficial and is indicated in patients with acute limb ischemia of less than 14 days duration in those who have a low risk for developing myonecrosis and ischemic nerve damage during the time period required to achieve revascularization. Mechanical thromboembolectomy may be used as an adjunctive therapy in conjunction with pharmacologic thrombolysis. Although many patients treated with thrombolytic therapy will subsequently require surgical or percutaneous revascularization, the magnitude and complexity of the procedure required to revascularize the extremity is frequently less than in those who do not receive prior thrombolytic therapy. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Thrombolytic therapy versus surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In spite of advances in care, acute limb ischemia is associated with rates of limb loss as high as 30 percent and in-hospital mortality rates as high as 20 percent. Cardiopulmonary complications account for the majority of the deaths, underscoring the severity of the baseline medical condition of these patients. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/3/13368/abstract/1\">",
"      Norgren L, Hiatt WR, Dormandy JA, et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg 2007; 45 Suppl S:S5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/3/13368/abstract/2\">",
"      Yeager RA, Moneta GL, Taylor LM Jr, et al. Surgical management of severe acute lower extremity ischemia. J Vasc Surg 1992; 15:385.",
"     </a>",
"    </li>",
"    <li>",
"     Quinones-Baldrich, WJ. Acute arterial and graft occlusion. In: Vascular Surgery. A Comprehensive Review, Moore, WS (Ed), WB Saunders, Philadelphia 1993. p.648.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/3/13368/abstract/4\">",
"      Abbott WM, Maloney RD, McCabe CC, et al. Arterial embolism: a 44 year perspective. Am J Surg 1982; 143:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/3/13368/abstract/5\">",
"      Nasser TK, Mohler ER 3rd, Wilensky RL, Hathaway DR. Peripheral vascular complications following coronary interventional procedures. Clin Cardiol 1995; 18:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/3/13368/abstract/6\">",
"      Messina LM, Brothers TE, Wakefield TW, et al. Clinical characteristics and surgical management of vascular complications in patients undergoing cardiac catheterization: interventional versus diagnostic procedures. J Vasc Surg 1991; 13:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/3/13368/abstract/7\">",
"      Rutherford, RB. Acute limb ischemia: Clinical assessment and standards for reporting. Semin Vasc Surg 1992; 5:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/3/13368/abstract/8\">",
"      Karmody AM, Powers SR, Monaco VJ, Leather RP. \"Blue toe\" syndrome. An indication for limb salvage surgery. Arch Surg 1976; 111:1263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/3/13368/abstract/9\">",
"      Katzen BT. Clinical diagnosis and prognosis of acute limb ischemia. Rev Cardiovasc Med 2002; 3 Suppl 2:S2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/3/13368/abstract/10\">",
"      Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation 2006; 113:e463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/3/13368/abstract/11\">",
"      Alonso-Coello P, Bellmunt S, McGorrian C, et al. Antithrombotic therapy in peripheral artery disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e669S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/3/13368/abstract/12\">",
"      Riggs P, Ouriel K. Thrombolysis in the treatment of lower extremity occlusive disease. Surg Clin North Am 1995; 75:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/3/13368/abstract/13\">",
"      Huettl EA, Soulen MC. Thrombolysis of lower extremity embolic occlusions: a study of the results of the STAR Registry. Radiology 1995; 197:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/3/13368/abstract/14\">",
"      Carpenter JP, Barker CF, Roberts B, et al. Popliteal artery aneurysms: current management and outcome. J Vasc Surg 1994; 19:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/3/13368/abstract/15\">",
"      Ouriel K, Veith FJ, Sasahara AA. Thrombolysis or peripheral arterial surgery: phase I results. TOPAS Investigators. J Vasc Surg 1996; 23:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/3/13368/abstract/16\">",
"      Ouriel K, Veith FJ, Sasahara AA. A comparison of recombinant urokinase with vascular surgery as initial treatment for acute arterial occlusion of the legs. Thrombolysis or Peripheral Arterial Surgery (TOPAS) Investigators. N Engl J Med 1998; 338:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/3/13368/abstract/17\">",
"      Results of a prospective randomized trial evaluating surgery versus thrombolysis for ischemia of the lower extremity. The STILE trial. Ann Surg 1994; 220:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/3/13368/abstract/18\">",
"      Weaver FA, Comerota AJ, Youngblood M, et al. Surgical revascularization versus thrombolysis for nonembolic lower extremity native artery occlusions: results of a prospective randomized trial. The STILE Investigators. Surgery versus Thrombolysis for Ischemia of the Lower Extremity. J Vasc Surg 1996; 24:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/3/13368/abstract/19\">",
"      Ouriel K, Shortell CK, DeWeese JA, et al. A comparison of thrombolytic therapy with operative revascularization in the initial treatment of acute peripheral arterial ischemia. J Vasc Surg 1994; 19:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/3/13368/abstract/20\">",
"      Kessel DO, Berridge DC, Robertson I. Infusion techniques for peripheral arterial thrombolysis. Cochrane Database Syst Rev 2004; :CD000985.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8213 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-58.240.98.179-8913731101-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_3_13368=[""].join("\n");
var outline_f13_3_13368=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H506059593\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION AND DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Arterial emboli",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Arterial thrombosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Arterial trauma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CLINICAL EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Blue toe syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      CLASSIFICATION OF ACUTE LIMB ISCHEMIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      IMAGING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Anticoagulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Viable extremity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Thrombolytic therapy versus surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Recommendations of others",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H506060463\">",
"      Threatened extremity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Patients with nonviable extremities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H506059593\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/8213\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/8213|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?2/15/2289\" title=\"picture 1\">",
"      Blue toe syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/8213|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/0/11276\" title=\"table 1\">",
"      Causes of acute arterial occlusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/47/41723\" title=\"table 2\">",
"      Classification of acute extremity ischemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/9/14486?source=related_link\">",
"      Clinical manifestations and evaluation of chronic critical limb ischemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/31/23034?source=related_link\">",
"      Clinical manifestations of the antiphospholipid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/42/42665?source=related_link\">",
"      Complications of diagnostic cardiac catheterization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/4/12361?source=related_link\">",
"      Echocardiography in detection of intracardiac sources of embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/35/10809?source=related_link\">",
"      Embolism from aortic plaque: Thromboembolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/15/31994?source=related_link\">",
"      Embolism from atherosclerotic plaque: Atheroembolism (cholesterol crystal embolism)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/23/5497?source=related_link\">",
"      Left ventricular thrombus after acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/57/12186?source=related_link\">",
"      Severe extremity injury in the adult patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/7/25721?source=related_link\">",
"      The role of the vulnerable plaque in acute coronary syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/58/19370?source=related_link\">",
"      Treatment of chronic lower extremity critical limb ischemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_3_13369="Lichen planus penis";
var content_f13_3_13369=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F60985%7EDERM%2F76913&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F60985%7EDERM%2F76913&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Penile lichen planus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 269px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Lichen planus. Wickham's striae are visible.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Goodheart, HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Annular lichen planus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 306px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEyAbADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDz2ST0qjPKQSSaknJxiqFy21Tle3Ws+ZnXKKKV9dFsqDyfWqCAJMwYEOg3Ag8E1Dfz7GA25yelSCFJWjkclXXng81ojmkdDAuLVpCcso5561dtQr2QkcZmPQ5HA9Kybe8iClXVxg8KO49DVoSS3RdlEMSsNoQ8jHr9aCLvYp3ksUc0e75nRvlXrzSteSMSqxfNL1bGMY6VK+kysv2qG4gY78eW2M5H05qWKGf/AFU0YSJzuGP1pa9B6dR0MshhO+zkds/K+aDLeIDGIQjkfeccg+gPY1ctmWKPMxZkzhWfK/SrkMQuSFdpWDNkktwB3xmnZ2FZXMV72VplQ8Oc4LclzVhr+aCMB7Yt5gwWHJ/CrotLm382FFEykYBkQMU5yNrVGsVxP5sriJWU5CMcBqLMa5SKK8DeTGyBFUYIcHJ/xq+upwsWX/R4VC4CqDz7+1SRwy3EcKi2WNShdWikBYfUf0qrNY2720pnzDcjhQy/upBjnn1ouBZlkzGVDq82wZLADf8AX3qSN5An2aNiwA3BYflJPUEnvis61sniSB5WaPfHkP8AeU+2RUjx3FvtDyKpdCwVm4PuKBbGzb27Gx837M5453PuJJPWo1X7NcSSfZ8cfd/iz3qnZTShoyxaOJBg7XPTtWg7meYhkPUbSxIOatRuKUrDUmQOJFTBbg88/jT5H8uQMhAkVt0br6Ecqf6GqErtE3Dd84FPdy4X5yu77o681DVhN3Q66kR40nhRg/8AEuMcev1rKvCIiZVBaJj8w7n3q5cSskLDYGLgZx2xxUGAknl4xGwpFoqLL5UjKzsYW+42eR7H2qvco4uSoUKHBBJH3T2phh8u4eCRsqCMnPY9DT5zJHbyrNIm1CHilweMfwn6+tCFLVGBK7yLg/KyHGNvBq3pF48EUqQNtMjbjsX5j7buw+lVJFMczNjBZt3I6U60uDDZziKIvtlULJz8zn+AY7UxdDQhgk+3pdXaFYoocovsO5/HNaMLCadI3mCIv76UxjJJYcCq07SSaX5Ep/exRlCQMlwW3Yxjt71LZL5sKS5k8uYYhUgR5APc+tGw1qaLypbjfNNJEvA2xj52H9KRW+zyO8m5wi7lUnJQeoqJjELyW3zI77fmkIzj0+mau22nx4TzUeJRj5wxDevPqDSKH2UzOA0caMj8l5DgkY6596gmZ7o2iPuS12tMiKeNw+UZq5vMihWClD907cE46Vk3U0kFyqWojLy7lVT0Xvkj2o9Soo0pLtorwQLbh59q+YXOQo9SOxq3Mkbo0sbSfe+VQvJ/wqraWL2NudrSPLxJLM5yzs3Vie/07CrceHAg2l85dhnlDii5aQ5POwzksMsAQF+9jsaaGAnLAb92ApI5B9qnLsI1QOfM5KqOoPrTphDHDtjkf7UDlpgwKKuO3vUrc0uUdRmjjmMdrDIkwOFTO4I568mqNvYlSzS/vLnruc4Bx7Vs20CJIWkO5uinPJJ7n3prESJPFsxK53M+SSQOw+pqib9imWlhDPvDsdrlTg7vY07Zm5WNG8oFPnH3uD1wKaS961tG0Q8yJDucL8zDPGfcU+6l+eE79qqpBcenvTuFiKOSCGQ3Fq5kQkmPcvBA46fnSwqMGJm3NvyrrxyR3zVPRWSNLd3RJBGSw5IyCTW3p9k9xDLOJfLjZ/uDqR2P07VUY8xm2kRW9uracwldTtY9OoA5z9azr/zGtJJoEeSMnKYAGM1uTWptZ7u0kRGEceWUEEHcOCD+NYkSSSWklkZo4Y8lmcHsOmKp6Mm+pmNG814Y2fzI0yWYnlXA+4D6VYgctIhfPAyNx6AHt+tSCGO2s1MbK+6KRyuCRnPU+/vT7e38uG2Hms2YjlR2PXmos+oN3Iy7PPsR0IGXDk9R3qNDsJQsrhWDKaZNKIbWeaYNiPcCdvB9qcEK2i3BAHTHTgADIoEWbDzBFPsePdHksvTg0+AoFCx4Xa3IA9vWgQr9qTfklkO3BxjIyM+tRKSsTYSPg5+b3oFYrxTvcXSRyL5UxD8sBh++f6UauitBLM8LbFHy8gHI64PqDU0lrDdRLHOCTkgENnBx2PpVOQTRTLA8sbwjLKZlOAR24/CgLdjKF3e2gitZpmu4khB2yKXPzDkc8jH9KytdEbWb3FtaNC0Fwr+YPmQl16Z6jlSQDXRmG2DRS3ctzaKJ8eZZxiRgSPu4JxwayvEMljaNqNtZXFxcW19bqwe6j2MHVwcgA4zjI6UrAbE820Vk31xkNg4q1c3HJz2rC1Ccljis0dEpWKTTeZeIDnFace+KLaNxY52kisASE3Ua8kk4rqLWAhAWwx27gCeaswkO0sNHCRLHIJGHDuuea07W6JglSRmjkJ7Lz9adAJ3t2QxYjOD8x5JHpToYQ0n7+NnAxgg4I9D70xDRM6+XsjJZwctnlvwrat4hNBsCgBByScYrOgKTrKIQq3MS5cMcHjoPxrR0W8mj843FuCzjAyOn1FK/YaJhYrJbJHARJI+e+SuPalsbacQs06tJGoIDZ/pSE3UJR4UgbeT8qnaU+lSafetJDNDPtikIwNy8j0qW2Xa5s2bxi2IKICO+MGgwLcW5KWbSMgIYscDr1xWOLqVkZnYBkHPyfeA6muh0zyp0kklmYLtAEkZyGHcEe1CbWoJLcyltvsyRSR2yxiJjuYIG6nBNS3NpdXsKtApuIdpIBUA7fT3/ABrV03URaSF7SfzHXMZRlyrqR15qB8pKMfIwJbarcEH0xT5hPXoc9HaRJcOTEkMBBG1iR5Z6ZGO9MhtIWtIhkTPknzDJ/j3966WeUA7hBEfMwm5l5HvVK6t90lzANoWMbyW6Be5FO9xJFG2jDxEOvyEHcCRjPbHvUq6ak8F2cASRr5gYycjHat2Lw/OuiW94Jo3SY/fjOVIB6Y7Gq4gSFvMnVkgYYOwchj0zWqi7XE0nocqzm3BMynay4WQ8g1BNeW7QxGFmkckn5TgD8fWughtpLqBz8zYByqjrWBfW4itnEAEMZG0qBwD64qGTohu5Y9js4bjadp6/41CZY3fgPwfvdsVFnfbIxkVjtAzjH6VcskW6QQIyC5I+VDx5nsD60mgKepBRGssWGbG1h2IpkNwixOGQPE67TG/IqN3SISRysqHcVG/ufTHY1mXdwbeUwGQLvXcr54VPU+9ACNHBaXVxbyXQjtUQyxZUv8zcBMj+dT3MLWjWNtsaKRCJxg/xH+L8OlZd9FE99b280kvksiyM2NrFRyT+QrTs5ZL+/aeVfnuRiEdMp0AHv6igC8ZkW1lLBhKEwzg5B/H1qTzDdxW0EmxjKodmByyLxgA+tS3SiLS7I3ERbzrgpEit/rGxj9Kj0Hdb6VLPdHMkEjIobqwHTA9BTY1Yt6dGyrMzkzR7yAR12jiti7dprdRJMWkKgR7uM47flVLSYmhtUilDZdi4LnP3uSP1qzGom82Od+Yh8sI6y5P8hQUR3FyyuHtlVcHA4yRmq9xZeVHLcSIzzhgxccfWtGO3HmmMkZC42IPlQjtzV+WxJtY5HmcuRtMeeNhFFrlx7lc3BFi0ML4X5X4TP5n+lRTpGJZGZirMu5ZCOvscVX05JnS6iQDMLbHG7qOxNSXLbrYxwMRIg5cLnipL06EsbSRl5IJRGyrtMink8fc/GliMMUZDKysFzkchwfWnokcsDBEA3KuQTyRWjpFql5qOnW+4xLJIikkdSTz+lVFXHfqVIp0d9xZMoMqwXriq08uMRr/qWYEkDoe/HbFdX8QtCttLctZRPHIJnjk3/KRgZziuV85kuHlkzIZEG7BGN3aiceUSakrooWU6T2C3ClmuA5BULj5QepNN1Rd8TQ2aPtkUhyoz5eetVNDJOjQcr5zNJ37buM1oiPyRuiLhmQ+Z2BPbikFxbbfbwQlTt8tDCEK/eXpmt/R76IpFbxkqyxOhk4OQB0welc+rXCx2rTFzCuQMHBO7tmreww8vImVGCSpBBGcj3q4StczlFMjdVhkVSTLKV3j5sZPpk1m6lHO8uCYlG3DYA69quTJIZw7rwqbgVHGDUU7s+JJG2uMJgD73PX6+1Ju4Wsw+Z5ANwUmIR7V4HHJz6U/Z5xglQoDh1YHAAwOtJI0yxIBu3InmEr1XJ/liqNw8lwjRIrI4lTjHr1J9abJ3RSuyLy8ktUI+yLiVgP7y4rRbyzEpPzIF2j5cc/SmLDHBJPGXYhnBZlGCasBsRE7y3cA84xUpMfSxE+T9mMIYk/KzZ5yDxRe4N/JEgI2qHwegPNBR9kJAZolOW/2c9zVp4l89JCrATJjPXnpQSQ24EjAxM25o0dRs4681n3l1Ml9IsNtNMsaFt20YHqatQ+YJG3ORgsiY/hyOKyvLjl8pXVhcTxiNnd85bOScDt1oAqyWX2i9TOYxuDEQybsMRwQehNZPiaJ4rW3+1OsisDs3Lt2kHBziusEYiuYwyqqBcDHoOMn+dYutskiI6kSRQRuF39HPdfxoEV7lid2T+VYl9IFBJPNacsoGecn0xVFrVZ2y+SPSs0aSdyDQIDcTPNgMQcLntXYaZbxxlWmlPKbRntWPpdsolVEIj545rejDQJGjqHdif4eMe1UQa0RtZbQh5SkiqeR3NRNI6iaRvKM0pVAu3GBUNxD9niimgCusoyydDnNPkheR2mAaCZe2chqB2uNtNPW6vVkmZ42ztZ0HT6+1WZCzSthhJKAQJF53AdB9avWQuJtPkUho3OGBj7mnW2m4iFxdL5bMwUIBzj1NJIRVsrgXFlKqvIkgOTE8XPvUGp2rCwF1byyK+/JVgMEf06Vr3unO9wHgkUovykL1I+tPmhZrE20giHOQ2MEn+tO1wV3sVovtV1a7Y8ElMdOF6elNe5vNPVI1MEbO7ABRhSCOTV62heFV8s7RwCFJ5qB4o47sTTu8ycjyWHBJ96TXQtKVyaJYnWIyzMhX5/lHt0rTtWjXZcOvnxHlcgiseWGeWzEIGUHIDcH8DWzo0VvqNo9pPdJBfKC8CysVDj+5nsT2PSkoDu0i3qFpay6Sl1DNF5jsVktgxLIOzeh/CsdoAkDIzkrIvHzdq0LwJHbRWyK8ZOC29cNuHUHH5e/WtTVbvTtSs4lQWlnqEDeWkS5XzExnOD15zVJa6kvyOetrW4XTZJG1B40UhDbq3BB71dSado47TyYdoG9JVbJce49qypmeWVktY8scYQtzj6Gq7SNbOJWlzIT8o5wp960U7CcNDqNJhjXWVjDRmCRCTvJGWrlfEgWF71WdVU8BB0681rW0zTWMTl1Xywc7R1JPHNUNcsllsXEZMkg5L49e9W2pLQy5e5yMqljbTkllXHmIeMr9amYAxSiNFxOMY2gH8D1pdsZj8uPJ8oeWQ/3jjqaqswhnlibIDfMgbqD3+lZMaK2szzXUFvPId8iTAu23JbHGD+FYTXcUheQBZlST7g5yuemPStm6cDdgMCVDcE8+pqpcQrdCeG18tGliA3HAyQeST2pDvYq3Vzc6lqBmu1QecgiVI+Nij0/D0rdsbZLzd5p/0dDnIfaYwO4PY1izXrXcscEQEdhB+7jGerkYZh7GtSG3JEMcSGQ4JIH90cZxQMS6u1NuftrPJhwYriNTgAHuOgz3rbiH2jbgRANIHZIzvBJHVj/So3vSheJbZpAyeXtXDA8c5xxU3h/QkntpblIEib7o3ylSSO2BRq2NIuzzJbW80shjBjbeoZsbvYCnoWvpIJhF5NoW3gj5ZCR/TP51UtbS1W6V72JN+4qsbDKs3t61ru7gMZioiwQcAbiT6elFyktR15I9uZA8nm7xuBHVc9//AK1R2VzsLYcAYAZyckDvx2pkheaGGOFvMkzt2lMtj196VVWATxhlCucjauBIe+PWpcmapJLUz0eNtcu5I/MVCoJyeGPpxWnsMSiSIeXJ90qvRh6VRZFttbttpVonQpk8DPv75rUhDSPJuDRSHBAP5dfWhDS1uCwpNaI6kKfvBv7pHapbefyxGw8yK4gO9WUZyexzUXkqol2kgKfu9PrSK7xzT+XG43qAkb9yfei9irI3Nb1fUddu7dr9xJIoOfmwGGOWPqa43WLxbe1MqqxkIMUCY5LE4HT86tTySyrHEZp4Y5DuwGAUHOME9ajsdLT7dKzk+ZnduALDA/pVN8xn8OwfZFtrdLeR0MsaLuwchhjgj9alkJ+0IY4VyiKCM/e46/WnlAkm7zDtUFh8vAA7e9LvfyQ6lsbN7lgMOfbFNAokd/OsrOiBvJ3IVVhnbzyQfrT7uF0URr0ycq3OT9aqXREZAAL/ACj7q5yO9W42maKNsIqcqEHVlI7e9KPUTRFNHGDG24hygU5OOewpNjSIZVAOxguc+p54pkswa28orjyCDkg7s+lWpFEdjFHERnkse5brz/KnEGRmZo7tmjWRhLG8bcAgr+HTpS6Da7bm9Yv50rRmXJHAVem339qp3B8qDz4CwZWGRnHHqKsypELMhhtSToEO7OD1zTuYsrWro1zMJQROPnVOzKc881aRM6dJH5uGQYYkDn1x7VS1KN4rYXcS5mhfcAOSyjqMemM1PYpHMGXcCXUlCxxkdeD0pJltFeVWiszKdpIXDSBsjAPHFXL+KO1tba7ZmYTOGLg8bScDHpTLSDNrdHy84+ZU9j/9fioruWa50+GITGGS3QINnUAnI9qHqK1yrBexw5kaOR/LkLDKFQWHXOevHPFQwW7ssNwET7QSXAA6ZJ+Ue2Pxq/Yq+6Y3DtPKxLAyfNj6enUUXY8iFjtcBHBIKlTihiKF6CE81cjaoOD2GcEVk3ytJLbQKUCmfJJGDgitlVaWG5ZZfmEa7g/VueRWRq0kUlpaXCyFbkTAEkYG31AoE9Chf2hVyyjjNQqAkOQvPeuivINynK5+tYsdqZLgxDhV+YkelZmjQaW9ulxNHPIVYEOnBwfxrs7r7LFDazRvFJHIgZGU5IPcGqNu8NvaxuiBxkB0wMkVZj/eP5cEIESHcBszjPvWiizO5NcW832RblofL3NhC4wG9qI72KExTGJ1GMSRt8xRvUVajkmZIo3JjRFzlkzj8Kgk1EbWBEczSAggxD9KfICbvsX7fWrF5WkLiQt8xMQ+72wR2qe815bix8hLedRIw3EIOPxqpoyiw0yZYLe3ilkOT2b1/nSW93OuWkhVo9uCVOCPwoUGMt28qtbgrE4k3bRuBBrX0fTH1C6SSdlRfukMeBXPvqUc6rItqUlibiRScsMdxWvpNy11pMyogeKYlsnIKj+lXGKT1Li0kdXq/g63t7K52ytHJERuVG5CkfeHqKzf7GtrXzIPLDfLkbx0Pqajillt0jSW5ZkIx/rM8HtUk2recsJkVZERjuKff5459elaWW5mpy7kU2nMYUaVMRspZSp649qx7qBpI402hZVPyS7eRnoM+ldPb3FhKCb66dFVSQqry3tx60muR2cM9i8F0t7a3EXmOtt/yzPTac9SPSoqJdDSDdrM4Nbq6TUYoL12EQ9Djc3TrXS6rouqTw2/2e3hIcfIRIrsB+FOu9Otp4gNyNDMxVVkxv8AqRVGbRzYxGBZWtmX5Q6knFYRa2YnuY2oaTdpcxnIR48ghs/oaz2E88gguXChMFgx9OtdGPtUCtDdSJNwBFuzh/x7Gs64cxzbZkEasQAccZ/pTsmJtlizjkSJztKNKQVdjkFQew7Vekl8uRTGy8jDZ4zWfZXF1ElxdeSNsBCqF5P1qFJWuHuJNvmMwBOONgqo6Mm1yhLbp9q87ywTI+Bluvpz9aXXtKc2ouU6A8nOdpqRTK86qUYsJhghcqMd63b2VJ/MsVaPfngleB3rZKMjKpJwseaqwdwJQ0fzMCx9cdqzJi0ELxknc+Y1IA57k8+1bOtwCHU44xueEMZDt5AYDGR+dc1eq0d8XEjbZRhgw+Y9vxrB6Fx11JrdCzQRsAecvsHQe/1NdRaRSR2jXKz+TLJ+72AfMsXue2fSsi3D2dvKpVBc3GxFcdUjU5P5mteHdHGU6ljg57mpKsTW1qsixogZWVtwZDzkc9a2IEBWOSOUNG43DnvnkfWs+BWW0XhfNzxk9CPatWzcW7IwiQRSscEDhCByPxqkOzKV1bszxTQxGQ27s7Ix+bkdR7cVIupWjzvA8jRjy2ZVk6qfTNWbp0RfNZVQsCASec+n0rLnMc0TNNCscZGx2Ay5zx8oqNjRO6NVbiOzhi2SxS3kyYBRgSq9cH3qNZI5Eje4uI1eM5SNnAMee4qiLEXKnyQiNKVypgViGUcfp1qyLCcjzYpLWMuMAfZeGPvSSGTXN1Bvhy8UrAjO1uPpU8Nwu4K0iybRuGX+8Omaz7uK+iUJcRWRAkVQAu3P0pL0ARSyPom0qFhUxOCAe5pvcpXNWN1IkdShCMoKnJz34p8cqSSukx8onMke05IYdB/Ws228u5khWDTroTP8m1XBLvkAcZ6c0yNE+2TRzWskckcpUlshVK8HBzz0psb1Lx3YmBbzZWwCc5H/AOupoHksrRXkdvIfcgMbc7T2xUMjJ57yyiNfm8wAA8+lQxmKZ5iWYncNkTEjIJ7UxcrZYVJkjBiJTYjZct95cfLxSQosBInYiApnA5+buKekhtoy7NuCuFMWdwODyM+nFNcr9pjL+QtvKWm3ytgAHqPwo2DUhuOFCzxOhRQdxUAc85+nNHlYKJEFbIUqzDBVq0SYo9NzC0rG4Xy5vNXOB/CV9sCsiS4lvTZ2szJ9pl3IHRMAY5ycegFD0EmRwfvpPPkzmSZgrHnJFWvLQRb5ckqxGF7HPFVrVIlhwgzFCMOQcck/ez71a83yo5I4mCK7DeSOAOwpoCpfPH5cP7pfJYFZg3JXPSpLGJzGlvEj/MN6kDgY6morgGeGOIxjzJHMe5OPlHOfrU+nzssSmN38wRmNSWwSD978xQTyjwWjDxKv73lZOmMH0qOyjjt7WaHa2wHuMgH2qOzCpMyybkB4JA5BAxmpSY0na3K+YJYwOWwN3r9aLdRN2I0kKXkhjIMjoM5ORt+nrUcSGWafOGbZuIzgn86hulmXUFgt3kQlcOd38HB6+uavMYbqIysTFP5btgHqQelAupVgtZPsk/ksflbKkHBx1NWtQnS6F7Ok0uS4G2U5ONozj2yKq2wjWWQo22VDhVz1BHepFMPl3UMqskqhirBuAQeh9sUPQkzonc+YMKPPAXk42isy9hZrWBWyCCyc44960WHmRjaMq7qOTx+NVtZZ0sLR4Uzcmbyiu3gdiPfPFDE9zVulVFIYkt/dA5z6VQXT/L3zkOWYfdyKvaPE1zJJcTuVcgBVzwPamuFM7cg9QM01BLUpu4+3tME7iN/BwR0+ta1vA8shtrfLFMtIV6fj61FAm6MxxIQNq72K1sabI1jAXtpGSe4UpleGC9wfY1rEkybyL5UGCWxgkk4/CpLGyigthcOC0jNkHrtx7Ul6GmvViQ5XblT/ADrXOYLXy40GSMhsciqS1KeiM2ZmkZpULGVznk4x71SdJMBSykkE9a0W3iJg7MS52gEfrUdvCTtkHCkdD3qrEp6GXLGVf7wRgO3epNPlubacC1maMPw65+VquXttI8OQGKKc9AAM1VtoY1LjHz43Erz+VRKOpa1Rdk1O6kcrMAcjAUKAfSpre6njB8pHQryWJFQWduXdZUWTYg2jdyTnvWvbWqG3kM0oR1O5Tj5WHpntVJGdrClYpsS3DpvIwY+nPrUOy4DkwxNEp+YE5AP4elWILqCKWN5YVmhAxtK9/UUlrdmW5EDykoMlEJyevQVEo3L55JCvY3ZuLVpp4obaRWxM6k5IHT2ot7LVQLK6DwTW9w5A3HIGGx8w61ZcRBpAkrxj7xUnPP07VLZmawKGGYQTGQOkmcY4/XvxUqmhKpcq39lcWV5NDdISd7AGFgVVx1x2qvsaYlJFilLtgqR1Pp7Vpi6CQSnes2x8vnjB6cUyQxnwvKlpaqXWYfvM/OX68HsMVSpoG7nN30SwRxSQlxKrGORM43D0/Cqk11HDIWjVsbdrKDjJrau0dVZ1O6ZiCydj2Jqve6bus/NdZBJJgqf4nHTj1pOPVE3SMYSqtoVt1PmOCec/MfXNMC/ZtLurppC0qqpARuPerccVxAkcMrIwYHZggnryKx5YpJLSWBCEkIddmOMY6mpi3F6ilqUbiT/jzNxkJKHY/N0GOKotpunpPpsiCaR41d51Z8gnqCKj1Nt1vp6rIQmHBKgDoKoi5WS0uDFMPtIZU+YckHg4+lZt33CKLVoY5jeSySt5h2+UAuQ3POa2YJHGWCkSBlIUnisvT7c+QqqwjCtueQnOBnBrasoFu78tJcL9m8piXIIEm3oD6Z6cUIotwxhmkuF42ttEfGWJ7g/Wrj3kdnYohQeeHJCDqx7n6VRgEsl9bXs0IS2nLiOJGBCAHAwOwq/cAJEbqZ0Yg+WiKOQDTvoMrxxSyMHuNjuW6D7qewp7It1fW0LvsEasXyMrnPyk+oq5ocK3V4sUrhET5XYfTg4qaVY4rgj/AICHx27Z/GnyaXKv0IUeMlZo3VZF4YdNx74qxHOExEyyCPO8OOQB3zSTIG3o6o4AyRnv7VnzSIttcRwvIyfwxl8lCeoPrUaoq1yzcyhCD5imPduIxkH0+lMaV/LCTmSLcu4k/cJqLT43udOWaD5kEZaVFGdu3gkitFB5cgEx3pGgKgfMpz6ipSuXsN02Y2r21420yRTKNyqQRjkD86J5ZmmupZIiyuGLuF6E84x+NRbfLD4Z4MSLKUJPQjH3amtZGWRvPVHiOcsGwpx659qdwS6lGz2u4EiPJEi8IzYJ9waneEyQ2wj8tpA7ODjnAP3ajt4Xa0W5EoEUrEgIeQP6Zq+6hbtldESZEVlYNuJGOQB65qo2G9StcO7ECFi0ewyMAACjHqKpSLhZcRqIJFZWZxnYT7irbGF4l85HhkMbFZEBIdsdQemOenaq0JzbhDJ5jO+zy8EEE0NAmaUUqyyJBjzY4kVFlU5woHzHFZWnXM8Wq3OqQRptVTDDmHKhTwTj1IzUV15q3RsgvJCiVlOMLntjrmtbY8cc9om3yQU8uMN907hjmktWTaxTW33afMV3BGmPmr0B7jj2pPPkaCb7PsaJhtyU4Zvareou1zJNHcSFQ8paRQNpJ6cetVZ4BEyBI5YFUHZuOV6dadhMcIFgeCRiwVCCRn86bn/RlWJk8tyysuMkDtz6ilnnlYQSStgsmCR6E4xSzBEJiUnehIwxPLn0psEM3hZmkbIBXGQOSelVodsjvdMrjEvyqeflHBApzgKnlvvDk9CeDzT4Y45rQRxk7d7KGUkbGzzS3JGQNJNd5nO7KPGDtwSB0PHoKSWSVLvyJSuXbf8AdBXgdB9amfe15EJZiqb/AJO3OMc1XvZN0kMUaBpHl+cPztI4yD7+lC2AdMhN5DIirukZl2gepq1p8Im1sW0hMZnLW7GTBUMVx6+veolZm06a3uFjV45UdMnkg9f8aoSvLbQmblZraZZo2PKsA2c0EEbjyJIo5MABtjcnIIHX9DUsFubi6jt22gzXMdxbYfarTR8lfTJUng4zVjxekcfiDUQjxeX5olTaMAF1VuB/wI1nTTrarFIRk204vzzjdsU5XPbPSmxM2rZBFp7KqhixHzHqPpUEce6Zw5Xbxknj9aWzlQja7Hr061DqJMVy/kOXhHyoWG3I9/8APatZbBZo15Zvs8skbuVBIVyDuGO2KltLjdJA8+CIzscLxlfWufe45AK7SUGGzyrdKnurx2lXCFmfnevO7HaknYGXrxgs8HlgdThwevPFa1sxAiyCSQckniuTvZhG0WxvvLuKjse4q7pOomQ7JCAFIB+boO2KcJluN4m/I3llVkdDtQkLnOc8UlrGrJkyZWOJiQO5HemGRyqSxKNqA43Yx+P1qb7T5USkwqrNuwUXjJGMH2rUzSK8MCtaS7ASSjZaRyNox+VS6Dpktx5geNgEhVhxzj+oq35mbOb93IEKAcLxsxjj1Oa6jS50jt47W+kVJkjUxTAjDYHC/jn9KaBy5SuNCa0aLNuyCEKSuOY93Rj7ZqHV7JreR7WYwuQPOkVG/AnHbmt6+8Z2VlY3saxL9skgSAC4IY792Sc46cVzcup2+r6rLJJapBatFteO3b7zdS3PvipcraBFS3ZnGy81FQgo4QyjY2RisXfNvkaBFLQn5wTgmu8Op2sl5Pe6jbIzSwRwh0favmKeXYAdSBjiqs2l6dq/iK9j09GjxGrQh12mR2z8vP0pJ3NlO5y6SCaHeHPm5x5Z/wAabJclkJkTcuQCScYq7Y2oE0yNGyMMgo45U1hagSl3LGyHZnAxxk1bjoZNLm0NyyurOVSkk+1jwARnJ9KtSXUccO2J1BhOW4xkkdD6iuJQb5eDkryat297b+a3m5G7jPPXHcVCE2aq6gxZLeFGZslmkPRRikW5kuIfLhJkWMEglR61Uu3ktLbFuspHUKxxk9vwqS1b7Dp7i4Ur5gy2zkg+1CdiXrqLLEbWyVUBdHchX46+1cjq+qGOzQNgO8jxO6rlkHr71089wI4DJJuMQBfAPTjr9a5OG2ju9CjbKPJPK024j5kXP+A/Ws6u5SMu9WF9NiFpJtTcQrMeV9ePfrWfZwr/AGfGbYbcXTDzDyz4A4p2q2cw2Bpom6ZOOSvv71JpzeTbW8DRAQoDKxzg8/p0FZMZradAUuZJrZYyioVkDfMOf4vrVnKCJ0WUkIPvY4cDqc+tMiES2uno0QjkuGa63s+NsKn5eOpyfXiprJmeyVcH/SpGkyyfdQ9qQLzNHy0VVhkYhl2/KD/Djg1MWlt53+2ESRPgKyDJBHTNV4DBB57RcxvtxkdOMflWlZ3Uar1Tzo8AK3FMpprYrToYLlXtptqzIG3bud1akcs32JivlO8o2NuOSnPWs28hsJDJbkr5yN8rqMB88kim2OY72VjD5cUIjhmKnIYHJJA9wf0pp9Bo0ElYTSKCPN6lGIG76Go5ZdrQ7kxI5DBQAR+dWZbS3dkSNsKpwshOMrUO4QgxKUAwU2qvQeufepZqkrFTT5l06+1GMu6tMhCqmVHzsAwJq8xS2UQxgRxF/LLk5I9PwrGurkvdosZVktzukycb174PqK0NQeM3cMCbtkpAeRVzhcc4H5c1KdgtcktpJbm4kv5i8i8xrITnJUf4VDdzm5hksoVVkU72YMAQO/X8OKVZ2hsTa27AQK+4nbzGCMfrTmVY28m3ZdjHzYXKgseMc+3FPRjsW4VgQSf88mC7AzYAP909qoyqInVTI2wMQpOSEOeme9STyiKBhCrN5gHmoe7A9qZbLsklku4DMiAEox3BWPrTvYEiwqQmzJuXlABKqFzgZznj1qi8kpKJGuJIzvMm3qOg/GpYiLixIiXy7ZZsYx8yt6fSrkNusKBisTKkigo3JIzz0pN32BK2rI204W9gtxCSzwYeTghiD1+uOtTzNDJa2saHMvn7zL0B7nj06VJeH7PqGdxVyGYpnKkEYqjp0sSI0DcKkZCFh3JHFCdmJiPI9zOkjDDgnac0y+YzOG27SFxktlSa07YMsu63VJFC58rI3YOckCs24kEnPCDeSAOMgDvmruJ2Yy4uEhhhEkG0bcjA7A9akugwdJmyVlJ5z1JHTPrUJleVcOxZQBt/wFMuJWLwx73eFP3rKG4B/wDrUMlj7FC88yk4VI+Sw5x2pkSxmRUPmZ3BsZwOnX86tFld5HdyokjyDj+Ic/kaz5QyXDtI4K42H60r2ET6u7reW0b4Vgy8qMnIGaqSw+bepNI2E3jIB/Wp9UaQXsGxw4jX7+cLuI4zUVw7J9pRgu5VAcqMnJA6e1BLJCp81gdzRk4D4B4NVL8GS3DfMZAjIyhscdAD6D3q4kiozNIDHEuCOc8Yqi8avDM0jgMcKhxjdnk59qYjW8VO99qEzoZNqQ2xJljVSQIlHT0461zeuu/2VydhkdRHgejf/WBrflado5ZpC8zi0hSQs3C9gPXH+Fcx4guXk+2RzxpstmLcIA7OcADPoMH86lgzWt3KzBFbLYBB/ve9azL/AGhZttQMWDAjGcnrn2rndwARo2345U5zkDj862dLk2XW1i6q3OOhORW3SwlqihJtbzEVAG2h1GPmG0/NxV6B0eyIfcZoXymB8pQjr7Go76BiUeEhXVyp3HkZpsTsCvlnYSm0Ky4BYdvyqGBNcxkW4UBCkcm4L6Fh2qoUFveL5ZZkYY+YfjV9ImlguRkkRgPheuB3/CqkyATIWBwVB6dAalOzLhua9teI9skT7Qhb58Z+atEvGbH7THAERJf9WxyenFYdvbNK7COMvIEJCpkE49vXFP8AMcwolsQoK5LOchiOldCnoHJ7x2mhTQSyKLieSFJ4y4JXKjdxg/lVCa4W3hFvauhErFVduhwf0rItbyZNLWJpQZAcKx4CjOcN+vNWJfKutX8xbeSOzCrvTeXTdt5IIHFJ1NAVOz1I7a2mvZEkuRGN7FSd2VyD1zXQWcMUMbzAAbcBAO4zyMelR2cZaKDKoIo12pz+pqzd25EoikkQ4AUsjfKAec1mpX3FKd9B6Az7v3WxixIBGR/+qpbqaNZbWZppS82VkjUHgA8D6enpWdIwePAY5jQsXBwyr3FLJFKsdqyy7EYFc53Mo6ZNOMhpGqIrdbxLlVaRHYo8ecFhXN+M7RVkiyioqAMUU5I57mt0pbwQLGZnlCDLAHn8D2z+nSszVlW7VikIt4GwBEjFsfUnk11PYzt71zkI0bccgKSNyup6UwLvywZgyHOeK2TbLEJWAAUAFUTJJ7E1jKWS5JAyu3ac/wB3NQ0Nq5al1NZwRJGzBMBpXH6CnQXqThPIJCKOcLVaBkhl3yw+cmCro2Rz61OpgMSeVEyowJMhYAM2f8Ki9mRZFHxTdkW5t45HEsp8pMD73r+lNumtNPsoklKkpA0oJXoAOAarKklzfG5kCCEZWPqQF9RTb8tcea8YRgiF3LLwQOigVjJ3Y3ZKxz2srDd3unWMce0XJjMrDqoJ7e+KZdfZDPNFZrIto9w2C7fMEB2jt6c0x2kPiW0a6k/1bRyO6nB25AIH0zT9TMdveTeTHtIZlCZ98CpZSLNgDO88ys20YijVxjKqcAVu3kpthIWUqYztKZ7DtWLBE0Nnbpli+4KzDkDPOCa6DUAHj+1ELGGIYqnIHr/LmjoPcAVWBpAoVVVVXHqf51r6TaI+orb/ALuaWVQ5mzyOOn0rFNycWk9pO6mSaVHVBgtHtA57EcnNbmg2/kXru6ghMBiDg46Aj+dVBXYN6F6/sYZkihLKsu4Djrj2rKs4g0t3dpGBcLcbFGdwkA4wf1rauo/Pl87MaGPPHXOPT61mPpTC7UWlzdEXcxmdYXG0nHKkH7v1+tXKGoRZFezSPK39mKwjVsXDDlV/2c+p/pV3/XLE8Z3KOM7c8kcj2pt1bPp+lPatFs8qTeFTgSHsWPc0kxa0C7Aqs0IZkLZXOO2OM1m42Nou5RTT1kMxuI/KjkJCspxt/wBrmlsCHcyM++5VthAO1MDjj0rWt9Nnu7H7RBuMSsIidwOGbsagvdOuYDIhh2TxEh06Dil7Nl8yZXiZgZZI5CjDls/MM54GKghMkku1FXeT/FxjPVeP0p2PMWKZZMhAQAwGVz2z/jTIHNsqyKHW5VvNjdW9OOR6VKsDJGjijnO0iY5I5bAb3FSxOsNsrKPn5MitwSc5GPXFV5R5SxOsoaUguMj+I9Rip5blxHJO2QqFVMhOA4xgL65poYk+3akcJMTODLIGXgH0B7VKkkcZgfLeY7ESRkcNnnrUACLtIVZCr5YZyOnGfalaAvdpDIhSKRgMsT8vrg9qlILiTz/apyNowoO0M2CoHbPenmBpkbOPNQjdHnHNIsVuVSRlPlIx2lvmJwePrjirM8wkuGmiG75vnTuw/vCqsQy3pAe0v7Ylfu8EydVGO3tVSV1gWRpfnifO3AHGat6fcCeZFXjAIUk8msqJ1kmyz4gLnJIzyO1Miz6kUX3YJPtCADnbg/Ic80NFJI0siMT5jFnIHY0RIqzMQ4Co+4IwyCaUS/LJOhG0vtGDgD6Ci4C3Eu6yRU2DZx26e1VQ0U32qeaNnB4AHXgY61PM9uZrWS+h/d74/OK/e8vPPH0qLUliVr2O0d3azkaIuCAsi5+Qr6jBGfepe4kNvrO6/sSK9Mbra3E3lZDDG9AOPWor4bNVHAMc0JBIydw/xrQvNS3eFhpjoXWO6S8R92CrFdrrj9azpi3lTylHG3mNTyWz2H4VWwhRkhSkecdSRwB06VDbo0eEMhdwG4UdOamuAI7AmMqxcqgG87mzTdQ3QQlxvw6kDyzySP4c/XtTJLl3IUgiaZdkFy8ChwcIyR4znjnBOTz2rlNbAj/tAQTNNCs7FiPmEgYnGD7CtbWUmtYotPnVJZLcCE+UcAM3zHIJPPPOPSsW7CRxqgBcICGjHUe/vSEw8LzpqJhtZmVHUOvHBZvT8a2bO4XyYJAzt5Z2sWGTwfT1FcNFK9vcJdwk5BG8Zxj0Ndrp0zXFo93APLUv+8XZ8o9TVxYtmbusQkWzlWDeZhyV5BPas9JZBauwwxV1LJjjHY/zqaKRQjwuGQupCkDPT3FQWi+c/lOxw6kFsc/jUyGadukaXgQkeU/ykx9s9PbAqvOgRCB/yxZkZSDkr7GpbWRltoJEYiVPkceq9j71Yuo8XZdMypOwOGXBBI5P51JUdwti7S5tWIITjLc4+tXLaAJbyApA4cgCQg74+nbt9aqLby2MmJkyYkJLLzuHrVu0IeQ+ZIyFWznGMgj1o5mU9xfsMQlJLMSRtKSZIyOpzWxZFhaGN9sS8NvUdMdPpVUxCR5GtVC5XPlyHac98VZgjmcTQsEKqeQ45wO1MG9NS7FIZZGkdHCr8yMqj5j2z7VM1thMSKSzPliOB70KrmUhIxHHgAqGP6VYhK7PLKszZJLNwRTMn5FR7WB7ecb2U/dVVXIIzzk1UvbQW8BaNw6BfuoTlT6GtWWYSNngZ+XZ3P4UslsjbnVG83cEzn5W/D1oKi7bmLZSKcAMWQKNxbrmrsjRyqBgPnuMjHr+NVp9OlNwY1t2diwyuDlce1VImeea3jkkmeRyY9ipjYAe9bwqX0ZpJJ6osNYCSR2t8rGRgseQP/r1gahaR28zpGJGVFU72PUk811z6hEpgt8LHFENuVGSfU/WoBpkbCe/LsIuUUDq7djitDG7TOOETMcYXkhecjr0NUtQ09SEVmKlCS6LxvHoK6CaGRrZ3ZHyZwFYHtjnj9ak1CGECVV3PJE7KWxwykZFTJX0Gzl4YfOCYWRI9oCj7vGe9TauY2jkW3UomzcFAyT2/rRcFrS3juERpI1bayp1zinp/pGlzS3EmZJ1zheCo6AfUVg462JaPO4UabUGiSZJV3b/ADHwoBB5BJ7CtW6hjn16/ghlEsUD7w6jAYcHis+OV7hrm4uEZyiSW4cKAx4xk+v1xXQvaortIoCC6ghmieMggYjwVPoeOaz6jXYgnjItpPs/zCQ7wC3AYHg4qzDeNLFFFdL5ZRWLhT396WOKd1soJdiPL+8WbqJUA42/jxnpULy/c81T5oH7whRgnPU/WmUjQmLi3WSPe32aIbVUYA3Hk/yrptHnlg3KVzvRd28bu2c1x2nzsBcSyg4kbhSegxwK3dM1iKGzKuN8qsPmz0HpV09wkro3ZQjyxM5wgb593HX0quEMWoW6W8gbDsI9/Q8etNuQWtknRFZSem7gn2+lXpIoYYDDOWi1ABZrd2bgr3+tbiKO2/vZ2tJP3kRZmcbScVmySTeYomVUdP3bKvOcdxWrBdwxFZpZpI5cOgZPmfPv6isry5HtpJYsPJG+XV3xvXHpWM0zWMja0meT7JsibZGrhhkgfN/WtLxFcPFp9vKUV7hJNzSqPx5rnNPeKzzJJgecoYIBkIw6Umo3Yu7gyLgxgDkcfXiqU1y6icbyIboW/mpsmKxzESHtk+pHrTZFKzl1ZlQnCsT19aoWc323VFRG2RWqszjghuen4VqzIbcRyEuYnPyuB2Nc6jd3NvUhR2aJGwroTz+PX8ao/apXlKkMRCAuYhvBbt+H61pTxFbdlhPA/eA91P096rWWA0ZEDhic7IzjcaQ7k1vdI8EaKG3liSrpt596mguWC3Cyo+0lVbBwwH92ozc71W4JzKpJKuM8f/Wp86+VLvLCQOFkU47kcgiqIElY204jkYLGAXTcMkr6cdaiCeXLhZEJzuUIedpoidQsguAxQ/dA/gPr9KijMYdpFkUSrwu48PntQM07V40e3aVFYqrEMvUnkciqFlI0XlPIrFF5OBkMM9TUhmhd7h5CySeV5aAcYY4zTreU21tKsbYErc7x90e1F9SJDL9RbT3DJwZXHkqoJxu5zRPGNsASMtMp+fkAH3HvVGZzLfFvvLD8qseQSeuPSrCMqC5klTcDHsiY5+Vic5ponYpnbe3UzOQqxRkAkEHIHHWieWWaTZcHLIYxjocHHJ+lSbAUcOrKONvPBP1qvrP7qCKXLLsYJJt5yp7/AIUmNbFmRF2tcSkhQWVGzww9we1NCukTMGMh+RQRyDnt+AqrcBpJreON/NtznAPJx2496dGzowtWJ8pmLLycZ9PbFLcRb1A/voWjTAkI3KRwzdyD2psU/wBiu/JvfJdGcTId3ccBT2II7H86fNCVmVZCrI3zhQeVGOhrM1GCNyY43CJI6q7jnHPaqIK19HcXCkNlJHlaVX+6N4549u1ZtxcGSIyxqVaZFZj0JyOf1rSvJJAxeI9MqpBwMdM4rFt1RpjFIrbI920dCOuKCTFs7kcLIu5en1FbGlzJZXSQsxSCT7rDJAP+NcxG/lSgjoeMV0VnIJoXty5CN6dz2/WhDO0s5igXlcKD8w447ZpRMzndGSjxnOGHUH+lY9jc7khkJ+eP5JY29hyfoa0rVm3vGxKy4yC3deuBQwNOHoyTquUbOV5yvt6VeWWSWBFcBlClOBjdj7pPvWfFL5TwTB/9YDG6nn5u3HpV1WjSzEcDiTzl3HPG1wenNItIsurxhSSy7o1JLDIDA81ZaKX7fLHA26InEiuenHUGqlpDLPbhkOUjfJHXg9QK0rJlW8IlRXRsKwcfLnHX1zSSsMsQZMZQcbyFAIzg/wD160bYYibzR+/5UMDgH2NYloHa7kgDYEcuQ3QMP5itmCNla48sB1cEnv06n/69USx/mn5FmZs5ycH7uKnDia4RxIoIbCblzj61nPBM8cJ8thEzkrN07ZxmrlrK/nxoyojRDKuqHLntkelSnqJRNlilxcqZXEckfHmeXgMAOp9O1RnYJJHYuqbd24tu2nqOKNOt7W5iubi8neO5tijxRBd3nZbkZ6YxSz7ZjdTRp8hOcPjuehFWTYfDaTXlrKbSKTfbZkmlVsFVPfrWSLaKGKaaNriK7KEROuCDk8k5rRvIXULJulEhi2syLhVHZc/xe+aglaFNO/0pgkyKvkxlSA4/iOexzRfUSb6HOf2c6zvN9qdljXCkpjLd8CmpLJay7fmUgBir88Hsfat3MTKGl+ZMFvTmsp0gC+ZIsWW+bJ+8fpWsHqaxd0Nkk+3MVgUnK5zswOBzxWbPdCV3t4m8ssBuI5qS5uWW6xbFlh2YB9z1pNHtWWbcyh3YngDkAVcpWBJJXKb2T/YXQqMSFiO+c+1YWsbprM78KYlwzAbfm7L9Pauvul/dKx+8OMHjAzXN67bxJLBcSZNrHukbLAAkA4JrOWqIctdTjIVWV9qiMvJKMqCBt9a1rSSMIyPLbrBZAmQLn54wQcNj16cVmaEIrjZe3axjc7HGP7w4NbNzDbx2x0+2tkDufMlcEgOOynsPWsyW3cfq1xdajdR3ExFtlNluFbIhjzwgrOu9hUiPdlsMxZuc98mtOQyQoII9kqBRtbH55/Gs2OMwmSNo/NAydwwc5NBSJrcsrLD5flGRCV8w4AA960YrSOaYq8jgKcKUAB/H1rMlhcabfw7HLKVAdAWVFYgAk/XFaNncC2y00ZVWTyiQOVI7/jQhpu5eskntp5La5kcxIxbA5B+lVriWW4geGCaR3hBMG4+hyU56ZqfTdSEccsMkKyiTgMBllHXrUt8weCG5idPMbG6RRkE+hB9q2Suhp9xbNvtVrE6ZieZS4B6gd/14pbsSRIwVY3ZV6g8PnuPWq+jj7K1/bGUp9mYTQY6bW+8v50s8klxJAMlmDZ2jjK46UpNWGrtj0khM6jLKnlja23JB7jHoD3qC6WeENDBtXzF+ZmGcJnll9ar20wkuZxG/yDIbnoc1ckMbQjzkEj5wnzHgVz3Zoirapb24uikTeWuI45AuQPrW82rQNo6QXozJ0Cqn3fesu2ijV13TPErH5hsyCuOtQ+UzQK2Y2TPL8/L9RVRlyodlsXTEPIj81m8x842gj5T0qKFXtpIJUaMwrKIwwPO7qQR245zUMtwzh4pj80Z+Q5+XHfn+VJBOWRnKhYG+WAY5yT98+p7fSsm7uxVrFt3RpGc7fKmdmaNDgKO9QtK3yI2WidsqS35VLEGFsjHdvYlWwP0qONYQGiupRtZcLg/cYd6sRaSdFspSAwllBDAgEY7YqhGhG2Rx8g4Zeu33p9z5kdrErDdwCzJggA9P0FNKeUzESDceOvBGOhouIkUxlxNG7SOz4YE9PercvlC4YeaxQKCEYdj1wayvNWKRZYY1AL7X3Hgg/wAVSgqyxuWGULYBGQR7ULclpslvpbeWGX7OCgVvl5Pzf/WqGZd9pu8wCEnaSOhP061DM6/aQFjwijI47mm3CBIRtbfEqlmdRgo3oauxm9CxKI4bJcFWVOBzk5I44pjmSOSNHZCm3c6jqPaktljSICXaXZtzOi5xjpitDQbQalqMVnI0WZo5X8xs5+VGYce+BUvYpMw7R2h1CWIcwwuGiZxhmU9sj0qUxxFFilaZOThkPIJ75plk52bT8kL4G3Oc+vParMUbPbu7xrsDsUHqR/nvSWiBjLm4c3O9huMaBBl+mR29TVZzI0TPGVYbj1Gdx7n608F40SSQKUwQpKjLfWqiyzQQR5YiI5cBR931P0qkQytdSMX2qQ8eQu0Dk+wrOScJJfSzo2QOMfMcngZx6VM53uJS5Kh8/MCMn+hqpdyyIt0rOwWUjHy8n8aZJyjNuNaelSAy+WxG7oPesun20nlzK3oaQzurJzMkkbJvYqcknPGMVrWUjvMZGmAaOJcBhnB6Z/KsXTnH2iIvjypY2R93GeODVq1l+VIiQWKgBlH3gPXNDGjoI5UeeJZwwR33ArjjjHNWbd9saqkiuyMWGVwRg45rMtYvMgiBTD4YFskdD/StG4dLdQ8ZygClgwwfekWkbtj5bQbQ7xlpCAx+UBh0J68VdJSREa4RWkyUaRc/MexNYVvO67owuVk+42fl9q1rUM8RjkjdZA2yVWbaAezA9j7UCkrFqR1jiF0IwEVQhPOTnvmrLXKQXwljH3vkYLyucZH4VUgeWOzlkKRzRlCrhjk4PGQO5BFFvKn2WOGSNjJGMZC4LcDBqWKxoWFs0TB58MHDKrI25VPrjtV9khENuiXB84gsdy8BuwDZ+YY+lZMQaMyAcDOVBODg1bDRJLGJT5UbHOZAeuOBkUIRpQ7YkTdKxbb8zoMkGrsSOqxNLELeGUZV7rKq2OduR3NYltJ5S7hCrly0e4fMh46c9DUq3LmFbaSBnYN8rlztUBfu7f6+1XcRb+3iXeXK7DuKQ5O0M3+FRXEKy3CyXMyOrDG8nglR3z+VVkjjkZTLIsQ2bygG4k9gPxpURvs0kfkJIQmFZ8AgZySPegSVia5lS5VmiiCjapIDDnPAxWJqNoYpGS6+V41wVxnPtU91I8RSYcknA249KjhZZZojMzqmcuzDJz6VSkVFWM923KkUaklWAGF696ul/md1XBQZY55AqwyRo8johLDgYwAKz7llRMzIw3E4Knt6Gi92U3zFG7l3ShH3HKbgQRis/UYI9R0J7Uq26VHXft/i7U+SJ5Y1dmxgbR9M1NOdtrhQ3lxZO7d1JGKdyZ6I4KwuBYaFbCeFNyccdSfQ/jW5Ebnyi5l/e3LK/Axsx2APoPWszV4WttZ05xCJYRJvZWPcAnFXr24aX7GC7KpVpAuOnHA/WixDRM0BjhBUHJJ+YcEjNN0+E3eqW9vCyLNLJjJXOUAJOfw5rQglW40oBY2Z5FyrjqMdsVk2d62h6qNSJUfZoZHRtu4lnBXGOnGc0pKwXIPt5Ky2cToIZ182TjrsbgZ7c1K8ivawF1G5CSHH3ucfKfUCqSYjmik+Qr9n2MAMBtxzkiptoyig4BBxjntU30LJpBJDIgIZDnA+arP2iJUiARjKnzMH+6xB9arLIwAZgWZcbkbBBGOtFy0bxiGBWMkgJVpJMZWhSZSdyW3unuvtspClxIPkBAAUDtTbq5a1RpFQklwkUik/e9sdeKpmULZ+dx5pYYiXjI96ksy8lw9zKEJyV8ntFnjj3pO7LReiBCoo2JMRhmzw565PpT3doywmGGXBLY4596q/aUi3B4/QKPSnTPFKzBWYIeDnHNBa3LoLzgpDjf2yMALULy/Z7eR/9Uqtlue59u+aJLpppUaQrGjsIxIq5wR7Ul1IqSM8kgkm3YUvjGPTApNBYgu4pbiRSiSLIrArCcZce+P5VqWbxzJF5+4CHBCBfvjOCB6e+aoxsYU3BNssgwjkdMelW7ARve8koM4fnj64pKN2O/Q6K0vTatIbaPekqlVRwCFXvWfqUYZ1juFjGV3BmTBz7mpFmkDuLGI3Dr1DZC4FLratHDbyStEXlh3siNxGa6JQVrGSldmPuClDGgU425Y8Z7Z/pTN3mB4pSVfPVx3/AMKYH3RossW8SAMpzgHHekI3xeYMyOCcj1T/ABrC1tjTYcXjJjBQK4YKVIxketU3caddMZ/M+yO2WPURN0we+0+oq9LH5fkvIqtEyc7iSVHvTmMMkZiR45IXJY706r02g+lFhNkUkXk3CrMoAf5gVOQwP3cGnNEzSrbqNvmctuYKD9TVa2tDb3pVW8yw8oloZG5T+7sJ/lU9yVRVETne+0eY/OB3A/xppmT1Irp3kdzAo8hcJGVUqQBwTjrz60/Tp5bXUVnhk2DeMO3y8AYIX+VVp5HuMrHkuCOh/hB6g0yedp32Qg7Rnhzn8aBpaF6BMXUkIwkSg7/lAIA6n/PrVeSRZSZEVjE2I4gW+ZVzyT2JI70x52lXzXgUQyJtcEkb26H9QKa7MmnW8akrtbcVPY0WBkVw0Qnkbe7BPkGecjrgVVlJdyU53YwD0x6VJdSZMY2sD989OQKRB9nRpEZWdlBIfPftTRBTmEhUJIgJL4JX/CqtyTdNPGHH7qMzNvPIA4qR3Vo5JGYhgMqoBO4nt7YrGv2byBI7HMuQMdSP8KZJh0UUDrSGdXpJL2vmIP8AVEH149q0YpDlCqEMuSODk1gaGxeIqCNwPQnGa1+TGCARsyTQB09oYjICjS7SueecMRzx9av2s/zHzU3KBsYYzlf61z2lyBWzuG4DJDd8dhWvHISzGNgFZhmMeh54pFxZejEccLlfLdDyNw2kA1sWsrKJC7kyFA2GXhsdVP1GDkVlWMyqJY3hjeOVAH3DO3uGB7Gr0EYZA+H3qd6kHkCgJO5q3EhxA7oAHTKueA3v9e1TF2SBgylQVWQPn5jzjis+GVpwYGDuFO/aDjqeo9TVqKSQyww3O0hSY2BPIHb8aVgRaZDOwWRt6uFUMepx/hSyiWSENIpCwnbtK8sOzAU2LJ+0GN1YxtlxkfMPXHcfSo1u42EiSMkrNGpjKkgw89Mf0osS9zQhuSv7tYkG8YbaTjPZwO2R1FTWc6yXsSmdolhOWboA3v7HpVKOZ105nPzeXISfLUbuR1qa2nSa1Ebog8wh9zKM+n1piLUjiWa3tY42Dsfm3OTk59e/HapXeKNitzFukVdijdkCojKI1MvysVX5ljymxvVh3qk12JH3ThuMBNvIPPWmRe5HKY4owHLB1fhV6Y/HvUYuI0LZjO0/NGAc4+tMvI4pLlSZXCMWYf3vypI2xH5QlLBV3uygZCetS2yiYPsEpJZyW3MR0FUdTSMsTuLYUEDNQPeCK2Ecb7fOYOctx36is9rsrGMuhCsASTU81mNIdqO93Ee/YjgHaKqoULxJtG4Nlj7DsabeyZnEgKyOwDAZyB7VDM7Rl24X5OB/OqTuOSINVCzuSy/KCCOOnvWXpkS3RDwlkurKZlwDnchHpWs77wUAJOzOQP0rBttQls/EFuhaOKKT5VJHR+2frWsWQyeO7S31GW3bzJId3mRtkqAe4yOh5rOv8Ij2kN1IfOZgySsCuByMZ5FaGvyySyglY4HYFiAuMnPNZOnRb76ODeJY34R2TJV+o+nPHeia7FIuGOZAqySqJoQFeMkHIxkfWk89RDyQAzfeHY+lRRSq5R8qjuCHZlyNwOCCfaniGZ5Yyjq+44wq9WA6VmNeZdF5C53SGLzSDwDwT/SqpnExWELk53HjBxUISLyl3csSQSoxgj+tTxjzWSDKtKTtWQqcqfXFBSsOnaBGRCADIwAZj0q1aRO87QW8YeYHO0dTgZPHqAKg+yJJPLbzSrIoUqWlXAJ/xq3pdtdw3sCytFdg/Isol2FAVIyT6+vqKCrlO5uQkMbhFaSR1CEirMDKiSgKWLfLkDoKht95uBPJIzJExWM4+UnoTirc0yyqqzoGDKMOPlOfWlcsn06aO3E1tqEJkgnU4OOjdj7VDdwrc3SwlY7cKAIyfQD7xpDNC+yOXJVTtcnjJ9jTVZTbEyuBOkpVeOqnsTTuK+pHFl4FRSCU4BzU1zcyxFZVEj+UAh47fWomR0vLaBm8ku+0rIMhQBk/hU8UTRSylZlbnO0A4YD29KFe9wuSNqs32WQQXUkMUmDIqDOTVN55JV/eHcpO0NnP51Zmt7OaVnkg+zSAZYrwAPXFMW1EQVSUZhHuAB28HoabbKTitiSFfNi8gSspzhQTlRRGXaTe5bCjDYXgYoiRkBfByQVP+NOSSOP95cO+G+WRVPP1A7io1E2AmdXDf8s24xn9KcuWuBDExaJx8vOee4qCW4aSJ1LglD8q1CjzQxCbakcn3YcnrkcnFVcl6mmWijiSR59uTgbDlhjjBFZju0mA2XVidh24JqpJAG3ySsxKjLZYfe9qS3QSRkK8sT4JVeoz65pmfLqW02iGGMxc7icg8nPb8KdaqVbDqcqedo+8ff2pbgIIRLEWAHy8tkg4/wAatw28sWj3E8QV5pytnEit/FnLMR6YwKRTlYqWUoV7hntSIZsnauce49uoNVJfMlYFEII4Bbkcdqs+RKmLcSsWQMzAnp61Rurho7YSyfKP4Rn+L/69AEMQldGuJmViX2tvPvwB7VYvXlfMm1F3jg5J4HH4VFAfLtY4gjxPgSbj1PqKsTFRo15cMFIVcAEcHPv9aaM2Y1/IbaJ0KnAT04XPeoG2ieIBVwA7njsqHikAL27I7kyyrtJ9j0rPv7uUO6vnzBF5P055piMiiiikMv6PL5d2M42kcj/CuhUlSsgO4EYJB6VyULmOVWU4INdNG+V3AAhh0ximBo2pXcxVl2tjhuw9a3LP5gGVxhRu/DODXNLCGACZDNxgHjPsa2LW6N3N5kgRGKhGG3A3AYP4n1qWNM6KORhEkiZSSN8Btv3ecjJ7iteCQSRu8TFbhDuAYn/Vse341gRSloFOE3bhG0chOVHY/SrkE+Y7VypDpuifaeQpPH1pXA3JMI5SWBtvAPPb1FBQTT7WuPLB5j3nIPouR3PSoWbMCHdlC23cwxxjitCNgsO9ypgJEbswyVTqG45yPX601qNOxF5cCXCMrfZ1ySruc7e/NNNwBK8iFmkf5mGBtf3FSuivePE9yibYyyyFMh0xgcfWstbaR/M3RsAndTtO4Y5x2yKTuCt1NVW4O0Avxgc5x/Q1a0+4nmumkZEuJYXRikg3E47YHUYpkAsUuWW2a6VDgEyuCQxGQc9CKFgFo/2mWXy4jKFAQ/vRkdvbNVYTsW7i8g8uWQh4pGO5UCE7iD93FMSMx3ZMg3rIqsAuBtPX88dqFaR54lkYS+eSyNIQDjsSaoCYRzyMVAkxyccAj096GTYsPPD+8aFS80Zym4D7vQis28EcqtgrCZWClVOPlNWZ9RSC4inNsDMUKyFhgMT0OKw5ZzPcvGDwUZg2Mc9qmQ0rjJPvosWCoJVlUdMdz7UyW3AsVaPcoLLnkHNOjXiZi0ZGwBSSflHTj6k0sk0dtavGNu4OcsevTtSSKfkUZmLQsB9yMhV56H1xUFzIVAUY6c96ezyLDL5hJMvQYAwD/wDWqszCNyHYYVQcAc5HTP8AOqsJvuSRTKLOaTO1+VAIPOK5/Uwk0jI+TA67jjGQw6EehrcmDgQIQVb7zZbjnuaw71xHdlPkkTacjPUZxkGmQ2iS0nZ/s8hzlk2b5GHzHvn3qrcxRljtOxCwYFv4W9u+RUdscRzwbC6FVfbj7u0/eHvVyBvNgO8IY93mIoBDcjk5NA0Qs80UrpN853Zk2uHBbruB7g1O6iKJpkYKow+d3HXsfWqkkQYLJyYm3CMqNrADpuB4NQBkmu5CxV0gIQRBeBx1pFGrNtjiMm6WTzv3hJI+Q+n0qeKJYh8qku65Hz/yqlKkjjbCGb5SSqDovXmpYd8bJNFLEyqAygc4HTHsaEBd8iJ4YVAO+bkqeob61ctNP3WrebLKJoZFkjHGMjrnPam2RaSFXL7EJwJguQj45BFNa5Yu7FsNtxuPGa0UBplq6WKYmSGMfZ5WLhFGzZk9Md6pTxzMIQFPk7ipYnp+H9KuRRtt+1xyqkbYUxhS2T7jtVK6n+zyAXSyorNkNtyp9we1Q4pGvMiOSKZYNrowiAyrDkfWmAEorlMw52uRyDntmpJLsJtWObawBAAPY9evY0amy2weK2RTIqKVwCOG6nHtSHcjiminv5WKeZbwIYoZRw+Tznn8qJmdCCA4UqMPnj3qtZwNBAkauC/U9AQc96uMJI+CoiBwSrcg0CS1uRG8eQbpOVC7QS3BA7Gpp7lrmSQO+3jCDbxj+7/9eoLi4VpVZlVMnOUGVzUVzMZn64QHcMDofWlcZoRXQeJIwcOpLDngr6VCLosMog2rkhZBxUMascvIw2x4wfUUxJVk37GyxJwQetFwHxqzlJQoK5yQP4TVhmmkyrwiWdR+7c8ZUnOP/r0xCI2DR7ivRwe+eoqWMwmEcbQCTyf0oYmiCV0kTy2B3gbcvgFTTiDDGHZ1KN8vB5H4UsVvI1uzEKzSIQSDl1wepqMMDJkgiRAO1NEEuEkNtGjKY5X2np1HqKs6jcqHCWxItYgQgIIOfXHY1WKxL5aTxnazZkKnBx6ikZsk7XUKQWUscYoAbKNkZMILHgOT2Lc4+lVZ1Mxgnx/o1vlnZsYZx0AHpTLgyXE0KhwsTY3FeTUbyKEWIJujjPBJ/pQDZI92ftHmSqGO0/IRxz6Vmzy+cskLtLJaRIMqo4L5GKndVMZMn+rKkhicZNV53aFNkeWadhtHTp3pmbYNKEyTnCsCRt79cViXh+0XBC72ld85PpWpqEypGkQY+Zu3FSP61iz3BUusYALcFs849KCUVKKKKCgFb+jyEwDccgcEAdKwKuaZKI58OSFfjj1oA6cfdXy0Ybx0ByCfUVPayk27NGo2clhj5ge/61RjkLKf3jKR91/7tOilaGYOXC7/AJZATxn3PvQwOqsLiGYKskhBkXGVHRuxPpV794hijlJy6BRj17VztiTtZiFwGxKitkr6H1/GtpW+0JHGobzWGVZemRz+eAaQ0X1lkV3jMhERALIDxuHerdhceW4Z3ZAAQccAqeefx5qhbNB+7kdWI+62R6+tW2iSOGcQ52Rtgow5wejA9xQWaM00ZgiSIODEdw+bOM88ex61aku3mZFU5YjbtPH0JrGhYTvEAFQp8gJbH0HtWjHIqsqzRsCrYYryRQQ0SSrLFL5MoERiBBB6kjnmlhN7KbcziERjIVgT36Zp811csHl/ikBj8yRQwKng/jVKyuEmg8qS8m81WOyMLwce9MVjQnSa0n8udo4pEXIXgqAemD3FUVmO3NzIodMhsHO71qB5JLkSjfCzvgLGQOfTrUUx+zTvH5URlIJJBOWz19utTe7C1y7dXm87Vi3mQqw3qSwwOMe1VYpGSWQylXkKApk8jJ6g9CfaoRdOkrjcCSoXcDn8jVeWVlt2Z5Bw+1Y+jZPXimNLoWLmcx2yCRC0ajBGQM/NkfrWT52+6dW2s+dxAPA+tL88pnYsWUEKhY8Ht+lQRfu/N2ISwwWJHL/59KTG1YgIMt7lFYn5c84xiiQ+fKwDDaXDAkHjHYYqu86m8Mcb7Qn3iw79Kk+2CAqyLu8gNtxxnHGaESxt3cqI88GQ569SorAsJDLeag54QII1+XJB6gAfXrU948sNmJ5QAig4Oc8ntVXQ0jjsWkmZzJJkgY6E9DmqEWGYs6yqn+qAYEnGSeCPz61oyztP9ncsqNsKudmORzn6Y4rOkJRiWRpDjII5ycc8VY0t1mtcuWlcvkB/4R6/hQAtzcEOQm1MqBjn5T2z/hVSW2+zlJfmJb907IPlfjPapzkXEmWZ2B3rjjn1pJnKiNAxXcQ4VW60hk9oonnaJX8qVV6Z6/8A16Ig0Usu9lIxzhfvU4MzlpJIkEJYo+0jJ9j3465pTjy0hIZ+eGD9s5z+lMEy9YIRGV8iRX3bz8+0AH2qYRwxRLG8hdSuT2KnP6io5Zlnu5pLiVFnBDCPdj5DVg26iFHWVGXBySeg+tbRFcbvltI5dshIkIII6ED19DTb25aTeqtiMHJUtnJxyarbpoUYRsrD0B4I9apXFwbhkVihVRtLAYwPepkaR7heSrKELqHUDCnuB7VEkEokZwwL7crk5GD2HoasNFasFJjKSYOxwePpinESRQlTCdy4ycZNYo05iWJxdxSkkrcRrmQleoHemRNIET5tyzLhABn86qXLmGUXcLqyRkIygduuPep0AiZmG7qGRcetIQK+1ZkIITqcnBBHHFSW8QmeMGTyyxw2RkYqJ0beXbDKG+bA4555qxG6ffwDGDhsdVOP5UFEqN5FxlgGiJKZI4PpToGjR0V4UMcfXjBOeozVeORlO1ORwfm5FWpZd6y/LyeDtX+VADWhX5/JmwuPlVh09s1NZwmAGS6iDCRSixMwG5uox/jVSN1iBuLiLz1VgAg4w/Yn1HtUUs0s0xnuJC8+ec8BQP7vpS1ZDZLL5uS8o8t+MiM/Lj0zTN3moyIp2secdgKbLO7b2jXCkdB1FIN0SJuLJJyGCnIFWmKxLLctJhCy5Hy9Ow6VAjYdvMiG9B0z1oaSNYAZFDqORng/nVQSLI4+ZQx+X73f1pdSiUyxvFJK64nIURbW2gc8k+tRzzGZusaJGRgL3HrS5I6GP930Jqjc3G8EzqpVvbg0zOW4jSmRg7MfLU8Lt4J96jgJkme7kzuXheO57j2p2VHLrtMn3UHQL61HcFzCF2svOxcDHvnNNEle5lXy3dmcDhCpGSxPUisVutamqvbvbRm3UqwlZRjOCABz9c1kmgSCikzS0DCgHByOtFFAG1Y3B8rcOCOvc1qK6M53t97G444YduK5m0m8uQFun8q20ffGFB+Qfd3dqBGjbztGWVsb8bcL0cVtxziENG6LIpUNC6ZKn1xjoRXNRTOki5+bB6HuMVt6bMQY3VmyDj5WwQD/AEpDNi1ldQGRi0bfKc9AO9bUbea+2P5kCGIp32dciuet2UedEsxhUSFQJFzj3OO1aVpcTW858tjG4GQw6Ef4UDLkEUIuI1Mg8psg72wAfr71eWeC2nIQYnQZKlshhjj+dUA0UxYMgijkzjacqpxz+dNLLGkHlqm0Aq7t3A9+tA99C/HdLGjS7fl28oTnH0qOEJP5bEzIAxztUcDt9OvSqvkKqSeZNGWUnYY3zz9fTmnxlnkVisjllG7fKCCaS8wJiIPOb7TGSEXKFM7cjpknpVRdk90zxAKC2FVOWJ9PpTiWW3kQQP5ZYBmz39Oaryzw2/zbS6Dnbuww/LpTEPBHntKU8kJ8+N2MHp+NU2cbJJGLyTPyATzUO5ZmViVcFssSeFHYUv2qKNi7gq+OGHOB9KAHSOsMCxoibyclxnj2qk03l7fs6hpWY5Unpz1NSRXDSuxRXVYyCSOMfiev0qF4gwlkeVABjaCOSepAoEMl2o7SPsZXOFQEZZs9KqSt5byLL92PavB4A/uj/wCvUw5UzttHlAYB9uMY/Ws+8kQW5VioPLyMe5+vegDI1uYyYhTrI3IB7DpW5bxPFaJDJCjRRgSIUPWuc0iJtR1fncF2s5wMkKO9dZEFhiGPOZIWDJuUYcEdPpTAglTbOTb5G471k3YKnuKh0+yNxLdySyhViTeGDdXPCqB9eav6bbteSy25MaNsd1OOmO2KzZiqny7pnjAOcqR8rdv1oERljwsjgSLkNheSRTovmO1sMwyQ23pmp4YIZpJd+r2USkDd9o3IWbHUYGPWoVdVkWFbiCVskq0LEqO3XFA9A48spJgqcB/l5z61G03yiPYoduCR12ikRJ5bhUaWOAE8Ntz+GajFuUty0fJBPQ4K+uR6UrhaxoARgANHvV0KoS2Cvoc+1CTNDIouomcKcM8QyWXt7VXt3eTEkTJIwRiY3XIIx1HvUkVw4jwijaw4deOPXFWpWAmvb4SowsYvLQtgGRssfwqFCglf7rADAz6+9QPLK97Ep8vMR3ZHJx2NWgqSMWuIjklgHTg7ux9Km9yloTW8gXYXA2qCCpPQmr8/lxwRShgJFyWIOcg9qyfJWSCRklIl3LkMOSPWgwXHkhid0SgZKNn86adhsc3kfZWjEQEbA856Z7inQu11LaQMxMu8RjJwCFHGahELSbsYCKMMSc/hS2TbrgtIoaTb5akcBT6/lWdikXgQlwFjQ7DwS3QsByKZIVjO0KPMbgDPBJ6ZqxcQmKNBEzFlbLRn7ufUGqkssnnyyzbBKDuUOuQ30+lPlsO9yUuAjLAzF1ADgdiOox3qFJpXYKgJGd2AcZx7VEJQriQcPnnHvTpJo1iYqqg7gOD3pgWgYGSUOrh+SMNxmoDO20pwVIAB/unvVVrjcWPY+/amKfNJIIEY6DOCaBMvKXaN945Qbk2HG4joaikMkzeZhhkA5PQ01S0aEsHUAZU9aPNkxudSYscZBz+B7UEj5oWjCLIypuXeoLZyM8mmNKqqUCIIwOCOp+tRzFGPyxhQBgbySR/+uopp14DgCLGBjop9KSBvQbcMUjLAAkjBUck//XqDbtVRKzADorfw+pPvTZS2cuPm9F9aEkMUkYm3OerE+lUQx/mbkYknaeA23otVLqdSjPAzLEi43FcZqW9upXPlgFIVOdo+nQVXuto+aWUYQByp6seygUCK14AiwQMeI49zD/abn+WKocHJFS3cz3EjySHLucsf6VCOvFAxMUUpBFBoASiiigArU0yfJ2nnHasunRuUcFTigDoWj3jCht4O5SP6VPZ3ThHikLbSc7c4ZT6//WqvYSedEgzgnoc8g+lPuLds712iUdBnrTA3o7jz8TTYdcBH2naTjoa1IxJFFC292VlIRmycEH7p/DBrjrC4XeGB2sAQ2Dyp9639NuZIikLzu0bkMyk7UPB5PoamwG8sksyr5TNG7feQAYJ7YzUqhmDeZ5ysoyUQDB+o/wAKy0kjEjjf5bAfIAM5P19KlaSZisTTbJTyMdAPZqYzTigjkVXE2WkIXyymAvoc/WluzcspTy5ZFhGMqR8o9jVC2LzmQbwxHB+fGT9KnidhEw8zKLwVVuPoaVhtjUUhVWRWx2DOSxPr7VFMrNGysoVBkKuOtE0/78yF1GeQASOfSopp1WORmYF920bWB+tAiG+YJIVhVwoQBdwx/Kn26J5LblUOeeSeFFQi5jKDaSzcgKx5z64qBDEsZ84NvxzubGTTFclbYJGZmYKPmb5sgn6VC84JAMOB/ez+oqHeixfvVy3UqBkUy4lU4IXavByR2pANv5FcRrAhjUAjJ6muZ1q5DzNFE5ZAec85rR1K9WGAuC29/lQHsO5rBtY2mmGScZ5NAHR+GTFZadeTkmS7uNsMaBeFQ/eJNXLWUNvV1GSuFCPyD7iq9ssMMcQaHdKCcE5JxU5JkRWWMKVbkL15pgaGnyLFdRiQribMQm3H5SR+nNVr1WlZku4VgZG8p+Bgle+fX+tRyo0MJaMTeRIcNnnJz+mK1WuWuUZJbJdQ2hY/MiIjmAA7g8NxikO2pzMiW0bO20+TnHzDp7+1STWq2yKqmJl+8jqc7gfetB3smiWRJbmKQqVaOe2wHPHAK8Z61VspJGhe0eBppzzGYQGOfTHbimIqYkYMEPAHf/CprifNo8scRRkXDSK3DZ45FRS3EYZjD5ikkFFmXBI7g496jEsdzFMmzYqAO2fr0pDZLahYym0OhVQeD19cU6S4APmOXVYjsTIAL5/pUckgjwiKWJHI9KrRLvky7hsN0P8AIUwRasxtIknQGV/nYHgEenHariO0AVesR+fYehqvsRFOCrdQcdvQ0gmlkQhT5cJGGzzuHqKQE63ioJjGsY8zCup5KjPBB7VIw3FmdXjXIITOQ4/z/OmTzImE2Q7XXC4xkj61HAJ7dkgt08+PJK28h4zjqDQAsrgMvlps8w/KmMYpF3QHepUPH98N1Oe9QNeWT7jNaXiTPjGyUOgPfGe3WlWeCfK20d0XHdwBtoHctvqM8wVRsK9QyHOR6UiSqJVDuyA/xIM4qltlR2G0rE/LE8YapRHIWGWTaP4CelG407EjPhsvGQQM7v71R7g0fmAfMDnHrSu+zeybenKseKSFd2GwFRBkjP3j7UDJXjYQ7WVMPhy3ce1PAyy4VeOVwKR54lAjjRy5xknpUcpjEeVDNNuyeOB6YoFclRnU8b89weg9qmkMy2wk3M0bNtxu4FUXYuwMrgHqGPT6VG/7yUPxjqq7qYmxykPO6SMY42y33sk+wpvmAIcHOPUdaZO5f90kYJOMgDnFQysIvl2hrjouD9z/AOvSEK0hYqir+8P3nY4x+FMRpQNykfL/ABHsTU8jXUsa3U+1YYo/LikYAbgOw/vH3NVWkL+RaRMcM4ZiB0piGrKIoXfcWAzye5/xrJd9x6EAnOM1c1O43OLZFCxwFlAA6nPWqGaAJkkMsfk7QRncvsajHBpImKOGH8JzU0y4mPoTkfSgCI5ppzmnU31pgFFFFIAooooAsWly0EmcAqeoNdDbTrMh2sqt1Ckdfoa5arNpcmB/myV/lTuBuX1uWi+0xHbOuAVA++Peltb55ipyCxHzJjPHpSWd55oAwWYdOetRXti0bG6tnZZl5Me04/A0AbFtOqBSfmjK7gVP6VoxzIgBiZTGedr8j8K5O1vlfhywbqVPQGr8UmZQFI3Y4O7ilYDo1kLfO0ccbYz8jbsCntKkkiiKcYRc78bT+VYdvMyqpff6EKQA30p4uYsFoy6jnPAY5z0GKY7mpIQVVQyMw53E9T7mqdwVDYDiNsZJY9T7CopLt2hVU+6DuIx1PvVcguN5BzjLEmlYVy9GzITicbyOCnP60klwZFbYjKu3bmQbj7kAdahE6RQiLywTjJwetKspVR5KkzMNmO2c5BBo2C5LKwjdjOwXYAeBnJI4rMuLwwvv5DKOMDNJeXoXPlsQFXDOzcu56/Wucu7gyMdoCKBjAOaQDbqVpZiWPHQZ9K1tCtizq42l+iq/3TWRaxtLMFBzXV2kMa2xVnYbORgZ5p2BlqJZYTvZ0SQcBFXrnuPpRCVhbMiNMB1UNj60kKFpEVJFG87VMh249ie31qe4hNpO4vrdUuFP7xFfKv7hh/SgCCWVFRYlYm3dxIEAJK89Kt+YktxJKiS2pZSyjGSSaqISAFjlHlE7sL1H1zTtzFX+dmZRgHPSkMZcWx5icsGf5omzx71RkGHVkmdJEIdWj9R0P1zWs0QvJCQzeZGgZACNvA54rMlknxsuIH2r0KYYc9waAIpriRpZZ5YlVmOXx8o3HuBTJ/8ARomt3bc7upBXn5ByacqNNMFkfKrwd/BHtSIssoeSJzEluCVZj94dwPWgRCFQABC23OWIbrQCC2CRg+g5BoaIiJZEw2Pm3r79qYZCCqsSFY84HSmBO5DkKGAjHQ9/xpSxZQvX5f4aj2o0bGLdsBIXdSxBcnzGMeVzj1oAaoeL5nK4Veg61JDcs11DtbY/Y49QetROBs3F2VW4Ax1/HtRcSJDBKrsfMwpUo2QcUWAs288yR+WFjCodxDLxkdxTiTncSqpnkpwT61VSZZSmCQr8Fn+6M06WVsCNyjNztKHPHvRYCeMLkYkYxEk5zz+NMacZBXEjt1XvVWMyzExgMoX+PHU+lWkWO3B2qu8jBJzmlYYfZ9zYEqEAZZemafG5CDeQxIIVQ3IqIPxjBzjjA6UxpWLKeFx045p2AupJJMG3ssQUDg96iSWUcICdwJ3AdqgluGIKpuPdtwwKh3yTEKpGP4UDdDRYVyw90ciMtuA6jPT6097lSDHFCME5Yfe47VEhMISPcGOOAvP5mns8p0+4mgAIjkSORB1O4HB47UwuMnuUjBLFo5m42KmeO3Sqakyu3IRMfM7d6ZCpkZjIWCqcMQOSfQU95o3cwGR4IFPJRN3PpSAbLPvC7NzBcrEvp6n2FNtyodXYgpG2+RyeDj+EU8z2EDYhSeYdWL4TJ9OO1Z887yqqZ2xr91F6CgBly4kneTGNzFiB2zUdFFAAvWrt0hRbZj/FED+pqkOtWZJnmEYkPEa7FwMYFAEBpKU0h6UwG0tIKWkAUUUUAFFFFAEkMrRnIJx6ZrWs9UzHsmUsQODuNYtFAHQT2S3e6a1kjSUc7RxkYqkl49vmG5hDDOSQcH86pQXDwnKmrH2tJcCWMY9R1oA0FuoJVUxu6MDnBNTBpkQOqkj1JAA+orHeCF2HkSDJHIbjmoiZIWIJz685FFwN0S5L7nVWB3YzipYrlFXJ3ncCDt4/z0rn/tj4I2pz7U03BPBVSPemB0El8CMgknvtIwPqapS36hwQ2Xz17D6VmFzIp3MqqP4QOtNaTA2oigdM45oAlnuJJXJLDHTpVYAlulKalgQtIAMZJ4pAX9MgKupJAOetb8ZJIwNxwfyqpZpsjUlQSvBp8MjBZVIysTZyRjGaAJ47gmMqqggjgnv9ae7ss4KSsQCMbj/SqocENl15GQQKWGRgrKwY7iCfUigZcEy+YCYkyucsOOtPtlf7VHHGUyw3DIwOPXNVyQ+fLZsZxsxyPSgt5ZwxVyeCMnNIaVzRuYpbeaOZliMuSwMbAj6YHeqRmmdjtJR4yWKAcNnrTUaFsgAs24AEHAWmkR+ePMdAwyAxJoEJcC4kVsNtwMPlclh61AbcSGNIYyhUYGXwp96kju5oTGDIrFflB3Hp71FcLczhow+Y3OSMY3Y9DQBWjkRXkXfuKHkIfvfSoZmiZXdD8p4wwxt9qneAeUfKPktG2APT3quyyEnzDGNw5yuc0xE1hHFKUXe3yg8da01tvNJIkUAcjjn8qwLqORX821Vo+hMajj6io01WdVwcMfX1NAGzqVp9nn2pKNjjf8y/0rNFqJEXy1zISd2TkY9ajvZ5LucNGNkTICAWzj1+tRSNJFGIFTy1PJb+IigCWRlUeUjyvMvygEZXFORVQneUyRnceQtV0cxr+7OCD1B5oRzCpPPmMeSRmmBdjmT5VMjRwAdU/iNSRQ+aHd5SqgZH+fWqLmVHKyoqyemelQl5VXf5oG7oc0AaE7puAi3gnAxnLGmBl8xWffK3VlLAEVnRmRjlWdpO2Kcw8rlsbz15yaSC5dMoXk9+2c5odwq5lBjJ52rgcVRScowZSqsOhxnH0pjPuYsfmJ5LNTAtT3HmO+391ER0HP61NZkEXMMRZRNFxu4JZTmq0Nu8rpho1RztUyHGfenXLR25ljQ5kxtJDZ578+lAiU3Swqsdup84DaGbovuPf3qvcyxoix25YjHzM3du9VQ205wOaIwCTnpgmkMaetFHYUUAFJS0UAKtSZyBUQp4PHFMBCaQ8ilIpKAEopMUtABRRRSAKKKKACiiigAo7UUUAJSkn1oooASg0tFAAD604c5ptKKAF+vFbxtY4Bprlt/m2/mNjHB3GsSPO5dozg96uwfM5ymwk8AUCuaSyz7CsUpUD0xmnq/nOziXbO2M5+6QPWqqSOHWKJczE4HHNSx2m5XZpP3pPzYGMUwLpibynaaGQhuCUXKihYDGiSvI0KNwMnDH8Kpo0sMuUmcgDHUinIczK8g3SY6sc8Uhmp9peRBHgbQOTt+ZvrUSKssRbMqkHgBeoqIsN208HrvGe9IbhhjJGF6e9A7lhpTOIgSpkA2ZAx+fvUcrIiyI0LebkYbd8oNNnkSZVJt41eQ5DoxB/KmkBdiKzbeSwPOD60gJZWikZmQyAAjClQc/U0shCRKodGjBzxximQmEw4YSHAzvDd/pTWWSMgFCu5c/OO1ABhH3FejNwQ3IqOUy4WMMrgZAx94j396RgqMGimAyMn5cimb3BJ2RFj32kUAQbVDna5Y/y9qhmt0ZsmMFu5Axn8KuN84+ZAGJHK8AVFI8gnYMok5xuzgEUCZTCRiPYQvHAJqu6AtmQ5xwMd6syRqJDkce/SnMiADZgKR1zTEZrbVC+WxLd+KWJ2LglwCvI3d6uSKrABdgG7GR/OqssO0jBzntQBd1GOCPUHcviBgsgEZ5IYdAfbpVa4vfNliMUUcKxLtUKo59z6mq8z52jJ+VQvNRryQPWgZae4klkA8w49emPyqsXIGMnmrF5EqzFEBV14Zf61HHayyZ2oTgFjyBxQBFtB5LYqRSiEEHe2e44qIjA9qAeKAL8iOVaWa4jAx8qqckj0A7VFcTrKkeyBYUjGOOdx9SfWoY4zI2FH19h60SPxsUkqKAEmiaNsP97GcU1SATn0oZix5pKACiiigAooooAAOKUHAoFBFADjSGn4phFMQnWkpTwOKSgAooopDCiiigAooooAKKKKACiiigAooooAKM0UUAGcVZSXK4x82euarVb025W2uN0sayRMCkisOoP9aALUUfkyGTcPNGCMHNTQzRnIZgr9cZ603XdO/s543t51urOVQ8c0fQZ/hPoR6VQhmCbSQcg9aAN1EaVCUKjby249vWnSKba4SOTy2YckhvlYe1ZaXKyKZPPCyL0DA81esLuKe2/s+6YLCctDMw5ibuuf7p9PXmmImLxr5qg45BAZqM7izQxlI0wGOd3NVFeSRcGRUKfISerLTy/lqViyVA+9jrQBZkYKRsRvLIAxxkf41IkkJTcJhvXsF+Y1SWTeSG+Zu2e1PEkYXzGB8wHhT3pDL93IsYEJZGI+ZSp65HeqhYMjMxwB1O7NRNKskpfG0H36+9RTMD83btg5osBLk9W2+3NC7icZGT6UohVUSW8mFtG3K/Luc/RaLi4V2aO3WQquSskigEigLgI3CliQQc9TjiomlYBVGNoHHvVd5cON7EnHTFRtOz4ztDE8D0FAFl9rMXxg9MZqJzubIVVIHYYzUXzMu8ttPf3qFp2bMeB9TTEWzmNPmI3HtVF5eW2ncT09hTJZWbrUeT1zSAD82eaWJCzcY455qxb26NHJJLIqogGR3OfSmSyoF/cqVB4OaAIpnLys7YLE803ccDmmiloGBJPWlVQepwBSUUASGTAKx5CHr71HRRQAUUUUAFFFFABRRQAcUALRShTSEelMCSmmiigQhpp6UUUAIKWiihjCiiikAUUUUAFFFFABRRRQAUUUUAFFFFABQOtFFAG5oXz6fdI/zJtJ2nkZ+lYp60UUAKvUVMeoHaiimHQcpOzqaWF3Mqgs2PrRRQIsSk5H1qZecZ55oooBDbflTnng1oQgCNyAAQvUUUUAYyOz3sjMxZt3UnJrQB+/8A7tFFAFb/AJeFquB+9uPYH+dFFICKT7p+lNl/49l+tFFMbIKVaKKBEjf8e6/71Q0UUhi0UUUAFFFFABRRRQAUUUUAFFFFABUkVFFAmSGoT3oopgj/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Violaceous annular plaques and papules are present on the penis and scrotum.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Copyright &copy; Kosman Sadek Zikry, MD, Dermatlas; file://www.dermatlas.org.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_3_13369=[""].join("\n");
var outline_f13_3_13369=null;
var title_f13_3_13370="Prevention of malaria infection in travelers";
var content_f13_3_13370=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Prevention of malaria infection in travelers",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/3/13370/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/3/13370/contributors\">",
"     Paul M Arguin, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/3/13370/contributors\">",
"     Jay S Keystone, MD, MSc (CTM), FRCPC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/3/13370/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/3/13370/contributors\">",
"     Johanna Daily, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/3/13370/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/3/13370/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/3/13370/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 9, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Malaria is an important cause of fever and serious illness in returned travelers [",
"    <a class=\"abstract\" href=\"UTD.htm?13/3/13370/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Among nearly 7000 returned travelers with fever seen at a GeoSentinel clinic between 1997 and 2006, for example, malaria was the most common specific etiologic diagnosis, found in 21 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?13/3/13370/abstract/1\">",
"     1",
"    </a>",
"    ]. The relative risk of malaria is higher among returned travelers from Sub-Saharan Africa than those from Asia or the Americas (",
"    <a class=\"graphic graphic_figure graphicRef67552 \" href=\"UTD.htm?36/36/37455\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef63029 \" href=\"UTD.htm?34/30/35308\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/3/13370/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Approximately 1700 cases of imported malaria were reported in 2010 to the United States Centers for Disease Control and Prevention (CDC); this is likely an underestimate given underreporting in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?13/3/13370/abstract/5\">",
"     5",
"    </a>",
"    ]. More than half of the reported cases are due to P. falciparum, which causes the most severe disease; patients with P. falciparum may progress to life-threatening illness within hours and it is associated with widespread drug resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?13/3/13370/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Since 1997, there has been an average of six malaria deaths per year in the United States.",
"   </p>",
"   <p>",
"    Prevention efforts should be aimed at all forms of malaria. In addition to P. falciparum, other Plasmodium species that cause human malaria include P. vivax, P. ovale, P. malariae, and P. knowlesi. These forms of malaria usually cause febrile illness but less commonly result in severe disease and are rarely fatal, although deaths have been reported in the setting of P. vivax and P. knowlesi infections [",
"    <a class=\"abstract\" href=\"UTD.htm?13/3/13370/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. In general, most chemoprophylaxis regimens are designed to prevent primary attacks of malaria but may not prevent the later relapses that can occur with P. vivax and P. ovale. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Drug mechanisms'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H15\">",
"     'Primaquine'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Most travelers who develop malaria do so because they do not adhere to an effective chemoprophylactic drug regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?13/3/13370/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. In addition, many travelers frequently fail to use personal protection measures for mosquito bite prevention.",
"   </p>",
"   <p>",
"    Issues related to risk assessment, counseling, mosquito bite prevention, and antimalarial chemoprophylaxis for prevention of malaria will be reviewed here. The clinical manifestations, diagnosis, and treatment of malaria are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/26/5543?source=see_link\">",
"     \"Clinical manifestations of malaria\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/0/10248?source=see_link\">",
"     \"Diagnosis of malaria\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/1/13338?source=see_link\">",
"     \"Treatment of severe falciparum malaria\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/41/25241?source=see_link\">",
"     \"Treatment of uncomplicated falciparum malaria\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RISK ASSESSMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of malaria transmission depends on a variety of factors including the geographic region visited and the type of traveler [",
"    <a class=\"abstract\" href=\"UTD.htm?13/3/13370/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Destination",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the geographic region visited, the risk of malaria transmission depends upon the type of accommodation (eg, open air, tented, air conditioned, or screened), the season (rainy versus dry), the elevation, and the duration of exposure.",
"   </p>",
"   <p>",
"    Geographic risk assessment for malaria requires detailed review of the planned itinerary together with the most recent United States Centers for Disease Control and Prevention (CDC) guidelines and advisories [",
"    <a class=\"abstract\" href=\"UTD.htm?13/3/13370/abstract/14\">",
"     14",
"    </a>",
"    ]. Listings of regions where malaria transmission occurs, the presence of antimalarial drug resistance, and recommended chemoprophylaxis for specific destination are available in the CDC publication \"Health Information for International Travel\" (also known as the Yellow Book), which may be accessed online [",
"    <a class=\"abstract\" href=\"UTD.htm?13/3/13370/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. An interactive malaria map is also available at the CDC web site [",
"    <a class=\"abstract\" href=\"UTD.htm?13/3/13370/abstract/17\">",
"     17",
"    </a>",
"    ], and the World Health Organization (WHO) provides useful online information including maps and malaria data [",
"    <a class=\"abstract\" href=\"UTD.htm?13/3/13370/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An excellent summary of areas where malaria transmission occurs and prophylaxis by country is available at the following web site:",
"    <a class=\"external\" href=\"file://wwwnc.cdc.gov/travel/yellowbook/2012/chapter-3-infectious-diseases-related-to-travel/yellow-fever-and-malaria-information-by-country.htm\">",
"     file://wwwnc.cdc.gov/travel/yellowbook/2012/chapter-3-infectious-diseases-related-to-travel/yellow-fever-and-malaria-information-by-country.htm",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Type of traveler",
"    </span>",
"    &nbsp;&mdash;&nbsp;Important risk groups include travelers born in regions with endemic malaria who relocate outside the endemic area but subsequently return to visit friends and relatives (known as VFRs), pregnant women and military personnel.",
"   </p>",
"   <p>",
"    VFR travelers are at greatest risk for malaria infection; this group includes individuals born in regions with endemic malaria who have emigrated outside these regions, as well as the subsequent family generation of children born outside endemic areas [",
"    <a class=\"abstract\" href=\"UTD.htm?13/3/13370/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. VFRs pose unique challenges for malaria prevention since their acquired immunity afforded some degree of protection against malaria while they resided in the endemic area, although such immunity wanes outside endemic regions [",
"    <a class=\"abstract\" href=\"UTD.htm?13/3/13370/abstract/22\">",
"     22",
"    </a>",
"    ]. In addition, such individuals may have difficulty seeking or accessing preventive services, may receive incorrect information regarding appropriate prophylaxis measures, and may not appreciate the risk or severity of infection once their immunity has waned [",
"    <a class=\"abstract\" href=\"UTD.htm?13/3/13370/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pregnant travelers should be advised to defer travel until after delivery whenever. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Pregnant travelers'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Military personnel represent another important risk group; these individuals may have inadequate protection from mosquito bites given prolonged periods of nighttime exposure to biting Anopheles mosquitoes with accommodations that have inadequate screens or bednets [",
"    <a class=\"abstract\" href=\"UTD.htm?13/3/13370/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     COUNSELING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Travelers to malarious areas should understand that their planned itinerary puts them at risk for malaria, a serious infection that can be fatal [",
"    <a class=\"abstract\" href=\"UTD.htm?13/3/13370/abstract/25\">",
"     25",
"    </a>",
"    ]. Prevention measures include avoiding mosquito bites and adhering to antimalarial chemoprophylaxis. However, travelers should also understand that no chemoprophylaxis regimen guarantees complete protection and that fever during or after travel is a medical emergency requiring urgent medical attention [",
"    <a class=\"abstract\" href=\"UTD.htm?13/3/13370/abstract/26\">",
"     26",
"    </a>",
"    ]. Other symptoms may include headache, myalgia, cough, nausea, abdominal pain, vomiting, and diarrhea. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/26/5543?source=see_link\">",
"     \"Clinical manifestations of malaria\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Travelers should be counseled that their travel history is an important clue to bring to the attention of the healthcare provider in the first year following exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?13/3/13370/abstract/26\">",
"     26",
"    </a>",
"    ]. Because most chemoprophylactic agents do not eradicate the dormant hypnozoites of P. vivax and P. ovale capable of causing relapsing malaria (with the exception of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/59/38837?source=see_link\">",
"     primaquine",
"    </a>",
"    ), infection with these species may present months following exposure in spite of full adherence to chemoprophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/3/13370/abstract/26\">",
"     26",
"    </a>",
"    ]. Among imported malaria cases in the United States in 2006, no cases of P. falciparum occurred more than six months following travel, although 18.1 percent of P. vivax cases occurred after this interval [",
"    <a class=\"abstract\" href=\"UTD.htm?13/3/13370/abstract/4\">",
"     4",
"    </a>",
"    ]. However, in semi-immune individuals born in endemic areas, P. falciparum may present years after their last period of exposure. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Drug mechanisms'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H15\">",
"     'Primaquine'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Travelers planning prolonged visits to endemic areas should continue prophylaxis throughout their stay. Local laboratories in developing regions may have high rates of false-positive malaria diagnoses; travelers who become ill should be advised to seek expert advice concerning malaria diagnosis and therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/3/13370/abstract/27-29\">",
"     27-29",
"    </a>",
"    ]. In such cases the chemoprophylactic regimen should be continued together with treatment offered locally, unless there are significant drug-drug interactions (such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/21/17751?source=see_link\">",
"     mefloquine",
"    </a>",
"    with halofantrine). If the initial evaluation demonstrates negative blood films, thick and thin blood films should be repeated twice (12 to 24 hours apart).",
"   </p>",
"   <p>",
"    Pregnant women are an important risk group, as malaria can be a life threatening infection for both mother and fetus [",
"    <a class=\"abstract\" href=\"UTD.htm?13/3/13370/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. Risk of stillbirth, spontaneous abortion, and other adverse pregnancy outcomes is increased in the setting of malaria, and pregnant travelers should be advised to defer travel until after delivery whenever feasible (see",
"    <a class=\"local\" href=\"#H17\">",
"     'Pregnant travelers'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     MOSQUITO BITE PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Travelers to malarious areas should receive instructions regarding methods to prevent bites from Anopheles mosquitoes; such measures also help reduce bites from sandflies, ticks, and other mosquito species. These include [",
"    <a class=\"abstract\" href=\"UTD.htm?13/3/13370/abstract/32-34\">",
"     32-34",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Avoiding outdoor exposure between dusk and dawn (when Anopheles mosquitoes feed)",
"     </li>",
"     <li>",
"      Wearing clothing that reduces the amount of exposed skin",
"     </li>",
"     <li>",
"      Wearing insect repellant",
"     </li>",
"     <li>",
"      Sleeping within bed nets treated with insecticide (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/22/28004?source=see_link\">",
"       permethrin",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Staying in well-screened or air-conditioned rooms",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Insect repellents recommended by the United States Centers for Disease Control and Prevention (CDC) for reducing the risk of malaria include DEET and picaridin [",
"    <a class=\"abstract\" href=\"UTD.htm?13/3/13370/abstract/33,35\">",
"     33,35",
"    </a>",
"    ] (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/1/43031?source=see_link\">",
"     \"Prevention of arthropod and insect bites: Repellents and other measures\"",
"    </a>",
"    .):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      DEET (30 to 50 percent) is generally protective for at least four hours, although lower percentage preparations provide a shorter duration of protection. When used appropriately, DEET is safe for infants and children over the age of two months.",
"     </li>",
"     <li>",
"      Picaridin is a synthetic repellant. This agent (20 percent concentration) and DEET (35 percent concentration) have comparable efficacy for protection against malaria vectors up to eight hours after application [",
"      <a class=\"abstract\" href=\"UTD.htm?13/3/13370/abstract/36-38\">",
"       36-38",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to insect repellants applied to the skin, fabric may be treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/22/28004?source=see_link\">",
"     permethrin",
"    </a>",
"    or other residual insecticides [",
"    <a class=\"abstract\" href=\"UTD.htm?13/3/13370/abstract/32,34,39,40\">",
"     32,34,39,40",
"    </a>",
"    ]. Permethrin is a synthetic compound that causes nervous system toxicity to insects with low toxicity for humans [",
"    <a class=\"abstract\" href=\"UTD.htm?13/3/13370/abstract/41\">",
"     41",
"    </a>",
"    ]. It is available in outdoor supply stores as an aerosol clothing spray (eg, Permanone Repellent).",
"   </p>",
"   <p>",
"    Clothing and bed netting treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/22/28004?source=see_link\">",
"     permethrin",
"    </a>",
"    effectively repel mosquitoes for more than one week even with washing and field use [",
"    <a class=\"abstract\" href=\"UTD.htm?13/3/13370/abstract/32,34,42,43\">",
"     32,34,42,43",
"    </a>",
"    ]. Standard nets dipped in permethrin are effective for three washes whereas newer formulations can withstand 20 washes [",
"    <a class=\"abstract\" href=\"UTD.htm?13/3/13370/abstract/44\">",
"     44",
"    </a>",
"    ]. Long lasting insecticide impregnated nets (LLINs) can remain effective as long as three years [",
"    <a class=\"abstract\" href=\"UTD.htm?13/3/13370/abstract/45\">",
"     45",
"    </a>",
"    ]. Use of such nets is very effective for reducing the risk of malaria infection, and travelers to endemic areas with accommodations lacking screens or air conditioning (such as VFRs or hikers) should sleep under insecticide treated nets [",
"    <a class=\"abstract\" href=\"UTD.htm?13/3/13370/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CHEMOPROPHYLAXIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individual itineraries should be reviewed together with the most recent guidelines and advisories to determine the appropriate approach to chemoprophylaxis (",
"    <a class=\"graphic graphic_figure graphicRef80738 \" href=\"UTD.htm?27/47/28406\">",
"     figure 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef67536 \" href=\"UTD.htm?37/6/37993\">",
"     figure 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef75158 \" href=\"UTD.htm?3/44/3782\">",
"     figure 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef72797 \" href=\"UTD.htm?38/32/39430\">",
"     figure 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/3/13370/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Listings of regions where malaria transmission occurs, the presence of antimalarial drug resistance, and recommended chemoprophylaxis for specific destination are available in the United States Centers for Disease Control and Prevention (CDC) publication \"Health Information for International Travel\" (also known as the Yellow Book), which may be accessed online [",
"    <a class=\"abstract\" href=\"UTD.htm?13/3/13370/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. An interactive malaria map is also available at the CDC web site [",
"    <a class=\"abstract\" href=\"UTD.htm?13/3/13370/abstract/17\">",
"     17",
"    </a>",
"    ], and the WHO provides useful online information including maps and malaria data [",
"    <a class=\"abstract\" href=\"UTD.htm?13/3/13370/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Drug mechanisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are three major categories of drugs for prevention of malaria (",
"    <a class=\"graphic graphic_figure graphicRef70176 \" href=\"UTD.htm?16/23/16760\">",
"     figure 6",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tissue (hepatic) schizonticides &mdash; These drugs target the liver stages of the parasite, the active tissue schizonts.",
"      <span class=\"nowrap\">",
"       <a class=\"drug drug_general\" href=\"UTD.htm?11/5/11350?source=see_link\">",
"        Atovaquone",
"       </a>",
"       /proguanil",
"      </span>",
"      has proven activity against liver stages of P. falciparum.",
"     </li>",
"     <li>",
"      Hypnozoiticide &mdash; Hypnozoites are a quiescent stage in the liver that exist only in the setting of P. vivax and P. ovale infection. This liver stage does not cause clinical symptoms, but with reactivation and release into the circulation, late-onset or relapsed disease can occur up to many months after initial infection.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/59/38837?source=see_link\">",
"       Primaquine",
"      </a>",
"      is active against the quiescent hypnozoites of P. vivax and P. ovale. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Relapse prevention'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H15\">",
"       'Primaquine'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Blood schizonticides &mdash; This class of drugs targets the asexual blood stages of the parasite; it includes",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25447?source=see_link\">",
"       chloroquine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/21/17751?source=see_link\">",
"       mefloquine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      ,",
"      <span class=\"nowrap\">",
"       <a class=\"drug drug_general\" href=\"UTD.htm?11/5/11350?source=see_link\">",
"        atovaquone",
"       </a>",
"       /proguanil",
"      </span>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/59/38837?source=see_link\">",
"       primaquine",
"      </a>",
"      . Because the first three agents act on blood parasites following release from the initial maturation phase in the liver, these drugs must be continued for four weeks following exposure to eradicate parasites released from the liver.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/59/38837?source=see_link\">",
"     Primaquine",
"    </a>",
"    has schizonticidal activity against the tissue stages of all species and the blood stages of the non-falciparum species, but lacks blood schizonticidal activity against P. falciparum and therefore cannot be used to treat or prevent this illness. Since",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?11/5/11350?source=see_link\">",
"      atovaquone",
"     </a>",
"     /proguanil",
"    </span>",
"    and primaquine act as both blood and tissue schizonticides, they interfere with development of actively replicating parasites in the liver, and so can be discontinued one week after the end of exposure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Drug resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antimalarial selection should include the considerations of regions with malarial drug resistance (",
"    <a class=\"graphic graphic_figure graphicRef80738 \" href=\"UTD.htm?27/47/28406\">",
"     figure 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef67536 \" href=\"UTD.htm?37/6/37993\">",
"     figure 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef75158 \" href=\"UTD.htm?3/44/3782\">",
"     figure 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef72797 \" href=\"UTD.htm?38/32/39430\">",
"     figure 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/3/13370/abstract/46-49\">",
"     46-49",
"    </a>",
"    ]. Individual itineraries should be reviewed together with the most recent guidelines and advisories [",
"    <a class=\"abstract\" href=\"UTD.htm?13/3/13370/abstract/14-18\">",
"     14-18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The resistance of P. falciparum to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25447?source=see_link\">",
"     chloroquine",
"    </a>",
"    is widespread; regions with chloroquine-resistant and chloroquine-sensitive malaria are summarized below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25447?source=see_link\">",
"       Chloroquine",
"      </a>",
"      -resistant P. falciparum (CRPF) is widespread in endemic areas of Africa, Asia, and Oceania.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25447?source=see_link\">",
"       Chloroquine",
"      </a>",
"      -sensitive P. falciparum exists in Mexico, the Caribbean, Central America west and north of the Panama Canal, and parts of North Africa, the Middle East, and China (",
"      <a class=\"graphic graphic_figure graphicRef80738 \" href=\"UTD.htm?27/47/28406\">",
"       figure 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef67536 \" href=\"UTD.htm?37/6/37993\">",
"       figure 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef75158 \" href=\"UTD.htm?3/44/3782\">",
"       figure 4",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef72797 \" href=\"UTD.htm?38/32/39430\">",
"       figure 5",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?13/3/13370/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      P. falciparum strains resistant to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25447?source=see_link\">",
"       chloroquine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/21/17751?source=see_link\">",
"       mefloquine",
"      </a>",
"      and sulfonamides are rare, but are prevalent in the regions of Thailand bordering Burma (Myanmar) and Cambodia (eg, eastern provinces of Myanmar and western provinces of Cambodia Cambodia), and in parts of China, Laos, and Vietnam (",
"      <a class=\"graphic graphic_figure graphicRef75158 \" href=\"UTD.htm?3/44/3782\">",
"       figure 4",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?13/3/13370/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25447?source=see_link\">",
"       Chloroquine",
"      </a>",
"      -resistant P. vivax is widespread in Indonesian Papua and Papua New Guinea [",
"      <a class=\"abstract\" href=\"UTD.htm?13/3/13370/abstract/15,50\">",
"       15,50",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chemoprophylaxis agents vary with respect to cost, adverse effects, and dosing schedule [",
"    <a class=\"abstract\" href=\"UTD.htm?13/3/13370/abstract/51\">",
"     51",
"    </a>",
"    ]. Reviewing these items during the travel visit is important for facilitating adherence. In 2009, almost 90 percent of the United States travelers with malaria took no chemoprophylaxis, took an ineffective drug, or took an appropriate drug incorrectly [",
"    <a class=\"abstract\" href=\"UTD.htm?13/3/13370/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Antimalarial therapy should be started prior to travel, continued regularly during exposure, and for a period of time following departure from the endemic area (",
"    <a class=\"graphic graphic_table graphicRef75761 \" href=\"UTD.htm?8/19/8510\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef54777 \" href=\"UTD.htm?11/59/12222\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/3/13370/abstract/52\">",
"     52",
"    </a>",
"    ]. A prescription for the full supply of medication should be written and filled prior to departure; the sale of counterfeit and poor quality antimalarials is an increasing problem in Asia and Africa [",
"    <a class=\"abstract\" href=\"UTD.htm?13/3/13370/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. Travelers should understand the importance of careful adherence to the chemoprophylaxis regimen, even though no chemoprophylaxis regimen guarantees complete protection. Individual agents are discussed in detail in the following section (",
"    <a class=\"graphic graphic_table graphicRef75761 \" href=\"UTD.htm?8/19/8510\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Atovaquone-proguanil",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/5/11350?source=see_link\">",
"     Atovaquone",
"    </a>",
"    acts synergistically with proguanil against",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25447?source=see_link\">",
"     chloroquine",
"    </a>",
"    -sensitive and chloroquine-resistant P. falciparum, as well as the other malaria species that cause human malaria [",
"    <a class=\"abstract\" href=\"UTD.htm?13/3/13370/abstract/55\">",
"     55",
"    </a>",
"    ]. Its efficacy is equivalent to that of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/21/17751?source=see_link\">",
"     mefloquine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?13/3/13370/abstract/56\">",
"     56",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/56/902?source=see_link\">",
"     Atovaquone-proguanil",
"    </a>",
"    does not prevent hypnozoite formation by P. vivax or P. ovale; in areas with high rates of infection due to these species, presumptive anti-relapse therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/59/38837?source=see_link\">",
"     primaquine",
"    </a>",
"    may be necessary to prevent relapse for persons who had been to those areas for extended periods of time. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Drug mechanisms'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H15\">",
"     'Primaquine'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/56/902?source=see_link\">",
"     Atovaquone-proguanil",
"    </a>",
"    is administered daily beginning one to two days prior to exposure, during exposure, and for one week following exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?13/3/13370/abstract/57-59\">",
"     57-59",
"    </a>",
"    ]. Dosing is outlined in the Tables (",
"    <a class=\"graphic graphic_table graphicRef75761 \" href=\"UTD.htm?8/19/8510\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef54777 \" href=\"UTD.htm?11/59/12222\">",
"     table 3",
"    </a>",
"    ). The drug is well tolerated, with excellent profiles of safety and efficacy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/3/13370/abstract/55,56,60-67\">",
"     55,56,60-67",
"    </a>",
"    ]. Adverse effects may include gastrointestinal upset, insomnia, headache, rash and mouth ulcers [",
"    <a class=\"abstract\" href=\"UTD.htm?13/3/13370/abstract/60,68\">",
"     60,68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/56/902?source=see_link\">",
"     Atovaquone-proguanil",
"    </a>",
"    is contraindicated in patients with creatinine clearance &lt;30 mL per minute and it is not recommended for use in pregnant women due to insufficient safety data.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Mefloquine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/21/17751?source=see_link\">",
"     Mefloquine",
"    </a>",
"    is effective for prevention of malaria due to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25447?source=see_link\">",
"     chloroquine",
"    </a>",
"    -sensitive and chloroquine-resistant P. falciparum, as well as the other malaria species that cause human malaria. In a study of almost 140,000 travelers to East Africa, the prophylactic efficacy of mefloquine was 91 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?13/3/13370/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/21/17751?source=see_link\">",
"     Mefloquine",
"    </a>",
"    is not effective for prevention of malaria due to mefloquine-resistant P. falciparum, which is found along the Thailand-Cambodian border region, and parts of China, Burma (Myanmar) and Vietnam (",
"    <a class=\"graphic graphic_figure graphicRef75158 \" href=\"UTD.htm?3/44/3782\">",
"     figure 4",
"    </a>",
"    ) and (see",
"    <a class=\"local\" href=\"#H9\">",
"     'Drug resistance'",
"    </a>",
"    above) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/3/13370/abstract/15\">",
"     15",
"    </a>",
"    ]. In addition, mefloquine does not prevent the development of residual hepatic hypnozoite forms of P. vivax or P. ovale malaria. For those with extended exposure to areas with high rates of infection due to these species, presumptive anti-relapse therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/59/38837?source=see_link\">",
"     primaquine",
"    </a>",
"    may be necessary to prevent relapse. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Drug mechanisms'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H15\">",
"     'Primaquine'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/21/17751?source=see_link\">",
"     Mefloquine",
"    </a>",
"    is administered weekly beginning at least two weeks prior to exposure, during exposure, and for four weeks following exposure. Dosing is outlined in the Table (",
"    <a class=\"graphic graphic_table graphicRef75761 \" href=\"UTD.htm?8/19/8510\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef54777 \" href=\"UTD.htm?11/59/12222\">",
"     table 3",
"    </a>",
"    ). Some travelers experience adverse effects from mefloquine; most are mild, self-limited, and do not require discontinuation of the drug. The most frequent adverse effects are gastrointestinal upset, lightheadedness, headache, difficulty concentrating, mood swings, and strange dreams [",
"    <a class=\"abstract\" href=\"UTD.htm?13/3/13370/abstract/51\">",
"     51",
"    </a>",
"    ]. About 5 percent of travelers experience disabling neuropsychiatric adverse effects requiring discontinuation of the drug. These include anxiety, depression, nightmares, paranoid ideation, and dizziness. About 1 in 10,000 travelers experience severe neuropsychiatric reactions such as seizures and psychosis. Adverse effects appear to be more common among women and less frequent among children [",
"    <a class=\"abstract\" href=\"UTD.htm?13/3/13370/abstract/70\">",
"     70",
"    </a>",
"    ]. Most adverse effects requiring mefloquine discontinuation occur within the first three doses. Therefore, some favor starting mefloquine four weeks prior to travel to determine drug tolerance.",
"   </p>",
"   <p>",
"    Contraindications to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/21/17751?source=see_link\">",
"     mefloquine",
"    </a>",
"    include known hypersensitivity to the drug, a history of seizures or major psychiatric disorder, and a recent history of depression or anxiety. Development of psychiatric symptoms (such as depression, anxiety, restlessness, or confusion) while taking mefloquine should be viewed as a possible prelude to other events; in such circumstances it is advisable to stop the drug immediately and switch to a different prophylaxis agent. Mefloquine has also been associated with sinus bradycardia and QT interval prolongation; therefore, it should be used with caution in patients with cardiac conduction disorders.",
"   </p>",
"   <p>",
"    For pregnant patients who cannot avoid travel to areas with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25447?source=see_link\">",
"     chloroquine",
"    </a>",
"    -resistant P. falciparum,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/21/17751?source=see_link\">",
"     mefloquine",
"    </a>",
"    may be safely administered during all trimesters [",
"    <a class=\"abstract\" href=\"UTD.htm?13/3/13370/abstract/71\">",
"     71",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Pregnant travelers'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Doxycycline",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     Doxycycline",
"    </a>",
"    has activity against",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25447?source=see_link\">",
"     chloroquine",
"    </a>",
"    -sensitive and chloroquine-resistant P. falciparum, as well as the other malaria species that cause human malaria [",
"    <a class=\"abstract\" href=\"UTD.htm?13/3/13370/abstract/15,72-74\">",
"     15,72-74",
"    </a>",
"    ]. Comparative trials have demonstrated equivalent efficacy of doxycycline with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/21/17751?source=see_link\">",
"     mefloquine",
"    </a>",
"    (eg, 93 to 99 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/3/13370/abstract/73,75-77\">",
"     73,75-77",
"    </a>",
"    ]. Doxycycline can provide some protection against infection with some rickettsial infections (eg, scrub typhus) and Leptospira spp [",
"    <a class=\"abstract\" href=\"UTD.htm?13/3/13370/abstract/78,79\">",
"     78,79",
"    </a>",
"    ]. However, doxycycline does not prevent the development of residual hepatic hypnozoite forms of P. vivax or P. ovale malaria. Thus, for those with extended exposure to areas with high rates of infection due to these species, presumptive anti-relapse therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/59/38837?source=see_link\">",
"     primaquine",
"    </a>",
"    may be necessary to prevent relapse. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Drug mechanisms'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H15\">",
"     'Primaquine'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     Doxycycline",
"    </a>",
"    is administered daily beginning one to two days prior to exposure, daily during exposure, and daily for four weeks following exposure. Dosing is outlined in the Table (",
"    <a class=\"graphic graphic_table graphicRef75761 \" href=\"UTD.htm?8/19/8510\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef54777 \" href=\"UTD.htm?11/59/12222\">",
"     table 3",
"    </a>",
"    ). Noncompliance with this daily regimen is an important reason for doxycycline prophylaxis failure [",
"    <a class=\"abstract\" href=\"UTD.htm?13/3/13370/abstract/60,80\">",
"     60,80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     Doxycycline",
"    </a>",
"    is usually well tolerated, but has been associated with gastrointestinal upset; less commonly, ultraviolet photosensitivity, Candida vaginitis, and rare cases of esophageal ulceration may also occur [",
"    <a class=\"abstract\" href=\"UTD.htm?13/3/13370/abstract/81-83\">",
"     81-83",
"    </a>",
"    ]. The drug should be taken with fluids and food; it should not be administered immediately before lying down. Sunscreen should be applied liberally for the duration of prophylaxis. It is advisable to offer women antifungal self treatment for management of Candida vaginitis (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    ). Doxycycline is contraindicated in pregnant women and in children &lt;8 years of age.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Chloroquine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25447?source=see_link\">",
"     Chloroquine",
"    </a>",
"    may be used for prophylaxis for individuals traveling to malarious areas without chloroquine resistance (",
"    <a class=\"graphic graphic_figure graphicRef80738 \" href=\"UTD.htm?27/47/28406\">",
"     figure 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef67536 \" href=\"UTD.htm?37/6/37993\">",
"     figure 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef72797 \" href=\"UTD.htm?38/32/39430\">",
"     figure 5",
"    </a>",
"    ) and (see",
"    <a class=\"local\" href=\"#H9\">",
"     'Drug resistance'",
"    </a>",
"    above). Chloroquine has activity against all Plasmodial species causing human malaria with the exception of chloroquine-resistant P. falciparum strains and uncommon strains of P. vivax in Oceania and Asia. In addition, chloroquine does not prevent the development of residual hepatic hypnozoite forms of P. vivax or P. ovale malaria. Thus, for those with extended exposure to areas with high rates of infection due to these species, presumptive anti-relapse therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/59/38837?source=see_link\">",
"     primaquine",
"    </a>",
"    may be necessary to prevent relapse. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Drug mechanisms'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H15\">",
"     'Primaquine'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Formulations include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25447?source=see_link\">",
"     chloroquine",
"    </a>",
"    phosphate and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    &nbsp;(",
"    <a class=\"graphic graphic_table graphicRef75761 \" href=\"UTD.htm?8/19/8510\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/3/13370/abstract/15\">",
"     15",
"    </a>",
"    ]. Chloroquine is administered once weekly starting one week prior to exposure, once weekly while in the malaria endemic area, and then once weekly for four weeks following exposure. Dosing is outlined in the Table (",
"    <a class=\"graphic graphic_table graphicRef75761 \" href=\"UTD.htm?8/19/8510\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef54777 \" href=\"UTD.htm?11/59/12222\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Apart from its bitter taste,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25447?source=see_link\">",
"     chloroquine",
"    </a>",
"    is usually well tolerated. Minor side effects include gastrointestinal disturbances, dizziness, blurred vision, and headache; gastrointestinal problems may be alleviated by taking the drug with food. It has been associated with triggering flares of psoriasis and pruritis, although serious side effects are rare [",
"    <a class=\"abstract\" href=\"UTD.htm?13/3/13370/abstract/84\">",
"     84",
"    </a>",
"    ]. Pruritus occurs in up to 25 percent of blacks due to concentration of the drug in skin; this is not an allergic reaction. Retinal injury, which can occur when high doses of chloroquine are used to treat rheumatoid arthritis, does not occur with the weekly dosages used for malaria prevention [",
"    <a class=\"abstract\" href=\"UTD.htm?13/3/13370/abstract/85\">",
"     85",
"    </a>",
"    ]. Chloroquine is safe for use in pregnancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Primaquine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/59/38837?source=see_link\">",
"     Primaquine",
"    </a>",
"    has activity against many stages of the malaria parasite including hypnozoites, tissue schizonts, gametocytes, and asexual blood stages of P. vivax (",
"    <a class=\"graphic graphic_figure graphicRef70176 \" href=\"UTD.htm?16/23/16760\">",
"     figure 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/3/13370/abstract/26,86\">",
"     26,86",
"    </a>",
"    ]. It is useful for preventing relapses from the hypnozoite forms of P. vivax and P. ovale; it also has activity against P. falciparum gametocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?13/3/13370/abstract/73\">",
"     73",
"    </a>",
"    ]. The efficacy of primaquine for protection against P. falciparum and P. vivax is 74 to 95 percent and 85 to 92 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?13/3/13370/abstract/73,75,87-89\">",
"     73,75,87-89",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/1/39959?source=see_link&amp;anchor=H3#H3\">",
"     \"Pathogenesis of malaria\", section on 'Life cycle'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/59/38837?source=see_link\">",
"     Primaquine",
"    </a>",
"    may be used either as presumptive anti-relapse therapy (PART) or as primary prophylaxis (see",
"    <a class=\"local\" href=\"#H16\">",
"     'Relapse prevention'",
"    </a>",
"    below). Primaquine primary prophylaxis is appropriate for travelers to regions where the principal endemic species is P. vivax (such as Mexico and Central America) (",
"    <a class=\"graphic graphic_figure graphicRef80738 \" href=\"UTD.htm?27/47/28406\">",
"     figure 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef72797 \" href=\"UTD.htm?38/32/39430\">",
"     figure 5",
"    </a>",
"    ). Primaquine is administered daily beginning one to two days prior to exposure, once daily during exposure, and daily for seven days following exposure. Dosing is outlined in the Table (",
"    <a class=\"graphic graphic_table graphicRef75761 \" href=\"UTD.htm?8/19/8510\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef54777 \" href=\"UTD.htm?11/59/12222\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/3/13370/abstract/87\">",
"     87",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/59/38837?source=see_link\">",
"     Primaquine",
"    </a>",
"    can cause hemolytic anemia in those with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Therefore, a G6PD level must be determined prior to administration of this drug and patients should receive primaquine only if G6PD deficiency has been excluded. Primaquine may also cause gastrointestinal upset that can be minimized if taken with food. Primaquine is contraindicated in pregnancy and breastfeeding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Relapse prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Late-onset or relapsed disease due to reactivation of hypnozoites can occur up to many months after initial infection. Hypnozoites are a quiescent stage in the liver that exist only in the setting of P. vivax and P. ovale infection. According to CDC 2010 surveillance data, 120 travelers who took appropriate chemoprophylaxis were diagnosed with malaria; among the 243 cases of P. vivax or P. ovale in this group, 50 percent developed symptoms &gt;45 days after arrival in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?13/3/13370/abstract/4\">",
"     4",
"    </a>",
"    ]. Hepatic stages cause no fever symptoms and one does not need to have had a primary clinical episode of malaria in order to have a relapse.",
"   </p>",
"   <p>",
"    Use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/59/38837?source=see_link\">",
"     primaquine",
"    </a>",
"    for presumptive anti-relapse therapy (PART; the term terminal prophylaxis has also been used in the literature) is appropriate for travelers to regions where there is substantial transmission of P. vivax or P. ovale, even if P. falciparum is the predominant endemic species (",
"    <a class=\"graphic graphic_figure graphicRef72797 \" href=\"UTD.htm?38/32/39430\">",
"     figure 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/3/13370/abstract/51,90\">",
"     51,90",
"    </a>",
"    ]. This is especially appropriate for travelers with prolonged stays where P. vivax or P. ovale are present [",
"    <a class=\"abstract\" href=\"UTD.htm?13/3/13370/abstract/51\">",
"     51",
"    </a>",
"    ]. In addition to administration of an agent with activity against blood stage parasites prior to, during, and following exposure (such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/56/902?source=see_link\">",
"     atovaquone-proguanil",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/21/17751?source=see_link\">",
"     mefloquine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    ), primaquine is added for activity against liver hypnozoites, which can cause disease after completion of the primary chemoprophylaxis regimen (",
"    <a class=\"graphic graphic_figure graphicRef70176 \" href=\"UTD.htm?16/23/16760\">",
"     figure 6",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Following departure from an endemic area,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/59/38837?source=see_link\">",
"     primaquine",
"    </a>",
"    should be administered for 14 days together with the remainder of the primary prophylaxis regimen. If the primary prophylaxis regimen has already been completed, a course of primaquine is still beneficial for prevention of relapse (",
"    <a class=\"graphic graphic_table graphicRef75761 \" href=\"UTD.htm?8/19/8510\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef54777 \" href=\"UTD.htm?11/59/12222\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Drug mechanisms'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H15\">",
"     'Primaquine'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    This issue is discussed in further detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/18/4394?source=see_link&amp;anchor=H20#H20\">",
"     \"Overview of non-falciparum malaria\", section on 'Preventing relapse'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Pregnant travelers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Malaria can be a life threatening infection for both mother and fetus [",
"    <a class=\"abstract\" href=\"UTD.htm?13/3/13370/abstract/30,31,91\">",
"     30,31,91",
"    </a>",
"    ]. Risk of stillbirth, spontaneous abortion, and other adverse pregnancy outcomes is increased in the setting of malaria, and pregnant travelers should be advised to defer travel until after delivery whenever feasible. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/33/16921?source=see_link\">",
"     \"Overview of malaria in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For pregnant women who cannot defer travel to regions where",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25447?source=see_link\">",
"     chloroquine",
"    </a>",
"    -sensitive malaria is present, mosquito avoidance measures should be used in conjunction with chemoprophylaxis with chloroquine [",
"    <a class=\"abstract\" href=\"UTD.htm?13/3/13370/abstract/15,92\">",
"     15,92",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/21/17751?source=see_link\">",
"     Mefloquine",
"    </a>",
"    is also acceptable.",
"   </p>",
"   <p>",
"    For pregnant women who cannot defer travel to regions where",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25447?source=see_link\">",
"     chloroquine",
"    </a>",
"    -resistant malaria is present, mosquito avoidance measures should be used in conjunction with chemoprophylaxis using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/21/17751?source=see_link\">",
"     mefloquine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?13/3/13370/abstract/93-95\">",
"     93-95",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/21/17751?source=see_link\">",
"     Mefloquine",
"    </a>",
"    may be safely administered during all trimesters [",
"    <a class=\"abstract\" href=\"UTD.htm?13/3/13370/abstract/93,96,97\">",
"     93,96,97",
"    </a>",
"    ]. Safety data on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/56/902?source=see_link\">",
"     atovaquone-proguanil",
"    </a>",
"    in pregnancy are limited, so this agent should be avoided in pregnancy.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     Doxycycline",
"    </a>",
"    should not be administered during pregnancy because of potential adverse effects to the fetus including dysplasia and inhibition of bone growth and dental discoloration.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/59/38837?source=see_link\">",
"     Primaquine",
"    </a>",
"    should not be administered during pregnancy given the potential possibility for fetal G6PD deficiency.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16818608\">",
"    <span class=\"h2\">",
"     Children",
"    </span>",
"    &nbsp;&mdash;&nbsp;All children traveling to malaria-endemic areas should take antimalarial prophylaxis.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25447?source=see_link\">",
"     Chloroquine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/21/17751?source=see_link\">",
"     mefloquine",
"    </a>",
"    are options for use in infants and children of all ages and weights (",
"    <a class=\"graphic graphic_table graphicRef54777 \" href=\"UTD.htm?11/59/12222\">",
"     table 3",
"    </a>",
"    ).",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/56/902?source=see_link\">",
"     Atovaquone-proguanil",
"    </a>",
"    may be administered to individuals &ge;5 kg;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    may be administered to individuals &ge;8 years (",
"    <a class=\"graphic graphic_table graphicRef54777 \" href=\"UTD.htm?11/59/12222\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Drug interactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to prescribing antimalarial medication, the traveler's medication history should be reviewed in detail with consideration for potential drug-drug interactions. Some relatively common drugs with important interactions include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       Warfarin",
"      </a>",
"      :",
"      <span class=\"nowrap\">",
"       <a class=\"drug drug_general\" href=\"UTD.htm?11/5/11350?source=see_link\">",
"        Atovaquone",
"       </a>",
"       /proguanil",
"      </span>",
"      may diminish metabolism of warfarin. Coagulation parameters should be monitored closely if these drugs are used together, and the warfarin dosing may need to be reduced [",
"      <a class=\"abstract\" href=\"UTD.htm?13/3/13370/abstract/98\">",
"       98",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Antiarrhythmic agents: these drugs should be used with caution in the setting of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/21/17751?source=see_link\">",
"       mefloquine",
"      </a>",
"      administration, which has been associated with been associated with sinus bradycardia and QT interval prolongation.",
"     </li>",
"     <li>",
"      Protease inhibitors and non-nucleoside reverse transcriptase inhibitors: these agents may diminish metabolism of antimalarials and lead to potential interaction that may require close monitoring, alteration of drug dosage or timing of administration [",
"      <a class=\"abstract\" href=\"UTD.htm?13/3/13370/abstract/99,100\">",
"       99,100",
"      </a>",
"      ]. In light of limited data,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      seems to have the least potential for drug-drug interactions with HIV drugs.",
"     </li>",
"     <li>",
"      Immunosuppressive medications:",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25447?source=see_link\">",
"       chloroquine",
"      </a>",
"      may increase",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      levels and both",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/21/17751?source=see_link\">",
"       mefloquine",
"      </a>",
"      may increase levels of cyclosporine and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?13/3/13370/abstract/101\">",
"       101",
"      </a>",
"      ].",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/56/902?source=see_link\">",
"       Atovaquone-proguanil",
"      </a>",
"      does not have known interactions with these medications.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Suggested approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Selection of chemoprophylaxis must be tailored to individual itineraries and circumstances. For patients traveling to several destinations with different types of malaria transmission patterns, it may be simplest to select a single agent that will be effective for the entire duration of exposure.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For travelers to destinations where malaria cases occur only sporadically and risk to travelers is very low, mosquito avoidance measures should be used; no chemoprophylaxis is needed.",
"     </li>",
"     <li>",
"      For travelers at risk of malaria infection in destinations where",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25447?source=see_link\">",
"       chloroquine",
"      </a>",
"      -resistant P. falciparum malaria is present, mosquito avoidance measures should be used in conjunction with chemoprophylaxis. Options include",
"      <span class=\"nowrap\">",
"       <a class=\"drug drug_general\" href=\"UTD.htm?11/5/11350?source=see_link\">",
"        atovaquone",
"       </a>",
"       /proguanil,",
"      </span>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/21/17751?source=see_link\">",
"       mefloquine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      ; all three agents are highly efficacious for prevention of malaria. Comparative studies among travelers taking mefloquine or",
"      <span class=\"nowrap\">",
"       atovaquone/proguanil",
"      </span>",
"      have demonstrated fewer side effects experienced among recipients of",
"      <span class=\"nowrap\">",
"       atovaquone/proguanil,",
"      </span>",
"      although this agent is more costly [",
"      <a class=\"abstract\" href=\"UTD.htm?13/3/13370/abstract/67\">",
"       67",
"      </a>",
"      ]. Short-term travelers may prefer the shorter course of",
"      <span class=\"nowrap\">",
"       atovaquone/proguanil,",
"      </span>",
"      whereas long-term travelers may prefer the convenience of weekly mefloquine. Doxycycline requires a prolonged course, must be taken daily, and causes sun sensitization, although it is the least expensive of these agents.",
"     </li>",
"     <li>",
"      For travelers at risk of malaria infection in destinations where",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25447?source=see_link\">",
"       chloroquine",
"      </a>",
"      -sensitive P. falciparum malaria is present, mosquito avoidance measures should be used in conjunction with chemoprophylaxis. Chloroquine may be used, although short term travelers may prefer the shorter course of",
"      <span class=\"nowrap\">",
"       <a class=\"drug drug_general\" href=\"UTD.htm?11/5/11350?source=see_link\">",
"        atovaquone",
"       </a>",
"       /proguanil.",
"      </span>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/21/17751?source=see_link\">",
"       Mefloquine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      are also effective agents.",
"     </li>",
"     <li>",
"      For travelers at risk of malaria infection in destinations where the predominant species is P. vivax (such as the malaria-endemic parts of Mexico and Central America), mosquito avoidance measures should be used in conjunction with chemoprophylaxis.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/59/38837?source=see_link\">",
"       Primaquine",
"      </a>",
"      may be used in the absence of G6PD deficiency;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25447?source=see_link\">",
"       chloroquine",
"      </a>",
"      is also effective. Short term travelers may prefer the shorter course of",
"      <span class=\"nowrap\">",
"       <a class=\"drug drug_general\" href=\"UTD.htm?11/5/11350?source=see_link\">",
"        atovaquone",
"       </a>",
"       /proguanil.",
"      </span>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/21/17751?source=see_link\">",
"       Mefloquine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      are also effective agents [",
"      <a class=\"abstract\" href=\"UTD.htm?13/3/13370/abstract/102\">",
"       102",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      For travelers at risk of malaria infection in destinations where P. falciparum strains resistant to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25447?source=see_link\">",
"       chloroquine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/21/17751?source=see_link\">",
"       mefloquine",
"      </a>",
"      , and sulfonamides are present (such as in the malaria-endemic regions of Thailand bordering Burma [Myanmar] and Cambodia [eg, eastern provinces of Burma (Myanmar) and western provinces of Cambodia], China, Laos, and Vietnam), mosquito avoidance measures should be used in conjunction with chemoprophylaxis. Options include",
"      <span class=\"nowrap\">",
"       <a class=\"drug drug_general\" href=\"UTD.htm?11/5/11350?source=see_link\">",
"        atovaquone",
"       </a>",
"       /proguanil",
"      </span>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is appropriate to administer antimalarial drugs for as long as needed for prevention of malaria infection; toxicity after prolonged use has not been proven. However, use of the drugs may be registered differently in different countries.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?20/44/21187?source=see_link\">",
"       \"Patient information: Vaccines for travel (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?3/47/3826?source=see_link\">",
"       \"Patient information: Malaria (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?16/2/16421?source=see_link\">",
"       \"Patient information: General travel advice (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Malaria is an important cause of fever and serious illness in returned travelers. Approximately 1500 cases of imported malaria are reported annually to the United States Centers for Disease Control and Prevention (CDC); more than half of these are due to P. falciparum. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Risk assessment for malaria requires detailed review of the planned itinerary together with the most recent CDC guidelines and advisories. An excellent summary of areas with malaria transmission and prophylaxis by country is available at the following web site:",
"      <a class=\"external\" href=\"file://wwwnc.cdc.gov/travel/yellowbook/2012/chapter-3-infectious-diseases-related-to-travel/yellow-fever-and-malaria-information-by-country.htm\">",
"       file://wwwnc.cdc.gov/travel/yellowbook/2012/chapter-3-infectious-diseases-related-to-travel/yellow-fever-and-malaria-information-by-country.htm",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Destination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      High risk groups include travelers born in regions with endemic malaria who relocate outside the endemic area but subsequently return to visit friends and relatives, pregnant women, and military personnel. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Type of traveler'",
"      </a>",
"      above.).",
"     </li>",
"     <li>",
"      Travelers to malarious areas should be counseled regarding mosquito bite prevention and adherence to antimalarial chemoprophylaxis if indicated. However, travelers also understand that no chemoprophylaxis regimen guarantees complete protection; fever during or after travel is a medical emergency requiring urgent medical attention. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Counseling'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Travelers should receive instructions regarding methods to prevent bites from Anopheles mosquitoes, including avoiding outdoor exposure between dusk and dawn, wearing clothing that reduces the amount of exposed skin, wearing insect repellant (eg, DEET or picaridin), staying in well-screened or air-conditioned rooms, and sleeping within bed nets treated with insecticide (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/22/28004?source=see_link\">",
"       permethrin",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Mosquito bite prevention'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend chemoprophylaxis for patients at risk of malaria infection because of travel to destinations with malaria transmission (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Because of variation in malaria transmission and antimalarial drug resistance, individual itineraries should be reviewed together with the most recent CDC guidelines and advisories (",
"      <a class=\"graphic graphic_table graphicRef75761 \" href=\"UTD.htm?8/19/8510\">",
"       table 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef54777 \" href=\"UTD.htm?11/59/12222\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Chemoprophylaxis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H19\">",
"       'Suggested approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Late-onset or relapsed disease due to reactivation of P. vivax or P. ovale hypnozoites can occur up to many months after initial infection. Use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/59/38837?source=see_link\">",
"       primaquine",
"      </a>",
"      for presumptive anti-relapse therapy is appropriate for travelers to regions where there is substantial transmission of P. vivax or P. ovale, even if P. falciparum is the predominant endemic species. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Relapse prevention'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pregnant women traveling to malarious areas are increased risk for life threatening infection and adverse outcomes for both mother and fetus. Pregnant travelers should be advised to defer travel until after delivery whenever feasible. Chemoprophylaxis in the setting of pregnancy is discussed above. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Pregnant travelers'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/3/13370/abstract/1\">",
"      Wilson ME, Weld LH, Boggild A, et al. Fever in returned travelers: results from the GeoSentinel Surveillance Network. Clin Infect Dis 2007; 44:1560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/3/13370/abstract/2\">",
"      Leder K, Black J, O'Brien D, et al. Malaria in travelers: a review of the GeoSentinel surveillance network. Clin Infect Dis 2004; 39:1104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/3/13370/abstract/3\">",
"      Hill DR, Ericsson CD, Pearson RD, et al. The practice of travel medicine: guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2006; 43:1499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/3/13370/abstract/4\">",
"      Mali S, Steele S, Slutsker L, et al. Malaria surveillance - United States, 2008. MMWR Surveill Summ 2010; 59:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/3/13370/abstract/5\">",
"      Mali S, Kachur SP, Arguin PM, et al. Malaria surveillance--United States, 2010. MMWR Surveill Summ 2012; 61:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/3/13370/abstract/6\">",
"      Humar A, Sharma S, Zoutman D, Kain KC. Fatal falciparum malaria in Canadian travellers. CMAJ 1997; 156:1165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/3/13370/abstract/7\">",
"      Bruneel F, Hocqueloux L, Alberti C, et al. The clinical spectrum of severe imported falciparum malaria in the intensive care unit: report of 188 cases in adults. Am J Respir Crit Care Med 2003; 167:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/3/13370/abstract/8\">",
"      Cox-Singh J, Davis TM, Lee KS, et al. Plasmodium knowlesi malaria in humans is widely distributed and potentially life threatening. Clin Infect Dis 2008; 46:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/3/13370/abstract/9\">",
"      Kochar DK, Saxena V, Singh N, et al. Plasmodium vivax malaria. Emerg Infect Dis 2005; 11:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/3/13370/abstract/10\">",
"      Froude JR, Weiss LM, Tanowitz HB, Wittner M. Imported malaria in the Bronx: review of 51 cases recorded from 1986 to 1991. Clin Infect Dis 1992; 15:774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/3/13370/abstract/11\">",
"      Svenson JE, MacLean JD, Gyorkos TW, Keystone J. Imported malaria. Clinical presentation and examination of symptomatic travelers. Arch Intern Med 1995; 155:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/3/13370/abstract/12\">",
"      Krause G, Sch&ouml;neberg I, Altmann D, Stark K. Chemoprophylaxis and malaria death rates. Emerg Infect Dis 2006; 12:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/3/13370/abstract/13\">",
"      Freedman DO. Clinical practice. Malaria prevention in short-term travelers. N Engl J Med 2008; 359:603.",
"     </a>",
"    </li>",
"    <li>",
"     file://wwwn.cdc.gov/travel/default.aspx (Accessed on September 26, 2008).",
"    </li>",
"    <li>",
"     CDC. Health information for international travel 2011-2012. DHHS, Atlanta, GA 2011.",
"    </li>",
"    <li>",
"     CDC. Yellow Fever Vaccine Requirements and Information on Malaria Risk and Prophylaxis, by Country. wwwn.cdc.gov/travel/yellowBookCh5-MalariaYellowFeverTable.aspx (Accessed on September 26, 2008).",
"    </li>",
"    <li>",
"     file://www.cdc.gov/malaria/risk_map (CDC Malaria map application). (Accessed September 26, 2008).",
"    </li>",
"    <li>",
"     file://www.who.int/ith/countries/en/index.html (Accessed on September 26, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/3/13370/abstract/19\">",
"      Leder K, Tong S, Weld L, et al. Illness in travelers visiting friends and relatives: a review of the GeoSentinel Surveillance Network. Clin Infect Dis 2006; 43:1185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/3/13370/abstract/20\">",
"      Fenner L, Weber R, Steffen R, Schlagenhauf P. Imported infectious disease and purpose of travel, Switzerland. Emerg Infect Dis 2007; 13:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/3/13370/abstract/21\">",
"      Askling HH, Nilsson J, Tegnell A, et al. Malaria risk in travelers. Emerg Infect Dis 2005; 11:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/3/13370/abstract/22\">",
"      Bacaner N, Stauffer B, Boulware DR, et al. Travel medicine considerations for North American immigrants visiting friends and relatives. JAMA 2004; 291:2856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/3/13370/abstract/23\">",
"      Angell SY, Cetron MS. Health disparities among travelers visiting friends and relatives abroad. Ann Intern Med 2005; 142:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/3/13370/abstract/24\">",
"      Ciminera P, Brundage J. Malaria in U.S. military forces: a description of deployment exposures from 2003 through 2005. Am J Trop Med Hyg 2007; 76:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/3/13370/abstract/25\">",
"      Newman RD, Parise ME, Barber AM, Steketee RW. Malaria-related deaths among U.S. travelers, 1963-2001. Ann Intern Med 2004; 141:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/3/13370/abstract/26\">",
"      Schwartz E, Parise M, Kozarsky P, Cetron M. Delayed onset of malaria--implications for chemoprophylaxis in travelers. N Engl J Med 2003; 349:1510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/3/13370/abstract/27\">",
"      Causer LM, Filler S, Wilson M, et al. Evaluation of reported malaria chemoprophylactic failure among travelers in a US University Exchange Program, 2002. Clin Infect Dis 2004; 39:1583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/3/13370/abstract/28\">",
"      Reyburn H, Mbatia R, Drakeley C, et al. Overdiagnosis of malaria in patients with severe febrile illness in Tanzania: a prospective study. BMJ 2004; 329:1212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/3/13370/abstract/29\">",
"      Keystone JS. The sound of hoof beats does not always mean that it is a zebra. Clin Infect Dis 2004; 39:1589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/3/13370/abstract/30\">",
"      Steketee RW, Wirima JJ, Hightower AW, et al. The effect of malaria and malaria prevention in pregnancy on offspring birthweight, prematurity, and intrauterine growth retardation in rural Malawi. Am J Trop Med Hyg 1996; 55:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/3/13370/abstract/31\">",
"      Steketee RW, Wirima JJ, Slutsker L, et al. Malaria parasite infection during pregnancy and at delivery in mother, placenta, and newborn: efficacy of chloroquine and mefloquine in rural Malawi. Am J Trop Med Hyg 1996; 55:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/3/13370/abstract/32\">",
"      Insect repellents. Med Lett Drugs Ther 2003; 45:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/3/13370/abstract/33\">",
"      Fradin MS, Day JF. Comparative efficacy of insect repellents against mosquito bites. N Engl J Med 2002; 347:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/3/13370/abstract/34\">",
"      Nevill CG, Some ES, Mung'ala VO, et al. Insecticide-treated bednets reduce mortality and severe morbidity from malaria among children on the Kenyan coast. Trop Med Int Health 1996; 1:139.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.cdc.gov/malaria/travel/drugs_public.htm (Accessed December 18, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/3/13370/abstract/36\">",
"      Advice for travelers. Treat Guidel Med Lett 2006; 4:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/3/13370/abstract/37\">",
"      Frances SP, Waterson DG, Beebe NW, Cooper RD. Field evaluation of repellent formulations containing deet and picaridin against mosquitoes in Northern Territory, Australia. J Med Entomol 2004; 41:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/3/13370/abstract/38\">",
"      Ryan ET, Kain KC. Health advice and immunizations for travelers. N Engl J Med 2000; 342:1716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/3/13370/abstract/39\">",
"      Kimani EW, Vulule JM, Kuria IW, Mugisha F. Use of insecticide-treated clothes for personal protection against malaria: a community trial. Malar J 2006; 5:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/3/13370/abstract/40\">",
"      Faulde MK, Uedelhoven WM, Robbins RG. Contact toxicity and residual activity of different permethrin-based fabric impregnation methods for Aedes aegypti (Diptera: Culicidae), Ixodes ricinus (Acari: Ixodidae), and Lepisma saccharina (Thysanura: Lepismatidae). J Med Entomol 2003; 40:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/3/13370/abstract/41\">",
"      Fradin MS. Mosquitoes and mosquito repellents: a clinician's guide. Ann Intern Med 1998; 128:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/3/13370/abstract/42\">",
"      Schreck CE, McGovern TP. Repellents and other personal protection strategies against Aedes albopictus. J Am Mosq Control Assoc 1989; 5:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/3/13370/abstract/43\">",
"      Gupta RK, Rutledge LC, Reifenrath WG, et al. Effects of weathering on fabrics treated with permethrin for protection against mosquitoes. J Am Mosq Control Assoc 1989; 5:176.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.maqweb.org/techbriefs/tb17bednets.shtml (Accessed October 9, 2008).",
"    </li>",
"    <li>",
"     file://www.who.int/malaria/docs/itn/ITNspospaperfinal.pdf (Accessed October 9, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/3/13370/abstract/46\">",
"      Baird JK. Chloroquine resistance in Plasmodium vivax. Antimicrob Agents Chemother 2004; 48:4075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/3/13370/abstract/47\">",
"      Talisuna AO, Bloland P, D'Alessandro U. History, dynamics, and public health importance of malaria parasite resistance. Clin Microbiol Rev 2004; 17:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/3/13370/abstract/48\">",
"      Bloland PB, Ettling M. Making malaria-treatment policy in the face of drug resistance. Ann Trop Med Parasitol 1999; 93:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/3/13370/abstract/49\">",
"      Wellems TE, Plowe CV. Chloroquine-resistant malaria. J Infect Dis 2001; 184:770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/3/13370/abstract/50\">",
"      Baird JK, Sustriayu Nalim MF, Basri H, et al. Survey of resistance to chloroquine by Plasmodium vivax in Indonesia. Trans R Soc Trop Med Hyg 1996; 90:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/3/13370/abstract/51\">",
"      Chen LH, Wilson ME, Schlagenhauf P. Controversies and misconceptions in malaria chemoprophylaxis for travelers. JAMA 2007; 297:2251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/3/13370/abstract/52\">",
"      Chen LH, Keystone JS. New strategies for the prevention of malaria in travelers. Infect Dis Clin North Am 2005; 19:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/3/13370/abstract/53\">",
"      Bate R, Coticelli P, Tren R, Attaran A. Antimalarial drug quality in the most severely malarious parts of Africa - a six country study. PLoS One 2008; 3:e2132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/3/13370/abstract/54\">",
"      Dondorp AM, Newton PN, Mayxay M, et al. Fake antimalarials in Southeast Asia are a major impediment to malaria control: multinational cross-sectional survey on the prevalence of fake antimalarials. Trop Med Int Health 2004; 9:1241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/3/13370/abstract/55\">",
"      Boggild AK, Parise ME, Lewis LS, Kain KC. Atovaquone-proguanil: report from the CDC expert meeting on malaria chemoprophylaxis (II). Am J Trop Med Hyg 2007; 76:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/3/13370/abstract/56\">",
"      Overbosch D, Schilthuis H, Bienzle U, et al. Atovaquone-proguanil versus mefloquine for malaria prophylaxis in nonimmune travelers: results from a randomized, double-blind study. Clin Infect Dis 2001; 33:1015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/3/13370/abstract/57\">",
"      Chulay JD. Challenges in the development of antimalarial drugs with causal prophylactic activity. Trans R Soc Trop Med Hyg 1998; 92:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/3/13370/abstract/58\">",
"      Shapiro TA, Ranasinha CD, Kumar N, Barditch-Crovo P. Prophylactic activity of atovaquone against Plasmodium falciparum in humans. Am J Trop Med Hyg 1999; 60:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/3/13370/abstract/59\">",
"      Berman JD, Nielsen R, Chulay JD, et al. Causal prophylactic efficacy of atovaquone-proguanil (Malarone) in a human challenge model. Trans R Soc Trop Med Hyg 2001; 95:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/3/13370/abstract/60\">",
"      H&oslash;gh B, Clarke PD, Camus D, et al. Atovaquone-proguanil versus chloroquine-proguanil for malaria prophylaxis in non-immune travellers: a randomised, double-blind study. Malarone International Study Team. Lancet 2000; 356:1888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/3/13370/abstract/61\">",
"      Lell B, Luckner D, Ndjav&eacute; M, et al. Randomised placebo-controlled study of atovaquone plus proguanil for malaria prophylaxis in children. Lancet 1998; 351:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/3/13370/abstract/62\">",
"      Shanks GD, Gordon DM, Klotz FW, et al. Efficacy and safety of atovaquone/proguanil as suppressive prophylaxis for Plasmodium falciparum malaria. Clin Infect Dis 1998; 27:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/3/13370/abstract/63\">",
"      Sukwa TY, Mulenga M, Chisdaka N, et al. A randomized, double-blind, placebo-controlled field trial to determine the efficacy and safety of Malarone (atovaquone/proguanil) for the prophylaxis of malaria in Zambia. Am J Trop Med Hyg 1999; 60:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/3/13370/abstract/64\">",
"      van der Berg JD, Duvenage CS, Roskell NS, Scott TR. Safety and efficacy of atovaquone and proguanil hydrochloride for the prophylaxis of Plasmodium falciparum malaria in South Africa. Clin Ther 1999; 21:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/3/13370/abstract/65\">",
"      Ling J, Baird JK, Fryauff DJ, et al. Randomized, placebo-controlled trial of atovaquone/proguanil for the prevention of Plasmodium falciparum or Plasmodium vivax malaria among migrants to Papua, Indonesia. Clin Infect Dis 2002; 35:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/3/13370/abstract/66\">",
"      Camus D, Djossou F, Schilthuis HJ, et al. Atovaquone-proguanil versus chloroquine-proguanil for malaria prophylaxis in nonimmune pediatric travelers: results of an international, randomized, open-label study. Clin Infect Dis 2004; 38:1716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/3/13370/abstract/67\">",
"      van Riemsdijk MM, Sturkenboom MC, Ditters JM, et al. Atovaquone plus chloroguanide versus mefloquine for malaria prophylaxis: a focus on neuropsychiatric adverse events. Clin Pharmacol Ther 2002; 72:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/3/13370/abstract/68\">",
"      McKeage K, Scott L. Atovaquone/proguanil: a review of its use for the prophylaxis of Plasmodium falciparum malaria. Drugs 2003; 63:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/3/13370/abstract/69\">",
"      Steffen R, Fuchs E, Schildknecht J, et al. Mefloquine compared with other malaria chemoprophylactic regimens in tourists visiting east Africa. Lancet 1993; 341:1299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/3/13370/abstract/70\">",
"      Schlagenhauf P, Adamcova M, Regep L, et al. Use of mefloquine in children - a review of dosage, pharmacokinetics and tolerability data. Malar J 2011; 10:292.",
"     </a>",
"    </li>",
"    <li>",
"     CDC: Malaria. Update: New Recommendations for Mefloquine Use in Pregnancy www.cdc.gov/malaria/new_info/2011/mefloquine_pregnancy.html (Accessed on January 24, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/3/13370/abstract/72\">",
"      Pang LW, Limsomwong N, Boudreau EF, Singharaj P. Doxycycline prophylaxis for falciparum malaria. Lancet 1987; 1:1161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/3/13370/abstract/73\">",
"      Soto J, Toledo J, Rodriquez M, et al. Primaquine prophylaxis against malaria in nonimmune Colombian soldiers: efficacy and toxicity. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1998; 129:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/3/13370/abstract/74\">",
"      Tan KR, Magill AJ, Parise ME, et al. Doxycycline for malaria chemoprophylaxis and treatment: report from the CDC expert meeting on malaria chemoprophylaxis. Am J Trop Med Hyg 2011; 84:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/3/13370/abstract/75\">",
"      Weiss WR, Oloo AJ, Johnson A, et al. Daily primaquine is effective for prophylaxis against falciparum malaria in Kenya: comparison with mefloquine, doxycycline, and chloroquine plus proguanil. J Infect Dis 1995; 171:1569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/3/13370/abstract/76\">",
"      Ohrt C, Richie TL, Widjaja H, et al. Mefloquine compared with doxycycline for the prophylaxis of malaria in Indonesian soldiers. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1997; 126:963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/3/13370/abstract/77\">",
"      Andersen SL, Oloo AJ, Gordon DM, et al. Successful double-blinded, randomized, placebo-controlled field trial of azithromycin and doxycycline as prophylaxis for malaria in western Kenya. Clin Infect Dis 1998; 26:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/3/13370/abstract/78\">",
"      Takafuji ET, Kirkpatrick JW, Miller RN, et al. An efficacy trial of doxycycline chemoprophylaxis against leptospirosis. N Engl J Med 1984; 310:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/3/13370/abstract/79\">",
"      Olson JG, Bourgeois AL, Fang RC, et al. Prevention of scrub typhus. Prophylactic administration of doxycycline in a randomized double blind trial. Am J Trop Med Hyg 1980; 29:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/3/13370/abstract/80\">",
"      Wallace MR, Sharp TW, Smoak B, et al. Malaria among United States troops in Somalia. Am J Med 1996; 100:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/3/13370/abstract/81\">",
"      Frost P, Weinstein GD, Gomez EC. Phototoxic potential of minocycline and doxycycline. Arch Dermatol 1972; 105:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/3/13370/abstract/82\">",
"      Phillips MA, Kass RB. User Acceptability Patterns for Mefloquine and Doxycycline Malaria Chemoprophylaxis. J Travel Med 1996; 3:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/3/13370/abstract/83\">",
"      Morris TJ, Davis TP. Doxycycline-induced esophageal ulceration in the U.S. Military service. Mil Med 2000; 165:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/3/13370/abstract/84\">",
"      Salako LA. Toxicity and side-effects of antimalarials in Africa: a critical review. Bull World Health Organ 1984; 62 Suppl:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/3/13370/abstract/85\">",
"      Appleton B, Wolfe MS, Mishtowt GI. Chloroquine as a malarial suppressive: absence of visual effects. Mil Med 1973; 138:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/3/13370/abstract/86\">",
"      Baird JK, Fryauff DJ, Hoffman SL. Primaquine for prevention of malaria in travelers. Clin Infect Dis 2003; 37:1659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/3/13370/abstract/87\">",
"      Hill DR, Baird JK, Parise ME, et al. Primaquine: report from CDC expert meeting on malaria chemoprophylaxis I. Am J Trop Med Hyg 2006; 75:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/3/13370/abstract/88\">",
"      Baird JK, Fryauff DJ, Basri H, et al. Primaquine for prophylaxis against malaria among nonimmune transmigrants in Irian Jaya, Indonesia. Am J Trop Med Hyg 1995; 52:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/3/13370/abstract/89\">",
"      Schwartz E, Regev-Yochay G. Primaquine as prophylaxis for malaria for nonimmune travelers: A comparison with mefloquine and doxycycline. Clin Infect Dis 1999; 29:1502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/3/13370/abstract/90\">",
"      Galappaththy GN, Omari AA, Tharyan P. Primaquine for preventing relapses in people with Plasmodium vivax malaria. Cochrane Database Syst Rev 2007; :CD004389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/3/13370/abstract/91\">",
"      Lindsay S, Ansell J, Selman C, et al. Effect of pregnancy on exposure to malaria mosquitoes. Lancet 2000; 355:1972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/3/13370/abstract/92\">",
"      Whitty CJ, Edmonds S, Mutabingwa TK. Malaria in pregnancy. BJOG 2005; 112:1189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/3/13370/abstract/93\">",
"      Smoak BL, Writer JV, Keep LW, et al. The effects of inadvertent exposure of mefloquine chemoprophylaxis on pregnancy outcomes and infants of US Army servicewomen. J Infect Dis 1997; 176:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/3/13370/abstract/94\">",
"      Steketee RW, Wirima JJ, Slutsker L, et al. Malaria treatment and prevention in pregnancy: indications for use and adverse events associated with use of chloroquine or mefloquine. Am J Trop Med Hyg 1996; 55:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/3/13370/abstract/95\">",
"      Okeyeh JN, Lege-Oguntoye L, Emembolu JO, Agbo M. Malaria in pregnancy: efficacy of a low dose of mefloquine in an area holoendemic for multi-drug resistant Plasmodium falciparum. Ann Trop Med Parasitol 1996; 90:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/3/13370/abstract/96\">",
"      Nosten F, ter Kuile F, Maelankiri L, et al. Mefloquine prophylaxis prevents malaria during pregnancy: a double-blind, placebo-controlled study. J Infect Dis 1994; 169:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/3/13370/abstract/97\">",
"      Vanhauwere B, Maradit H, Kerr L. Post-marketing surveillance of prophylactic mefloquine (Lariam) use in pregnancy. Am J Trop Med Hyg 1998; 58:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/3/13370/abstract/98\">",
"      Warfarin potentiated by proguanil. BMJ 1991; 303:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/3/13370/abstract/99\">",
"      Khoo S, Back D, Winstanley P. The potential for interactions between antimalarial and antiretroviral drugs. AIDS 2005; 19:995.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.hiv-druginteractions.org/ (Accessed September 26, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/3/13370/abstract/101\">",
"      Kotton CN, Ryan ET, Fishman JA. Prevention of infection in adult travelers after solid organ transplantation. Am J Transplant 2005; 5:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/3/13370/abstract/102\">",
"      Steinhardt LC, Magill AJ, Arguin PM. Review: Malaria chemoprophylaxis for travelers to Latin America. Am J Trop Med Hyg 2011; 85:1015.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5722 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-79.123.134.1-8BED796ECD-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_3_13370=[""].join("\n");
var outline_f13_3_13370=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RISK ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Destination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Type of traveler",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      COUNSELING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      MOSQUITO BITE PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CHEMOPROPHYLAXIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Drug mechanisms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Drug resistance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Regimens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Atovaquone-proguanil",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Mefloquine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Doxycycline",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Chloroquine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Primaquine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Relapse prevention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Pregnant travelers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16818608\">",
"      Children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Drug interactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Suggested approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/5722\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/5722|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/36/37455\" title=\"figure 1\">",
"      Relative malaria rates",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/47/28406\" title=\"figure 2\">",
"      Malaria western hemisphere",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?37/6/37993\" title=\"figure 3\">",
"      Malaria eastern hemisphere",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?3/44/3782\" title=\"figure 4\">",
"      Mefloquine-resistant malaria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/32/39430\" title=\"figure 5\">",
"      Global distribution malaria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/23/16760\" title=\"figure 6\">",
"      Plasmodium life cycle",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/5722|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/30/35308\" title=\"table 1\">",
"      US imported malaria cases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/19/8510\" title=\"table 2\">",
"      Antimalarial ppx adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/59/12222\" title=\"table 3\">",
"      Antimalarial ppx children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/26/5543?source=related_link\">",
"      Clinical manifestations of malaria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/0/10248?source=related_link\">",
"      Diagnosis of malaria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/33/16921?source=related_link\">",
"      Overview of malaria in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/18/4394?source=related_link\">",
"      Overview of non-falciparum malaria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/1/39959?source=related_link\">",
"      Pathogenesis of malaria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?16/2/16421?source=related_link\">",
"      Patient information: General travel advice (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?3/47/3826?source=related_link\">",
"      Patient information: Malaria (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?20/44/21187?source=related_link\">",
"      Patient information: Vaccines for travel (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/1/43031?source=related_link\">",
"      Prevention of arthropod and insect bites: Repellents and other measures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/1/13338?source=related_link\">",
"      Treatment of severe falciparum malaria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/41/25241?source=related_link\">",
"      Treatment of uncomplicated falciparum malaria",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_3_13371="NURSE acronym";
var content_f13_3_13371=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F75046&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F75046&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    NURSE acronym for dealing with strong emotions",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Acronym",
"       </td>",
"       <td class=\"subtitle1\">",
"        Request",
"       </td>",
"       <td class=\"subtitle1\">",
"        Example",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        N",
"       </td>",
"       <td>",
"        Name",
"       </td>",
"       <td>",
"        It sounds like you are frustrated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        U",
"       </td>",
"       <td>",
"        Understanding",
"       </td>",
"       <td>",
"        I cannot imagine what it would be like to be in this situation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        R",
"       </td>",
"       <td>",
"        Respect",
"       </td>",
"       <td>",
"        You are asking all the right questions and doing an amazing job of being an advocate for your husband",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        S",
"       </td>",
"       <td>",
"        Support",
"       </td>",
"       <td>",
"        I will be around to answer any of your questions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        E",
"       </td>",
"       <td>",
"        Explore",
"       </td>",
"       <td>",
"        Tell me more about what you are thinking",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_3_13371=[""].join("\n");
var outline_f13_3_13371=null;
var title_f13_3_13372="Viral skin infections after OLT";
var content_f13_3_13372=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F76657&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F76657&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Viral skin infections after liver transplantation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Virus",
"      </td>",
"      <td class=\"subtitle1\">",
"       Comments",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Cytomegalovirus",
"      </td>",
"      <td>",
"       Uncommon, indicates strong immunosuppression. Mucocutaneous lesions are polymorphic: vesicles, necrotic lesions, oral or genital ulcerations.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Epstein Barr virus",
"      </td>",
"      <td>",
"       Responsible for oral hairy leukoplakia. Sign of a strong immunosuppression.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Herpes simplex",
"      </td>",
"      <td>",
"       Frequent. Reactivation can occur in the days following the transplantation or years later. Sometimes unusual presentations: skin necrosis, ulceration, pseudo-tumoral vegetations. Primary infection via the graft is possible.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Herpes zoster",
"      </td>",
"      <td>",
"       Reactivation can occur in about 20 percent of the patients with a liver graft. Necrotic or hemorrhagic pustules that can be limited to a dermatome or have a generalized distribution. Should be considered as a threatening complication. Can trigger many unexpected complications such as pancreatitis. Like generalized shingles, varicella is a dermatologic emergency given the risk of visceral dissemination: meningoencephalitis, fulminant pneumopathy, and diffuse intravascular coagulopathy.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Molluscum contagiosum",
"      </td>",
"      <td>",
"       Due to a poxvirus infection. Multiple and often large lesions found on the scalp, beard, axillae, and groin. Biopsies are necessary to differentiate them from verrucae, sebaceous hyperplasia, and cryptococcosis.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Papillomavirus",
"      </td>",
"      <td>",
"       Verrucea appear 2 to 3 years after the transplantation and continue to grow and multiply over the years. More than 80 percent of the recipients of a liver graft have verrucea vulgaris or genital warts 5 years after transplantation. They are particularly frequent in patients with a strong immunosuppression. Papillomavirus lesions in the anogenital region increase the risk of a squamous cell carcinoma by a factor of 100. In this transplant context the type of papillomaviruses lose their tissue specificity. Papillomaviruses type 6 and 11 have been found in verrucae vulgaris. Conversion to sirolimus may be a useful strategy for recalcitrant cutaneous viral warts [1].",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     1. Dharancy, S, Catteau, B, Mortier, L, et al. Conversion to sirolimus: a useful strategy for recalcitrant cutaneous viral warts in liver transplant recipient. Liver Transpl 2006; 12:1883.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_3_13372=[""].join("\n");
var outline_f13_3_13372=null;
var title_f13_3_13373="Time course embolic stroke";
var content_f13_3_13373=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F73261&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F73261&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Time course of embolic stroke",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 422px; height: 275px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Embolic stroke occurs suddenly, with symptoms maximal at onset. This patient had multiple embolic events with different clinical symptoms (initially weakness, followed by paresthesias).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_3_13373=[""].join("\n");
var outline_f13_3_13373=null;
var title_f13_3_13374="Retinoblastoma less than 3yrs";
var content_f13_3_13374=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F50453&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F50453&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Unilateral and bilateral retinoblastoma age-specific incidence rates, age &lt;3, all races both sexes, SEER, 1976-84 and 1986-94",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 379px; height: 430px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Young JL, Smith MA, Roffers SD, et al. Retinoblastoma. In: Cancer Incidence and Survival Among Children and Adolescents: United States SEER Program, 1975-1995, Ries LA, Smith MA, Gurney JG, et al (Eds), National Cancer Institute, Bethesda, MD, 1999. p. 73.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_3_13374=[""].join("\n");
var outline_f13_3_13374=null;
var title_f13_3_13375="Imaging magnet";
var content_f13_3_13375=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F82585&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F82585&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 516px\">",
"   <div class=\"ttl\">",
"    Schematic diagram of imaging magnet",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 496px; height: 287px; background-image: url(data:image/gif;base64,R0lGODlh8AEfAfcAAMuXlxUVFRAvN1PU1AwrGr+ZckR2XUylecDAwHh0tp6+/2BgYDqKYvP6/Gtra7u7uy65XCWWltmzs5jl5Zk4OvL69VJ8z6XSvC+/v11cX8vLy+nU1M3e/6pWViyFWVFaVlFHLDMzAL9/f4+NkPX19a+MaSkpKnxnTJaVl3CD0zIyMjNLfZyZnoVZf6CgoB55eXV1dTSSY01jWBVTU5CQkVQjJUxxvklsWtDQ0B56PR5cPe7u7v///7CwsEB+X2ayjBQ/LZWVlZ19XnBwcCk2WH9/fzxbmODg4PDw8Orq6puZnBlMMkRERKSipXOsrLy8vDNsbD49P3p5en5+foaFho2NjnJwdFVVVa2trSWNSAkaFjVVRVNTeWxVRQ0NDbW1tVBQUJeWmIiGiaurmZKQk0d3d6ekqY2LjaGeojs5G4OCgubm5gYVDMTExH18fX58f4uLjJ6enhkcLL7Jwk5OTnh3eTOZZtnZ2QQLDQMKBoqIizPMZjPMzAAAAGaZ/4iIiN3d3aqqqkBAQFNSVH17fn/fn3/f3//MmT/Pb2hmaT/Pz8zy2OX460lHSRlmZoeFiX+/n5KPk5nlsmbYjBlmM7/v7yZyTL/vz9XV1R8fH2bY2FnVguXy68zy8pWTloqKiszl2OX4+H9ll0zSeT+fb9j19bLrxSl8UnLblXLb25nMslqrgoziqNj14oKBg3K4lW+f/yNpRo9HWqXo6IzFqKXovLLr67LYxbLM/4yy/7/fz+Lr/yedTrzS/+vy/9jl/9jr4mmS8vjy8nqk+ymlpYOBhGuM5NKlpZ6cn/Ll5YKs/5I/TBZZLFmF31+P74mJiu+/j5mZmajF/9/f33J8dZeXf3xspfz8/M3NwKWlpSY5LPr6+rKypYSDhXd3d3lyctLS0RwJCU+vr6inqXnFxWZ5eX19YJlycj9wVCY5OVlZjLS/vJm1tVlYWVtbVaWyrEZSTFtbPa+/3y6ysnzSmeLo5TA9NzM8PD8/M729s8fHwSZpPCAtJ359foXInHyLgSH5BAAAAAAALAAAAADwAR8BAAj/AHkIHEiwoMGDCBMqXMiwocOHECNKnEixosWLGDNq3Mixo8ePIEOKHEmypMmTKFOqXMmypcuXMGPKnEmzps2bOHPq3Mmzp8+fQIMKHUq0qNGjSJMqXcq0qdOnUKNKnUq1qtWrWLNq3cq1q9evYMOKHUu2rNmzaNOqXcu2rdu3cOPKnUu3rt27ePPq3cu3r9+/gAMLHky4sOHDiBMrXsy4sePHkCNLnky5suXLmDNr3sy5s+fPoEOLHj0UUJsHqFOrXs26tevXsGPLnk27tu3buHEDIo0YUxMa3oqIGUG8uPHjyJMrX868ufPn0KNLn07deRFv2Ic48HSEd+Evdcgo/zFDvrz58+jTq1/Pvr379/Djy59PHz4cGAsyXFkAw0G7BUVo4N1fO9BQBBr1ufcIIZGQFwkhjyQo4XuJmBDhhBi218iFGZqHRhFDZFAMGeeFUUw7LgzIlwZFwNGheib0oQJ5AfRhwovlxYjhIH0QguOPgwxiQgYmsICjJ1Ikksh46rHAXxIq4rVGEZ78iF6MfURiRR82mhFJFCaY0IiRZgjZyCCJmJHIIFaooMKFFQ5pBiE1DuJjeXGqYMWcbIK5pxmPqBBmj+clIuiYaD4yiKI+ErKoGW3KSZ6ZaJIXZwaTJkJkFEY+AqYKabLQSB8B3NkhMlIs4M17dSyAQJR1kf9AxghWXklqIyrUeCMhJgwSRR9RmDGqCjzeGGMAmZAqbB+49pFBIl7YmGZ5KpxZYyQ8eoFlJJF4gYeQhJbHI7Gl9hFtljKaoUKWW1bL7LLEdjlqs5hymUmNUUTSRya+zphIAMgW2WETRSQiRnxiXPEqrHI1QUWttmYQbQZdqglml8qa0aWOZiRrhhcBBLlxH+hha0KNjhI6KiEUp8mjqR8HQB4LLOybI7ozrmtkJl5oLLPGN4Is8o1d1mzhrRl0yoIJhMA8IRUOHCxfwgsz7NYDRTQB8Xkx1pwJIfIyCzbRNwJtBsc6khpkpRyX120mifyaso8vv1xmuORVnHfZau7/28eeaJNcMcYhB5nm4DdaYUK0mZT3CJkZjjCEHvVRbXVbmEiBzNZck/zIgyNbkUiXyYo+Mnk6rmvnmmf/zSHYKvDao90vwy47zOtmQEjseisRbc9mUMxmuqWPfqPqhLCOOCFRWEEIHsD/GAYMtCZo+eVq/VEl5+a1PTag0cZ44yO6nt66GSxE8fsgkE5s3q9eJDv33T6OGj/e6KtPqr58m/FrI+VpRLRU0Kny3Sh96zMb0CKRrH1xCEduqJ6EigED7KVFA27gnoQI4TweAVCDGEpWg9TDwZR9EITt8cSqMtQOTFjwLNpDIX1GZy5OyTBBj9BbemjoBRvecD1ueEaH/94QhBeWBYM/TKISlyihIFgBchNiwRWgZESxxJCJWMyiFs3jhiLgyAqBqGJYkLjFHykKTUYS03ka0b8MVegRjzDBtMrIHieS6EVkWIAYwUKD7dExQ7/KhPgUiCf24chRoDPkH9UDIiu5ao9d2YEUtLbICYGtceir15BMYEPWlWlNcgwUAc8TCTbqCVKCwhSfEok+NvaqkmZAAwwo9yMxVBCSW3mA1GCZIH3tqxF/she+zqexfUULWcAyDwu85SsTtGte9AMb+wLghUE04meLlBzEWohLrfyBSbxMkBVqxKVgFc18XbKbDlvmIJ11rGe16wP7oBeFQYxwkW54WK2I2P9NrAAig+FMEJkiQUMFovNG6uyf3VBHsvPFk32BqpEX7llGJTwRYlKkYj+pEggJBnQ+dNIdxci2N2Kmk1A6zOHXDCW8dkVTnmdLhOweuEUxdINzYNwoVUjgCgR9lD6RUMHvbIg4kyIUpW20QgPZJ0AZGemh6uJSAOZYxiZIAQWcy6NOp6IBNfz0q2BNjyf6ocFHbhUqvwmrWsNKhTtyrhgoOCtUirC5tdo1oJrTYBgcIFenrEEKdw0sLJEBAxRegQR9ZUob9ClY9K3JTvN5YxypCrE3nu2ETCSDF0GYCAElVilpbewjGJcsRb7nZdhyGnt0CB9EEpKJVDgDCt8Qxs//JoWujTVDjab1iD0lin15+lOgBsUgyLJASKfElhXYCFy1UbSUJjilp8RkJNdWjEhioigIpeBW7p2hCLZFyl9zq1L0mItL6rJWlrr1rRg1DaY8G0SyFsSlxfUhEfazUHmW+S0wvW0Q8aOf2f4nX9VyjrA+1SAarhDeoyw2t9/DEvts5iAhoYydD81hr35lJ5huacJtZKeXKLanUSkKqVElloGzWlgZLqA7DSbKAzx615p5QQmegmnF3ha32RHqoWNb23vZJ83XCnhSP/axj4oWhQb+CYUjuKkMrfCFGBMlGn6ckBI8EYYweILLXQ6zmMdM5jKbWcztYIID9qrmMDCh/x1ddkWbHcAEV9RhznWW85qZQIcwu0LPYQD0m8cs5wV0eQGATjObXeFmOK85DHd+9JknTekyUwEOlc50XdtDWysPJRrglJAS/vCMP/yBBn+oQqZXnekzpLnNjQ7znemwgDoHms+1/jOs7/zmMwD610xgwhnGXGtbu5oJhl50rF1BBz4zmtXQNjMVaBDtMKAaBW3INgrgsOn1fNfTQvkmhkb9BzgoQWujDnVu1w1Edb8HDm0oSBtc1B7NgjsoKxS1qcNwnnSz+9/q8QYU36OEuBoEBe4+j5PuDZR8JwgO4kZPGOgN8IqTx+H2AcdBwEHx9TCY4T35p5ZPvR5zW7ziSv/AuHsKnhCEt6cdGgV5TgDhVQnR4BmUTI+XK7mgpt2zaUAfeHssq0awKqHm8aGBxhECDhoM3YUy10lXJdSEiKtHCVWoJJa49EEueX3FJLSnkQPqCaS/p+qIRQgJcM6ezkZdJzPWd87T04RnJLiM7vVl3nrUNChC95SRUqV1D+hK02aTxu1RAhYWgoWEl6fTb8dJ3BNEA6ensLtbdG8Of8altSmTmX6SETQTqttqXjOcxJGP0hfSdPZAPvI2mTx9qu54D7Gdjlv3woW8jt7yiDiofdgZPFFMT7HzUg1ChE/d054QEvxh7ucRA3hhH3vEw2fU0FdPFWqvxBiNqg+7b+j/eRZKTB2RPqLm0i4d1cDYlS+eIY1fj72pXxPZz8fa8OnyH93LowAYqffnoVLJowItlS6kJ0czxUv5FB+eEG8M0QZZdh5kwFf0RxP2Jx9cln/8hnuEkizmJH7noVSdJywD9FQoti6kQll/5A1vkHR30BB3YHnq8XEVKBMXmHQb6B76d3LrxoLxUQUwthBHkHUeV4MzcYP2kYPtsYM8KFgWRVbw8QfMpxBrxx4LAHVG+BJI+B5/oITswYRNeFdKMAQteHZ/0BBIsAM9gABs2IZu2AR3sANyOId0WId2eId4mId6uId8qIdjgA0Ms4XtgQZdqIFhKFieMARgdx7IEAcK/3ENSHAEgDCJlFiJlniJmJiJmriJnNiJnqiJ4KAGaRAC1RCI1uceyFCI7wGGh6hWI5AIZYiK2YAQ17AD0/CJuJiLuriLvAgI+XACIRCMpGiK9REGqqiDXtiKYPWKAKWDT2AQ25AEt9iL1FiN1uiJYxAPwiiMpQgrgviFx7iEyaiMP5WIsbiEzzgQ0XiN7NiO7IgD1QAC2yiMIACI3niK7ZGK46hz+0iO4TSGi2geyDCLPEACa+COCJmQuagP5jCK8xgCaYAPKUKM9EGI/VgiF+mPlWRR58gedTAIX3CQCjmSJHmJ3ACMDwmRghBsTWA138ge4fiFGamRi+SD7/EMCP9QkjpZktwgjymJDysZbEzQkhRJH5hmiDQJVjbpHuMQCE75lFAZlVI5lVRZlVZ5lViZlVbpAA8ZkUL5lUR5j5Q3k+TBikkZTgv4HiPQRUXQlm75lnAZl3I5l3RZl3Z5l3gpl1KgjcLolV/5lQ/gkviYQmRpBmZ5lrDEfvAxAkVgao75mJAZmZI5mZRZmZZ5mZhJma7gDfKYBkH5l18ZcyrykuuhBDLYHjTAfYhZRsgHH2OVmbAZm7I5m7T5B1PgDqCZm4lwOaSpHlWXfejxm6v5UakHH/1Qm8iZnMqZmUWQAbkJmgZXlPSRmit3msMJS8WplmqwnNzZncvpCkPwnH//uXQMM3UJYpruQZ3XGU5lFx+M6Z3wGZ+xKQWvJp5ggD00R3XPxx7CuZ68dHTxAWnyOaAEKpmukAjiGWzTZzUiZ3Pch57++Z/N+B5UsJ0FeqEDSgXe0AgJGpjYo3LyoQS3lx7qGaGwBKLrQTAYuqLx6Qb1CZoZ8EIoGh9wYJ3l0Z8mWkkzqh5lx6I++p3h+ZwOiD1WV4xFWh74l6Ow5AaqiR79QAU/GqW1KQXOCZoeakGgNiHIAHGhpgRwwG1KmphNWiJFAKVSeqaZqQZSMAQveqVYGoFGuoHGWJhhmkRqAKcr5wqN2Q152ad++qeA+qdS4A1s6g5D+kK9uXLlBnGq/1ZtjvqokBqpkjqpZvaljloFqfYHbUkFzyEFNJAboBqqovoAWGhED9YhWxYElLqqrNqqriqpI0AFkfplYdBt6zEEVZaFMjFedeqPqHJD7RCEugoTuNWr5JhXIBQGejSsMtEEmGesTdhWKFQMn8CsMnGq0HqIZNB+nIOr1hoTvJqtYfirIBSs3xoTxSquTYisnKOs5xoTzqquYSit3EOtYkECmKABTqkBmDCFnmGe8npy7ck9iVA1V4Gv+uoCRQADV3AFMiADBnADNyADDQsDReACgcCv/loZJHAgAXtyVnV3VuIkG+sUR/AFCsuwDguxBuADDBADdhCzMhuzMcAAPv9gAAbwsBV7sV8grJHRUR97csPBOfwEFSf7CQvwATfQsi87s077tFBLszYbsR+wAJ/Qs5HRoEELcEowoY5UqklBAgiAtErrslF7tmh7tjZ7A1X7CQa7GEe6tbnFpBAzgUyBCUGwADJgtmnbt34LtTYrAwsQCKJ5GLoktwA3Arv0IzmFFEkQCA7wAQYAs39buZY7swxwA1cQBGBbGJIEnIhrV2gwSVaCBjB3FAhQBErLAJfbuq5rBzFgAB8AA29LGH0UuuxGJVZiS0aBCTDwAT5Aua87vJfrAx/gALUbGGSEu43lCV6bIWYlFJiguj5AvFB7CpbgATHrAZZwCtbrtMb/i7wW4QKCgANtcUXMK1hugKfWQ4FBkQRBILnC+70ySwB9QAAxywb3S78za7/Hm7wNUQR9AMBH9Lzpq1bOiyPR6xMkEARXcAPzy78xa7994AGxwCX46wFAQAAEAASUuwQdvAQ6YAc6sASxwMHeaweWwMEebAn6uwRb8L88QL6CAAY9wANHUAQ9MASCMH04AAaCIAgDXBAuAMRDgAQXiwNFoMSvkrrm2wNATAMD0QOCACDThwBGjAQ8cLE0UMVajAQ83MM4gb4HbFfr2yFi4L49QQKBsAAQLMFQa79ssMH6i7+WoAVLAAR9AAR2oMcEsAT7K8da0AdsYAcX3MH3qwN5/5DIdhC+KjAERZAsR4AAXCII0eIC00BNRSDEBivAYBDJlHwuR9AH9wkGfXAEPUDKQ9AHQ8ADqawCkdwHrqzKpMwDXKICyaJHPAMimYATy1vGa5XA0EvANvEFesu6cBzHfaDIy7y/JAwEg4y/hByzgdwHMTvIdmC/S7AE+pvN1jyzPgAPQZwsbNgH4JXKRUADfZAiAmyw8SMQSIAEMjIQQjzKpdwHWixUPFDP+yzLptyWyWLLgsAD8jzQIAMgPksTZAzMYXXGE5LGPqEBDiADyJzMyhwDfaAFlrC/egwEGy3N+GsH1TzB1qzN27wE3uy0HpAHWmAP5EzJ4AXT7bzFQ/88EH0w0DaN0zMsI31ww0IsED/90/3cz28p0AJx0zzww8niBQktE5ljqwz9U2HArvQRBu3gWTvxBcBr0Whrv3ZwCtxbzbGgA/s7yGM90ilN1gRgCbHAx/YbCymswvd7x30QBDDNAzBNyWCAAJxMEKZMA1hMyTqNBL8jEOqsw7W8yjoc0Oq81z2gR0ht1ILgAnzdB+YreVkT1a6Y2RU5uD0RvxXN1cossx/91Ytsv/h7CnWM1l5tB9yMwYa8yCMss3rM0je9AOaM17m9yl6wLgaLBAvAOKOs0zyA260sEEMQLWDwxUKcCQG9xQ10n5GN1Ka8LxOZEw6j2WpFBdwKH0P/8Aw8QQIwIAMRLNrDy9aWAMh8LMExIAMwULIUsS5NLRBHQNku0NtPQQI0MJja/UcEw9/o8QbvvRNH4AA3YN4STNZ9kAcebNE34ADzHRE4ENlMdy5gcNl+pbv9/VOowr7pIQYvthMasADVi+AmDsc+sABYnRcs0nEbzktT7eLq0SorfhNaXeInnuP0a7y5qhcF4rEvHk4fAuTp4SQwULg1Ado6HrUH8AM/AAmqoAq04OSrsOSA+wFFxBdfwF1jGuRLBAdcXiInct04Id7kreOkAOW3AAqgwAkCUQGLsAiXIAmScAlxXgFvzua6oAqQQAo63t4Dvhe+ARzCUR2GfuiI/57oir7ojF4c14EdwuEN//EJNW4TBX7gOf4Kt8ADiyAJrDAJk7AJezDqe8ALlEAJOQABe8AMBDDqmwDqMiAIi8ADt/AK36sDBOC9HRy1Dx7hdmEaoxrswj7sxF7sxt4aT+DrM4EJJH7iq3ABFcAIrDAKpF7tow7IHJwHrW6/1p4DlLAHo8AKjFABF1Dlr5ve2uvMUJvinfuumXEEzW7eB0ALnFABtSDq1m7tvHC/ow4BObAHBJAHWQAEQMALe+Dto47q6CAIcbAOHBzBGszBsfDVG9zg6C7S+BsDG/zH4LwASO7uHOsAOG7RkAAKPGAKqJDvKr8HEIDBzJAFoy7H9v+rBQDfB6OOwYusBfa7BZAgszGQB3mQxwSw0njM0q7dB5aA8XbABkEPBIU8swZwSyCfGTCA6clMCqrACYxQCIiw8l6fBfrLJUsA8HkQ8zYf8Dff6pTQBwbfB9rACJzQ82Q92x5A1hOvx6cAyEm/v0APBEugvU4rA2Q+9ZQRBDJg0QcA7YswCV7f+KrO8jnAJTVv9pO/B9q+B2vf9q1eCHAvA0hPs3p/9On9+ft7CgSgv3kA+D7/AZVO+I+h1eVNvKuw6aaA743v9bzABjmQBZG/7WVP9sC/B/ye+cLf6qNeCHOQ0ZaA66cw10wv+kpPADqwwn0Q1zKb4h/v+oqhAR//ENrW+wOgYO/Ufvu3DwFAsMhBT/mTz+2Wr/Zs3/7WngUUjNI6oL9a4L2hX82EPNtPCxAGYPAgWNDgQYQJFS5k2NDhQ4gRJU6kWNHiRYwZNW7kWPHIAh92RI4kWdJkyVecGElCtMflS5gxZc6kWdNmzEKMOL062dPnSBkuOg4lWtToUaRJlS5lKpGEg5A/pZKExIPVTawyJ00qJElSoa1Zxe5hVQHSVLR2YnzQ0NTtW7hx5c6lqxTGjbRTqxYaO3MTK0mLFjEiGKpTpwkTDociyEiwJFab+sbcVOFCXqk+FiSp29nzZ9ChRWMMIgPzz72T9yBCFZhHKFsTDGnSxMf2/23ctmkbmmCL8SJJqFr23cTo1mmfAkcvZ97c+XOjXz7EQH4y9dhCpggjTqUoN24MLxw5ivAdt6JUinkwMvWDQA5e720iagWKVHWRpwjosMNPBXQAAxRwQOc0+IAB/Eq6LqtJFgllggHM+44YPPoggIA+HJHwO00MWacPSiCghJebEFkEGFIwRM6DJSyxA8O2CJRxRhprLAqqBKniga+sRrmkgQk2NE+LPl6wjZjyxJvnhXkiAEIAAYzkA4MZBACiD2r8GdGlHC7MwSVKcuhyiVreYaOPFkmKQYcLl1ALCAKAOMUOFl3E0AESaBBEkCGOsPFPQAMN9AvTchRpwflq4f9hFu+EzI0YC78ToI8KI3BkBkcmNRLDGWboAwp2+thnD2b6YObKL/uw8MwlGPDCQv5GwhAIIPKwQ4s8lsDVA0vQfLEPGUzoY4giVEBAUGSTVZY5EhZA0FBEa5KkgkoidPS7CPoQgI9JM+S2DwxsCw/ODCGdgY9syeujiFryYIMSSizcQ14I5MWQp5FO6QMIkTzQl99Y+tChVzcxjCGTPsAo4thlG3b4YbcCKTTHaGdChZFOarvWPAwoxYAYTzWc9DYC8HDkhQzTRTflTzvp4114v8yDAJdm3gPDClYZieCdfSWYZxXRyUQFVXuA+Gikk8ao2WcTrFimQhowZGMhPRX/IIKQv72tDy2wzhADPLoOWeUrR8yBknlpTvvmPFZp44CR8sgjlli0sMNdSzA8Beg+7ADChDCG6IMGpQs3/HCEgsCL4h2xMqUBa6ne0BEitS1vZNtQ1tbbFyqcVF0NqawwD7Rt3sPmLPLo4x8U88PQQjtOIZIN/vi2YwnVvRgCcd57PzqJK6hzuvH5LimlUcmTV948RUq5ZDibTAHG0BuC8P167JFVnHEea6KvEuSXz00RTdKbQJPIxT+vklagr6mV4xJcC5Ps67d/QEymG757miqzRX3bKMIQs+hEKQiyi1/0ohe/8MVrOjELQ6RvebaogGTm04rLJMgHDrhfBz24/5wiGGB/N5lEBaYmPgFWggccwIUCcgELP8RQhjFURi5wwYEGlGIWGlueISowiZuMwiw5kkEgPnhEJMolf8JDziuIV5PKnFB5hlAhBxQAwxlawAZbbIYMtbhFGwyjF7toQCVS4agXCIAY3DqXDy0IxQrgqzoM2EwS7XhHpMAgKtXhxFXmY8LlaaITvrjiDGfYLVWtIIaI7IMi/TAMBZQxfLmx1Dz4oC3b+NB9FuPEffBjgCLgUZSjzAgCPuA0RpSoFf9L3gBs0QBcYNGQMpRDH2zQDFXFsJZG4OIMjTGEewChPCATwAzCVclLbosPL4iCNpgBAZssQhXyYwsprXnNh/8UYY/I4QT/ZnKJSiRPERNoAAeGMctZTsoGFuhDABbZByKsYAVdjKEz8ICHFbQjHfPAAwEc0U8+OKIP5cGkp2ZQBhOQqCaj4AHc8OODT2BTohMtSBL0Vx1IpDJ6x5NcKkLxi1ygE52IxIMF3qkqW8rQCH0wgh9gIQ8aDJQPniKGQAm6rSsBAQpPMMVNJAGKBNGRokO9ZiAWx0dv4qQBkxQSORUgUpFOagWqMqkf1DnLqdpAhlN1QkAHatNkTmkGr+tBUmGCCEbIETkf8BNR3XpHBzTtNBm1CSogRzVFVGIXyoCqSGtpg6kGwBl++Oss2SkHGxiBCOykgxO0gAev3nT/puTxVBkagIq6dhI/N/jCWz17xPwlqJs2aYUUHTWAUnBAln31QzASIApR1JILoggHPGOb0lnaoJaN9IMRAtAHFYgjsmH9J6XaqNGaSPOhEf1sc+0XBBFiFLkzmUQoqKYJWLJWhiloAQU6AADwhle8AOgABVqQAu3GEBcNOOPGOiEJmzDUoacRqnPt67tmMfE0o63JJYJ0rQE04KnaTYAsKCCCDTxkAyKggCwSEAztKoAHpt2QJiqwyZj8FD9svW+HD4eAic11ujIZxVKv1TxcEHgZHZCAMCYiDAmU97yslTCFJVSJWswnrdXhrId9nLRPbBMzujDrS0zBSkdVggOs/03AiiVwDYwsuMEJ6GuNAcyDUdiEFbqoDkR//OWHLUC/eSEFDzD8EkRUQILmmcAuVjvLBFDgGNeAskaEcQwKUBmqVnbULC5hk8pUJwYLAHOhk4WJEGMGEn+WVjgdlYoG8BWq1qCABIhyDQnkuco8aO+GFNEAINYkZ9WRAf0MfWobuSC6yCGyTRjBQwkpIhQDFmmcn2yUTFujr9IoxbUmsAibXIIW1TGAUFB9bBnBQK5kNnNNCtFrR03gF32ltKWPgmlNQ7UBsJZQKIpMFi4jhwEDQXa5AWRR/Cw62DbOTYBDWutK1xkpmTYGVHGB5A0ZgtF+qcCGOWNugDMHAUc9Tf+raYIIHjA1N7boxaQrzZRrAEAWUB3GNdY8vmbTZNTIuQHDAv5x0Ki6OmU+s0sK4egKN+Cc6LS1vJVyjQ6IAqoc+K+QKvFtYXf5GSDnuWdcIeS0qLu/7MZNJ1LM8oe/JRnZnmUuGnAtfddky3MkdM+tLhdlV8fgM0G4wm9jCF+8WYbLOIZcJLCMeqNzF0S/jSIyLpNAV4fDV6d7U4KHHJI7G+U3prUhrdEBukhcpArY+42/vfHT9Ljui0cKCa6A0X1/k+18cLvYY7iMW8sF5jKfJSwS7qio0yTnyPHBzhl/eqIgujqqgO/BP5/vJaPz751Zup4NyYHJU/7tGZ6muKv/jnrga0QDiU7LLfw4k5Mnue8zlEXm6XKMFqCT8Ne6OU2mLve2Bl/7FQnEqjEDilDPRBI1Zx4PLJ8CCri4LtfYwMQ7//oNTaD1WgEqjzu7ffxLpPvVAX9yJ2+I2JulFhAB0KAAkcI90AM26qo/5DAAI8o/CHSIn+OjN5KJReC23JiFozOkYKCABPuMDkCvWcKFWXAUTVBAuOs3YnvACGzBhCiCZUsLHnA1DCy65YuhBAA80BABXZslBegEExwxmOCBT2JBFzxCghCz6pjBmuABRymFdzMkUQAAjOiBIrjCKzSaiwCA6Gs6aBMSJpwJIlxBJCxDHng85DiACrAJJwRD/8ubQovYgZhCKZQaAhfYgYpoP3TyvGsJQ5lAPMxwQDM8QnRDjh9AQa2wLk/jAZGCQ4nYARcAAzrkAZRyAZQCA2ODiGtYOpGCv24Lv5hYhB8gw0FsQdUzRESMiUkAwgrbhUakQojoAUkEgT54FTqkw98Sgj7IBC2ECApIO0PahRosOlCECVEkxVKEwOGDPGdjRQlJhWlDJ0d0CEvsA2joA13sA0pUlW3cRV08BFXJRIcIQXT6hU6TkE4ostE7DUFMRgjcP+RgPWkhv++YgIaTRlhsiGoER3C8RX/sA35UFcJ5CBHgPEPqBXqsx/njPWR0x+2Dx9OQR5oYv6a6x1maxv+FmMOAPIEiQKlu7EaADMkA4EWH4EF0QshoW0iYkITeY0cjdEgPQgCZ9LiGGAJBWIplRA5aiLyYQAVnNA9NiMaLzEeEcIEiyITfCsh+/Ec6/MaQ1EVi6UWEIMdZ+oVhvI1OwKxvGrYGfEmYvB869AIcUIg+uEkeMMqIQIB1oYhTPI1DrIlVFJIB8IVXTAgEQEpsDMmN5EaP7Eu9DMkS6IMu6ANxLIhrMEB08oWLI0aaOMau/Moj4saYAoOz3BMwMBpLzIQiOAK05IGPEIQFGEujlEUwGMsFKMtQcgo0dMtUhIkScxRGxMcXpEWl/EumpMNrrE1w1EWpJAg9RKc2FJL/BsiymXBMl4TMD+JGtbxJMCAWhDkCwfECQcABQdDGI/ACFSiCAPACHqjOodlFHiCaTBAEBMBC8zzP8zSBJVhP9mxP92zPLaAGeJlP+qSEIhgP/MzP8VADeerP/oyCLkDPIqjOE+iDAq1NjvRLbVQV2vzLgEyDgTRM6EMnZVBEMBQ1nXlM5OwgVSkWwvTMAUWYYylLgqhOHoipBRjQPkAAEw1PbVTLUCpPAZ3RAQWC97zR9yyC+qxPaoAC/dTPcuAC/+xPIqiBN0BPQUgDA+2DAnDQ26RD3fzLsTwIk2y6nzSPAVhDmhhDDd1Q+1GVPRGK61QBFzjNETVLE+3IFL3C/yNoUROF0YpQA6BDCz+0wKvkAw0UKQ9EiI6MUnC8xgXlS5TKTScFR+6cShE0JBI0wdZ8CS49Ti/9Um0sCLUEAxZdUUrMBARoU23EAeDqAQQYAuqc1DdNmN58CJFDjgpKrnP8DgAUqQHk0waNUlpkyll10i6gTIRAzFlCQCFJhUbdAyEqwkiV1IM4TezE1I7sg1EliB4gGuDi1BIl1VqkCIj8vmJcyYTEjQATKfRTv4JoA7z000msRFUh10zQ1INgP/ebpbtqKpV8iUlgwMS7v2JdvJw8jf6jieQTEigUKVk4BwFFmCUtUINdUqY8WIVVlUyYAvREgAn1QuorsnndsP/su1e6a8shOz4SC04JmQWL9LsaeFKSLVmT7YNv6ADbm6FeKEHYJE6oCTf6+j2MpTvHW714hYlWaNXc0ARXRKdgGNmTHVqi7YMaaNdgvFM+SIVWkJaWxIzSq1nGu7u5ClaXkAR8Mw+VEykiKFqvLdkaAMYZGoancxRbyFmXWEfMUDyppbusO40yg1m4s1C+EykbqIFvcFgaRc8h8AIv2FvAxcIaUIfBKzzzCIUKjIkKmC/MmLu2vboJRA7jc7XFtA1Iszw/kIWyS8tMAAM8xIizg7DEzL0BEEJ55QSqe9y6S9XTeAXTNbJtxQ0lgzdrc4i+jdCLSIZlWNkZUgC6lZD/CeipiYyf04ha1b26LyA4zFhVmkCFL4w1AaPdhsABFRCEadiImIMqX8g9PigFrZyJVlCrvGDb4+W5Izil6riAHGvCyrXcBsBcW1uIjkxNjRC8wftdLL0G7+EBTzoNxy1fnnOW6lgFLRU97p1dkao2hAAEFVCBKdUIetNe7g09i5ke3wPgqwsy/OCE74Ua/P2OT7tBGYozAJA3GtCdjgAACkjUWZKGDx6fy6oJU3javDBeDOa55MUPWhBemmAE7oU0SUMnY5CFDkiGHRAEdd2IZOgAWRBbQ5Iwnv2OWbDaPWCEUeQ4e73hjztf/DiA3cOJF86NNsPcGBKFGgiABfjc/4yAMQowSOmbsGuxMLmNiWHFPi3uOQHmv2+rYu7lAwRGJ2cgAi+oARbLCClzsE3r41JAW5e4vpm9457TYOmyiUII4/MohQ2cIRsIACIYrCZjMXCFCBiTMRZ+4z6egKb1nh0jPdOD5I8DMdHaYx/emADrO2dYATxoqRkqsAP7wIY45AeLMDgGMFCzCQ3jMZp0ZYDLY+SgK2ezZNxIBR4YMAuQAzmgp1niLu8aL24m5fTyAz67lk5YX5qQL39TZpAzqlh2tT7mA0OY5qnS5b5yLdiqZ3uGrWD+5nB+tAuLJhrOi3FDZ5ADnjHLC2du3ne9FnJQATmoqm9+aBobZmLuYP+ZQAXNIrbCFOhyg651djYTQyM8gIJphmiSHjyJdpRP22O0El/MKDWN/rjQSrfXNTKOkpB5EICucWcekIaS7ukYkoaTFpLm4eGJpNfTGLSXBjk96uj+MlzbiAA8MKbbSIVSgKWV8+kI84VQiOIb48mOZdziZa6kBjhTQiVVyloMAAI8KA8OsYUVikKs9kGtbmfbsIX2uQnlwo+1SOaxRjYc2WCO5TpAemo8AIJw2ZABIKddKKS4fiQFmOsp6ufM6t8GpN++Nreyxo9XYF44MgTRkZKNoaIVYmyIzoUxKiO6/jrO7p84oiZTu2yA+2uMWm3qmgMtEABLUp4UWqEWeiH/kaqhG8qhHVIfH8rWmKCPDNos64HtgMts/LgARig5MMmDf8ha3R6gAjqgBFqgBjIMCGrfa6GgxJ0JUzDqmf035o7tOc2LW7hrmYgPAuCF7/G65SEf80EfABof9pHulygLykaOIkrvV0bfBAGF1swB0kEz46Hv/G7wtnMe/naJTeCBDH0oPBHwj5PtkQMGHoYAAmADhYKJxwFvB1efACNq76kArtTrD+BrDD8258YPUuCEHEudZ+JXqSlxHXffPTZG4v0ky35xc9PwAa6HWgnx5sUYpd3x0+qECqDomqiF1nFtIR9wQ4mFPAADehCLaakWJl8ecqqFCH+JQgBEHlvu/yoPOCLPixiolVjY7B5HM0VhlC/fGE0ohVYwbpqohQq44qCqozRvbgLHDEtgAwLwAJEgYHLGCh8Bkjr3tFmoAEaWCRMBhgpPkAAP9Axfb5/AnVgZiQPg8L5okFAwBAZ3cAFqgEWYY0CrgFv47y67cE0POAOJwZ6QHS2YE5MgBWBwb7EohEvggUowdSbf7UuAci3jgRXPEQaoplkfcFsvCR3wlZ9ob1YvEWAXdmIHIGMvhDE/K1Mwcxb3ymcvN+ko6JHwAALIdbS4ANoWC0TI9kqQDdqI4w6ZABW6BG9XjU2oD1jHDxlA83L/uNJAdx3IAyBA956AhAqIc+/pCsEgDP8HQgzF6ATGWI/H2HfV2IMyT25DsYMbgAESGPieK3g1+XAXaV2VYImNpy6u8Aqw0HPVyImd+PiR0Az0JnmQK4KJwXICUHi0+AFQqIBauPaWP3p+1YmzsHmRYIAruFid/zgSuIs2nxubX4Vb4AFTGG+k73qOV3qmH4m9jvqrc7x+AvrqOAB3XwSZ93rsAPuwF4kYCHiyv7q+jQLvC3tSUAWV0Hi3H4t4h/u4F4kbCPK6BzjqVYEj+AhO/3hIAAWtR/a/70lT4AFQWPrBFwkDkPXDD7j5LQjGz3ySOABa4ASi53q33wQ+5wRaAOvB1wyo7/xja1MHPggNAAnRL4lVcHf/RmAFo1eNUWAFRrCMS899zXht2fcMHJhJmXxgALHJg4B+hjjhIUCChDgCB1De3LeDV8h64GCFrUB9EtsKiOeBW2Dp3L8BB4j95KeL6qRDs4yLFjWI+UeI+u/OSU0IJACDJAYIHgIHCiQBQ0YMOwoXMmzo8CFEhaQgqdIFClQFgRUWLbokSZIpjow0XtSlChKpiCpXQowhAwYJgjJn0qxp8ybOnDp38uzp8yfQoEKHEs2JA8GCPgsQHC2CwwWCIwsECRqChIeLIj3AgMHBA8kQqkWwFkEgaMFVHjQEgekhMOsRGi4y9Sk7EAFdu2HPehXUp8fZq34FSuXLo4cXtDqD/3xgwPIx5IerfvygpUoVLcqrInOOzOBDkKKiR5Mubfo06tSqeRSpK7C1l7pmiyRdwMNvJhV9MvHI5KXIEN5+FwzpA4ZH8SFg/t7uE3tBbEEuBrqIPj0TcC/ClRY/PviIFxVFAng57Jbnlw8+OrNv7/59Qx8fvqyub/8+/vz6S7cey5r5W1P1IUhzAunGgxcBLFDEEQXycGB4XxnXXFqDyWQhDwiEFZuDBw5Gg1JF+IUAUBossB58Kaq44kI+LKDBfjHKOCONNZLW32t9kIhcH0MgMKCDg+EABl1eHGHhYEDyACSGGA5kYQ/G9eBhHwINNlhrCxbBYFBHOHADi2GKGf/ZDQ40aCOaaaq5pow4/rejXz24wGSVBUpnVh84jAjiccv10BoNDjbXg1dP/oVDfz3Q1RwCfBaIQx8q9KBhoUAZhNCYmWqqkEswsfkpqKGKGpSbre0ITnR0WlnlcrtNh9uAVyGxnBdDrDoQYn0EimtsNOygWyaL+hWdYHVO2UekZwrFmGObOqviZ6GNOi211Vo7mpPX4pQeis9625l89Gk7LrnljputuTNp4ACm37qrEgMyOABjuvXaey++oJLgwgcGvPsvQzHcsEAgMeV7MMIJK5zaEUU0BrC7MRgAWhILW3wxxhnn9MUCNyQE8abyFYGJxiWbfLLCJDDWLcgsxuv/wI4oyzwzzdpiwm6zLcMnMMEG1/wz0EGrGcgCBnysc2cSUyw00007nV8SDvuQM9IrxSAyyU9rvTXXo2nwyQIf3DB11Q4xYIAMC3wSc9dtu/22Tkd8AbbYZLfMgA83fAADGlnD/Tfggcsk9zNhj031pnjrrTYCFQv+OOSCy0334WIq/sECz3yhbOSde/434Ybbzd7lam/+OeqpBz654Qa4/jrssRuwuOacq3477m7LHQjvvfv+eyCn5z488cUbfzzyySu/PPPNO/889NFLPz311Vt/PfbZa7899917/z344Ys/Pvnlm38++umrvz777bv/Pvzxyz8//fXbfz/++eu/BT//PwcEADs=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A large hollow cylinder contains windings of superconducting wire bathed in cryogen (coolant). Additional shim windings provide small magnetic field corrections. Three sets of nonsuperconducting gradient coils provide spatial localization of spins. A radiofrequency transmit/receive coil provides the RF excitation for each MR sequence and collects the signals used to create an image. Control electronics are located outside the room containing the magnet. The part of the patient being imaged is moved to the center of the magnet by the transport table.",
"    <div class=\"footnotes\">",
"     <br>",
"      * Liquid helium/nitrogen.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_3_13375=[""].join("\n");
var outline_f13_3_13375=null;
